[
{
	"jumpto":"ENAS5195_12.14.0.0",
	"name":"5-alpha-reductase inhibitors (HF)"
},
{
	"jumpto":"ENAS5081_6.1.1.0",
	"name":"6-minute walk test (PH)"
},
{
	"jumpto":"ENAS5079_5.4.1.0",
	"name":"18F-FDG PET/CT"
},
{
	"jumpto":"ENAS5194_10.1.1.0",
	"name":"AAD (AFib)"
},
{
	"jumpto":"ENAS5194_10.3.0.0",
	"name":"AAD for the long term maintenance of sinus rhythm (AFib)"
},
{
	"jumpto":"ENAS5194_10.5.0.0",
	"name":"AADs, contra-indications in sinus rhythm (AFib)"
},
{
	"jumpto":"ENAS5194_10.5.0.0",
	"name":"AADs, oral drugs for sinus rhythm (AFib)"
},
{
	"jumpto":"ENAS5194_10.5.0.0",
	"name":"AADs, warning signs for discontinuation (AFib)"
},
{
	"jumpto":"ENAS5194_10.1.3.0",
	"name":"AADs for cardioversion (AFib)"
},
{
	"jumpto":"ENAS5329_6.2.3.0",
	"name":"Abciximab (STEMI)"
},
{
	"jumpto":"ENAS5328_12.2.4.0",
	"name":"ABC score (VHD)"
},
{
	"jumpto":"ENAS264_9.3.3.0",
	"name":"abdominal aortic aneurysm, asymptomatic patients"
},
{
	"jumpto":"ENAS264_10.2.8.0",
	"name":"abdominal aortic aneurysm, genetics"
},
{
	"jumpto":"ENAS264_9.3.1.0",
	"name":"abdominal aortic aneurysm, overview"
},
{
	"jumpto":"ENAS264_9.3.2.0",
	"name":"abdominal aortic aneurysm, screening"
},
{
	"jumpto":"ENAS264_9.3.4.0",
	"name":"abdominal aortic aneurysm, symptomatic patients"
},
{
	"jumpto":"ENAS5080_5.2.2.0",
	"name":"Abiciximab, glycoprotein IIb/IIIa inhibitor (NSTE-ACS)"
},
{
	"jumpto":"ENAS5083_4.1.0.0",
	"name":"Aborted cardiac arrest (ACA)"
},
{
	"jumpto":"ENAS5083_4.1.0.0",
	"name":"Aborted cardiac arrest, definition"
},
{
	"jumpto":"ENAS5079_5.2.4.0",
	"name":"Abscess, anatomic definition"
},
{
	"jumpto":"ENAS5079_5.2.4.0",
	"name":"Abscess, echocardiographic definition"
},
{
	"jumpto":"ENAS5329_6.3.3.0",
	"name":"Absolute contra-indications (STEMI)"
},
{
	"jumpto":"ENAS5195_7.0.0.0",
	"name":"ACE-I (HF)"
},
{
	"jumpto":"ENAS261_7.3.0.0",
	"name":"ACE-inhibitors, risk reduction in non-cardiac surgery"
},
{
	"jumpto":"ENAS261_7.3.0.0",
	"name":"ACE-inhibitors, risk reduction in non-cardiac surgery18.8.2.5.1"
},
{
	"jumpto":"ENAS5329_8.3.0.0",
	"name":"ACE inhibitors (STEMI)"
},
{
	"jumpto":"ENAS5326_4.2.4.0",
	"name":"ACS (DAPT)"
},
{
	"jumpto":"ENAS5197_11.6.0.0",
	"name":"ACS and undergoing PCI, dyslipidaemias"
},
{
	"jumpto":"ENAS5194_8.10.2.0",
	"name":"active bleeding in anticoagulated pts. (AFib)"
},
{
	"jumpto":"ENAS5530_10.0.0.0",
	"name":"Active standing [Sync]"
},
{
	"jumpto":"ENAS264_8.2.1.0",
	"name":"acute aortic dissection, clinical presentation"
},
{
	"jumpto":"ENAS264_8.2.5.1",
	"name":"Acute aortic dissection, diagnostic work-up"
},
{
	"jumpto":"ENAS264_8.2.3.0",
	"name":"acute aortic dissection, imaging"
},
{
	"jumpto":"ENAS264_8.2.2.0",
	"name":"acute aortic dissection, laboratory tests"
},
{
	"jumpto":"ENAS264_8.2.5.4",
	"name":"acute aortic dissection, treatment"
},
{
	"jumpto":"ENAS264_8.2.4.0",
	"name":"acute aortic dissection, various imaging modalities"
},
{
	"jumpto":"ENAS264_8.2.5.2",
	"name":"Acute aortic syndrome, a priori probability"
},
{
	"jumpto":"ENAS264_8.2.5.3",
	"name":"acute aortic syndrome, diagnostic approach"
},
{
	"jumpto":"ENAS5326_5.4.0.0",
	"name":"Acute coronary syndrome (DAPT)"
},
{
	"jumpto":"ENAS5329_9.1.0.0",
	"name":"Acute heart failure, mgmt. (STEMI)"
},
{
	"jumpto":"ENAS5195_13.1.0.0",
	"name":"acute heart failure, overview"
},
{
	"jumpto":"ENAS5195_13.7.0.0",
	"name":"acute heart failure, oxygen therapy (HF)"
},
{
	"jumpto":"ENAS5195_13.7.0.0",
	"name":"acute heart failure, ventilatory support (HF)"
},
{
	"jumpto":"ENAS5195_13.2.0.0",
	"name":"acute HF, factors triggering"
},
{
	"jumpto":"ENAS5195_13.3.0.0",
	"name":"acute HF patients, clinical profiles"
},
{
	"jumpto":"interactive_0000558",
	"name":"Acute HR control of AF (interactive algorithm)"
},
{
	"jumpto":"ENAS5327_11.6.0.0",
	"name":"Acute limb ischaemia, clinical categories [PAD]"
},
{
	"jumpto":"ENAS5327_11.6.0.0",
	"name":"Acute limb ischaemia, management [PAD]"
},
{
	"jumpto":"ENAS5327_9.1.0.0",
	"name":"Acute mesenteric ischaemia, management [PAD]"
},
{
	"jumpto":"ENAS5329_3.2.0.0",
	"name":"Acute myocardial infarction, definition (STEMI)"
},
{
	"jumpto":"ENAS259_6.1.0.0",
	"name":"acute myocardial infarction, pacing"
},
{
	"jumpto":"ENAS5082_3.2.6.0",
	"name":"Acute pericarditis, anti-inflammatory therapy"
},
{
	"jumpto":"ENAS5082_3.2.2.0",
	"name":"Acute pericarditis, clinical diagnosis"
},
{
	"jumpto":"ENAS5082_3.2.3.0",
	"name":"Acute pericarditis, clinical management"
},
{
	"jumpto":"ENAS5082_3.2.1.0",
	"name":"Acute pericarditis, daignostic criteria"
},
{
	"jumpto":"ENAS5082_3.2.1.0",
	"name":"Acute pericarditis, definition"
},
{
	"jumpto":"ENAS5082_3.2.7.0",
	"name":"Acute pericarditis, first-line therapy"
},
{
	"jumpto":"ENAS5082_3.2.4.0",
	"name":"Acute pericarditis, high risk cases"
},
{
	"jumpto":"ENAS5082_3.2.5.0",
	"name":"Acute pericarditis, hospital admission"
},
{
	"jumpto":"ENAS5082_3.2.4.0",
	"name":"Acute pericarditis, low risk cases"
},
{
	"jumpto":"ENAS5082_3.2.5.0",
	"name":"Acute pericarditis, management"
},
{
	"jumpto":"ENAS5082_3.2.4.0",
	"name":"Acute pericarditis, moderate risk cases"
},
{
	"jumpto":"ENAS5082_3.2.4.0",
	"name":"Acute pericarditis, non-high risk cases"
},
{
	"jumpto":"ENAS5082_3.2.5.0",
	"name":"Acute pericarditis, outpatient management"
},
{
	"jumpto":"ENAS5082_3.2.4.0",
	"name":"Acute pericarditis, predictors of prognosis"
},
{
	"jumpto":"ENAS5082_3.2.8.0",
	"name":"Acute pericarditis, prognosis"
},
{
	"jumpto":"ENAS5082_3.2.7.0",
	"name":"Acute pericarditis, treatment"
},
{
	"jumpto":"ENAS5082_3.2.4.0",
	"name":"Acute pericarditis, triage"
},
{
	"jumpto":"ENAS264_8.1.0.0",
	"name":"Acute thoracic aortic syndrome, classification"
},
{
	"jumpto":"ENAS264_8.1.0.0",
	"name":"Acute thoracic aortic syndrome, definition"
},
{
	"jumpto":"ENAS5081_6.2.5.0",
	"name":"Acute vasoreactivity test"
},
{
	"jumpto":"ENAS5531_12.4.0.0",
	"name":"Acute VTE, management [CVD Preg]"
},
{
	"jumpto":"ENAS5195_12.13.2.0",
	"name":"adaptive servo-ventilation (HF)"
},
{
	"jumpto":"ENAS5328_6.2.4.0",
	"name":"Additional diagnostic aspects, including assessment of prognostic parameters (VHD)"
},
{
	"jumpto":"ENAS5081_5.7.0.0",
	"name":"Adenosine, in vasoreactivity testing"
},
{
	"jumpto":"ENAS5329_6.2.1.0",
	"name":"Adjunctive therapy, overview (STEMI)"
},
{
	"jumpto":"ENAS5194_7.2.0.0",
	"name":"AF, acute and chronic management"
},
{
	"jumpto":"ENAS5194_9.2.0.0",
	"name":"AF, acute heart rate control"
},
{
	"jumpto":"ENAS5194_5.1.0.0",
	"name":"AF, classification"
},
{
	"jumpto":"ENAS5194_5.3.0.0",
	"name":"AF, clinical types"
},
{
	"jumpto":"ENAS5194_4.1.0.0",
	"name":"AF, diagnosis"
},
{
	"jumpto":"ENAS5194_3.0.0.0",
	"name":"AF, epidemiology"
},
{
	"jumpto":"ENAS5194_7.1.0.0",
	"name":"AF, integrated management"
},
{
	"jumpto":"ENAS5194_9.3.0.0",
	"name":"AF, long-term heart rate control"
},
{
	"jumpto":"ENAS5194_5.2.0.0",
	"name":"AF, patterns"
},
{
	"jumpto":"ENAS5194_8.5.0.0",
	"name":"AF, prediction of stroke and bleeding risk"
},
{
	"jumpto":"ENAS5194_6.1.0.0",
	"name":"AF, risk factors detection and management"
},
{
	"jumpto":"ENAS5194_4.3.0.0",
	"name":"AF, screening"
},
{
	"jumpto":"ENAS5194_7.3.0.0",
	"name":"AF, specialized service"
},
{
	"jumpto":"ENAS5194_8.3.0.0",
	"name":"AF, stroke prevention"
},
{
	"jumpto":"ENAS5194_11.5.0.0",
	"name":"AF after surgery"
},
{
	"jumpto":"ENAS5194_6.2.0.0",
	"name":"AF and newly diagnosed HF, management"
},
{
	"jumpto":"ENAS5194_11.4.0.0",
	"name":"AF and pregnacny"
},
{
	"jumpto":"ENAS5194_5.3.0.0",
	"name":"AF and SHD"
},
{
	"jumpto":"ENAS5194_11.3.0.0",
	"name":"AF and sports"
},
{
	"jumpto":"ENAS5194_5.3.0.0",
	"name":"AF in athletes"
},
{
	"jumpto":"ENAS5531_7.5.0.0",
	"name":"AF in native heart valve disease [CVD Preg]"
},
{
	"jumpto":"ENAS5194_6.3.0.0",
	"name":"AF in obese patients, mgmt."
},
{
	"jumpto":"ENAS5194_11.1.0.0",
	"name":"AF in the elderly patients"
},
{
	"jumpto":"ENAS5194_6.3.0.0",
	"name":"AF with kidney diseases, mgmt."
},
{
	"jumpto":"ENAS5194_5.3.0.0",
	"name":"AF with MS or prosthetic valves"
},
{
	"jumpto":"ENAS5194_6.3.0.0",
	"name":"AF with respiratory diseases, mgmt."
},
{
	"jumpto":"ENAS5194_6.3.0.0",
	"name":"AF with VHD, mgmt."
},
{
	"jumpto":"ENAS264_5.0.0.0",
	"name":"aging aorta"
},
{
	"jumpto":"ENAS5195_13.8.2.0",
	"name":"AHF, pharmacotherapy (HF)"
},
{
	"jumpto":"interactive_0001884",
	"name":"AHF during pregnancy, management (tool)"
},
{
	"jumpto":"ENAS5194_4.2.0.0",
	"name":"AHRE, mgmt. (AFib)"
},
{
	"jumpto":"ENAS5196_14.4.0.0",
	"name":"alcohol abuse, population-based approach (CVD prev)"
},
{
	"jumpto":"interactive_0001449",
	"name":"Algo. for DAPT in ACS undergoing CABG (tool)"
},
{
	"jumpto":"interactive_0001451",
	"name":"Algo. for DAPT in ACS with medical mgmt. (tool)"
},
{
	"jumpto":"ENAS5195_13.8.1.0",
	"name":"algorithm, management of AHF"
},
{
	"jumpto":"ENAS5326_8.5.0.0",
	"name":"Algorithm for DAPT in"
},
{
	"jumpto":"ENAS5326_6.2.0.0",
	"name":"Algorithm for DAPT in ACS undergoing CABG (DAPT)"
},
{
	"jumpto":"ENAS5326_7.2.0.0",
	"name":"Algorithm for DAPT in ACS with medical management (DAPT)"
},
{
	"jumpto":"ENAS5326_5.4.0.0",
	"name":"Algorithm for DAPT in PCI"
},
{
	"jumpto":"interactive_0001452",
	"name":"Algorithm for DAPT in PCI (tool)"
},
{
	"jumpto":"ENAS5082_2.0.0.0",
	"name":"Allergic granulomatosis"
},
{
	"jumpto":"ENAS5195_12.11.0.0",
	"name":"alpha-adrenoceptor antagonists (HF)"
},
{
	"jumpto":"ENAS5329_6.3.2.0",
	"name":"Alteplase (STEMI)"
},
{
	"jumpto":"ENAS5081_6.2.3.4",
	"name":"Ambrisentan + sildenafil, PAH sequential combination therapy"
},
{
	"jumpto":"ENAS5081_6.2.3.3",
	"name":"Ambrisentan + tadalafil, PAH combination therapy"
},
{
	"jumpto":"ENAS5081_6.2.3.2",
	"name":"Ambrisentan, PAH monotherapy"
},
{
	"jumpto":"ENAS5081_6.2.3.4",
	"name":"Ambrisentan added to sildenafil, PH"
},
{
	"jumpto":"ENAS5533_3.5.0.0",
	"name":"Ambulatory blood pressure monitoring [HTN]"
},
{
	"jumpto":"ENAS5083_4.3.1.0",
	"name":"Ambulatory ECG, non-invasive VA screening"
},
{
	"jumpto":"ENAS5329_3.2.0.0",
	"name":"AMI (STEMI)"
},
{
	"jumpto":"ENAS5194_9.4.0.0",
	"name":"Amiodarone (AFib)"
},
{
	"jumpto":"ENAS5194_10.1.3.0",
	"name":"Amiodarone (AFib)"
},
{
	"jumpto":"ENAS5195_11.2.0.0",
	"name":"amiodarone (HF)"
},
{
	"jumpto":"ENAS5083_6.1.3.0",
	"name":"Amiodarone (VA and SCD)"
},
{
	"jumpto":"ENAS5083_7.4.1.0",
	"name":"Amiodarone, SVT therapy"
},
{
	"jumpto":"ENAS5195_12.2.0.0",
	"name":"amlodipine (HF)"
},
{
	"jumpto":"ENAS5079_3.2.0.0",
	"name":"Amoxicillin, dental procedure prophylaxis"
},
{
	"jumpto":"ENAS5079_3.2.0.0",
	"name":"Ampicillin, dental procedure prophylaxis"
},
{
	"jumpto":"ENAS5327_11.5.0.0",
	"name":"Amputation risk, assessment [PAD]"
},
{
	"jumpto":"ENAS5083_8.4.1.0",
	"name":"Amyloidosis, cardiac"
},
{
	"jumpto":"ENAS5195_12.12.0.0",
	"name":"anaemia (HF)"
},
{
	"jumpto":"ENAS5081_6.2.2.2",
	"name":"Anaemia correction, PAH supportive therapy"
},
{
	"jumpto":"ENAS5082_3.3.4.0",
	"name":"Anakinra, in recurrent pericarditis"
},
{
	"jumpto":"ENAS261_10.0.0.0",
	"name":"aneasthesia, in non-cardiac surgery"
},
{
	"jumpto":"ENAS264_10.2.6.0",
	"name":"aneurysms-osteoarthritis syndrome"
},
{
	"jumpto":"ENAS258_7.2.0.0",
	"name":"angina, classification [SCAD]"
},
{
	"jumpto":"ENAS258_8.4.5.0",
	"name":"angina, microvascular: treatment [SCAD]"
},
{
	"jumpto":"ENAS258_7.8.2.0",
	"name":"angina, vasospastic [SCAD]"
},
{
	"jumpto":"ENAS5195_12.2.0.0",
	"name":"angina and coronary artery disease (HF)"
},
{
	"jumpto":"ENAS258_5.0.0.0",
	"name":"angina pectoris, epidemiology [SCAD]"
},
{
	"jumpto":"ENAS5327_7.1.2.0",
	"name":"Angiographic carotid stenosis [PAD]"
},
{
	"jumpto":"ENAS5081_6.2.2.2",
	"name":"Angiotensin-2 receptor antagonists (PH)"
},
{
	"jumpto":"ENAS5081_6.2.2.2",
	"name":"Angiotensin-converting enzyme inhibitors (PH)"
},
{
	"jumpto":"ENAS5195_8.4.0.0",
	"name":"angiotensin receptor blockers (HF)"
},
{
	"jumpto":"ENAS5195_8.4.0.0",
	"name":"angiotensin receptor neprilysin inhibitor (HF)"
},
{
	"jumpto":"ENAS5327_5.4.0.0",
	"name":"Ankle-brachial index"
},
{
	"jumpto":"interactive_0001465",
	"name":"Ankle-Brachial index (tool)"
},
{
	"jumpto":"ENAS5193_3.1.1.2",
	"name":"anthracyclines, cardiotoxicity"
},
{
	"jumpto":"ENAS5193_4.3.1.0",
	"name":"anthracyclines prevention, cardiotoxicity"
},
{
	"jumpto":"ENAS5083_5.4.2.0",
	"name":"Anti-arrhythmic surgery"
},
{
	"jumpto":"ENAS5079_12.0.0.0",
	"name":"Anti-thrombotic therapy (IE)"
},
{
	"jumpto":"ENAS5079_3.7.0.0",
	"name":"Antibiotic prophylaxis in IE, summary"
},
{
	"jumpto":"interactive_0000554",
	"name":"Anticoag. after ICH (interactive algorithm)"
},
{
	"jumpto":"interactive_0000553",
	"name":"Anticoag. after stroke or TIA (interactive algorithm)"
},
{
	"jumpto":"ENAS5329_6.3.2.0",
	"name":"Anticoagulant co-therapies, doses (STEMI)"
},
{
	"jumpto":"ENAS5329_6.2.3.0",
	"name":"Anticoagulant doses (STEMI)"
},
{
	"jumpto":"ENAS5329_6.2.2.0",
	"name":"Anticoagulant therapy (STEMI)"
},
{
	"jumpto":"ENAS5328_4.8.0.0",
	"name":"Anticoagulation (VHD)"
},
{
	"jumpto":"ENAS5328_12.1.0.0",
	"name":"Anticoagulation-related bleeding (VHD)"
},
{
	"jumpto":"ENAS5194_8.9.3.0",
	"name":"anticoagulation after ICH (AFib)"
},
{
	"jumpto":"ENAS5194_8.9.2.0",
	"name":"anticoagulation after stroke or TIA (AFib)"
},
{
	"jumpto":"ENAS5329_6.3.1.0",
	"name":"Anticoagulation co-therapy, fibrinolysis (STEMI)"
},
{
	"jumpto":"interactive_0001871",
	"name":"Anticoagulation in mechanical valves"
},
{
	"jumpto":"ENAS5531_7.6.2.0",
	"name":"Anticoagulation in mechanical valves: High dose VKA [CVD Preg]"
},
{
	"jumpto":"ENAS5531_7.6.3.0",
	"name":"Anticoagulation in mechanical valves: Low dose VKA [CVD Preg]"
},
{
	"jumpto":"ENAS5532_18.1.0.0",
	"name":"Antiplatelet and anticoagulant drugs doses [MR]"
},
{
	"jumpto":"ENAS5329_6.3.2.0",
	"name":"Antiplatelet co-therapies, doses (STEMI)"
},
{
	"jumpto":"ENAS5329_6.3.1.0",
	"name":"Antiplatelet co-therapy, fibrinolysis (STEMI)"
},
{
	"jumpto":"ENAS5329_6.2.3.0",
	"name":"Antiplatelet doses (STEMI)"
},
{
	"jumpto":"ENAS5196_12.4.0.0",
	"name":"antiplatelet therapy (CVD prev)"
},
{
	"jumpto":"ENAS5329_6.2.2.0",
	"name":"Antiplatelet therapy (STEMI)"
},
{
	"jumpto":"ENAS257_8.5.0.0",
	"name":"antiplatelet therapy, diabetes mellitus [DM]"
},
{
	"jumpto":"interactive_0001436",
	"name":"Antiplatelet therapy in LEAD (tool)"
},
{
	"jumpto":"ENAS5080_5.5.3.0",
	"name":"Antiplatelet therapy in NSTE-ACS, perioperative mgmt."
},
{
	"jumpto":"ENAS261_7.5.0.0",
	"name":"antiplatelt agents/anticoagulants, risk reduction in non-cardiac surgery"
},
{
	"jumpto":"interactive_0000556",
	"name":"Antithromb. therapy after ACS (interactive algorithm)"
},
{
	"jumpto":"interactive_0000557",
	"name":"Antithromb. therapy after PCI (interactive algorithm)"
},
{
	"jumpto":"ENAS5329_7.2.3.0",
	"name":"Antithrombotic agents, recommended doses (STEMI)"
},
{
	"jumpto":"ENAS5532_18.1.0.0",
	"name":"Antithrombotic drugs for MR"
},
{
	"jumpto":"interactive_0001879",
	"name":"Antithrombotic drugs in PCI (tool)"
},
{
	"jumpto":"ENAS5329_8.2.0.0",
	"name":"Antithrombotic strategy after STEMI, maintenance"
},
{
	"jumpto":"ENAS5194_8.11.2.0",
	"name":"antithrombotic therapy after ACS (AFib)"
},
{
	"jumpto":"ENAS5194_8.11.3.0",
	"name":"antithrombotic therapy after PCI (AFib)"
},
{
	"jumpto":"ENAS5328_12.2.4.0",
	"name":"Antithrombotic therapy in patients with mechanical"
},
{
	"jumpto":"ENAS5532_18.2.0.0",
	"name":"Antithrombotic treatment in SCAD undergoing PCI"
},
{
	"jumpto":"interactive_0001439",
	"name":"Antithrombotic Tx in LEAD requiring OAC (tool)"
},
{
	"jumpto":"ENAS5532_18.3.0.0",
	"name":"Antithrombotic Tx in NSTE-ACS syndromes undergoing PCI [MR]"
},
{
	"jumpto":"ENAS5532_18.5.0.0",
	"name":"Antithrombotic Tx in STEMI Pts. undergoing PCI [MR]"
},
{
	"jumpto":"ENAS264_6.3.6.0",
	"name":"aorta, 3D-reconstruction"
},
{
	"jumpto":"ENAS264_5.0.0.0",
	"name":"aorta, aging"
},
{
	"jumpto":"ENAS264_11.4.0.0",
	"name":"aorta, calcified"
},
{
	"jumpto":"ENAS264_6.1.0.0",
	"name":"aorta, clinical examination"
},
{
	"jumpto":"ENAS264_10.4.0.0",
	"name":"aorta, coarctation"
},
{
	"jumpto":"ENAS264_6.3.2.0",
	"name":"aorta, comparison of imaging methods"
},
{
	"jumpto":"ENAS264_11.5.0.0",
	"name":"aorta, coral reef"
},
{
	"jumpto":"ENAS264_6.3.5.0",
	"name":"aorta, cross-sectional/long-axis US of abd. aorta"
},
{
	"jumpto":"ENAS264_10.2.3.0",
	"name":"aorta, Ehlers-Danlos syndrome type IV or vascular type"
},
{
	"jumpto":"ENAS264_10.1.0.0",
	"name":"aorta, genetic diseases"
},
{
	"jumpto":"ENAS264_6.3.1.0",
	"name":"aorta, imaging methods"
},
{
	"jumpto":"ENAS264_6.2.0.0",
	"name":"aorta, laboratory testing"
},
{
	"jumpto":"ENAS264_10.2.4.0",
	"name":"aorta, Loeys-Dietz syndrome"
},
{
	"jumpto":"ENAS264_6.3.4.0",
	"name":"aorta, long-axis and cross-sectional TOE"
},
{
	"jumpto":"ENAS264_10.2.2.0",
	"name":"aorta, Marfan syndrome"
},
{
	"jumpto":"ENAS264_11.2.0.0",
	"name":"aorta, mobile aortic thrombosis"
},
{
	"jumpto":"ENAS264_10.2.7.0",
	"name":"aorta, non-syndromic familia TAAD"
},
{
	"jumpto":"ENAS264_6.3.3.0",
	"name":"aorta, parasternal and suprasternal TTE"
},
{
	"jumpto":"ENAS264_5.0.0.0",
	"name":"aorta, segments"
},
{
	"jumpto":"ENAS264_11.1.0.0",
	"name":"aorta, thromboembolic disease"
},
{
	"jumpto":"ENAS264_10.2.1.0",
	"name":"aorta, Turner syndrome"
},
{
	"jumpto":"ENAS264_9.1.0.0",
	"name":"aortic aneurysms, overview"
},
{
	"jumpto":"ENAS264_7.3.4.0",
	"name":"aortic diseases, arch debranching"
},
{
	"jumpto":"ENAS264_7.2.0.0",
	"name":"aortic diseases, endovascular therapy"
},
{
	"jumpto":"ENAS264_14.3.0.0",
	"name":"aortic diseases, follow-up after thoracic intervention"
},
{
	"jumpto":"ENAS264_7.3.5.0",
	"name":"aortic diseases, left heart bypass"
},
{
	"jumpto":"ENAS264_14.1.0.0",
	"name":"aortic diseases, long-term follow-up"
},
{
	"jumpto":"ENAS264_7.1.0.0",
	"name":"aortic diseases, medical therapy"
},
{
	"jumpto":"ENAS264_4.0.0.0",
	"name":"aortic diseases, overview"
},
{
	"jumpto":"ENAS264_7.3.1.0",
	"name":"aortic diseases, surgery"
},
{
	"jumpto":"ENAS264_10.3.0.0",
	"name":"aortic diseases, with bicuspid aortic valve"
},
{
	"jumpto":"ENAS5531_6.0.0.0",
	"name":"Aortic diseases [CVD Preg]"
},
{
	"jumpto":"ENAS5329_6.3.3.0",
	"name":"Aortic dissection (STEMI)"
},
{
	"jumpto":"ENAS5080_3.3.0.0",
	"name":"Aortic dissection; Renal dysfunction and associated cardiac disease"
},
{
	"jumpto":"ENAS264_8.5.0.0",
	"name":"aortic pseudoaneurysm"
},
{
	"jumpto":"ENAS5328_4.2.2.0",
	"name":"Aortic regurgitation (VHD)"
},
{
	"jumpto":"ENAS5328_5.2.0.0",
	"name":"Aortic regurgitation, evaluation (VHD)"
},
{
	"jumpto":"ENAS5328_5.4.0.0",
	"name":"Aortic regurgitation, medical therapy (VHD)"
},
{
	"jumpto":"ENAS5328_5.1.0.0",
	"name":"Aortic regurgitation, overview (VHD)"
},
{
	"jumpto":"ENAS5328_5.5.0.0",
	"name":"Aortic regurgitation, serial testing (VHD)"
},
{
	"jumpto":"ENAS5328_5.6.0.0",
	"name":"Aortic regurgitation, special patient populations (VHD)"
},
{
	"jumpto":"ENAS264_7.3.2.0",
	"name":"aortic root surgery"
},
{
	"jumpto":"ENAS5328_6.2.1.0",
	"name":"Aortic stenosis, evaluation (VHD)"
},
{
	"jumpto":"ENAS5328_6.4.0.0",
	"name":"Aortic stenosis, medical therapy (VHD)"
},
{
	"jumpto":"ENAS5328_6.1.0.0",
	"name":"Aortic stenosis, overview (VHD)"
},
{
	"jumpto":"ENAS5328_6.5.0.0",
	"name":"Aortic stenosis, serial testing (VHD)"
},
{
	"jumpto":"ENAS5328_6.6.0.0",
	"name":"Aortic stenosis, special patient populations (VHD)"
},
{
	"jumpto":"ENAS264_6.4.0.0",
	"name":"aortic stiffness"
},
{
	"jumpto":"ENAS264_13.0.0.0",
	"name":"aortic tumours"
},
{
	"jumpto":"ENAS264_12.0.0.0",
	"name":"aortitis"
},
{
	"jumpto":"ENAS5326_8.1.0.0",
	"name":"Apixaban (DAPT)"
},
{
	"jumpto":"ENAS5195_13.6.0.0",
	"name":"applied diagnostic measurements (HF)"
},
{
	"jumpto":"ENAS5329_8.3.0.0",
	"name":"ARBs (STEMI)"
},
{
	"jumpto":"ENAS257_11.1.0.0",
	"name":"arrhythmia, mgmt. in DM"
},
{
	"jumpto":"ENAS5083_13.3.1.0",
	"name":"Arrhythmia, not related to peripartum cardiomyopathy"
},
{
	"jumpto":"ENAS5083_13.3.2.0",
	"name":"Arrhythmia, related to peripartum cardiomyopathy"
},
{
	"jumpto":"ENAS5193_3.4.1.1",
	"name":"arrhythmias, cardiotoxicity"
},
{
	"jumpto":"ENAS5195_11.1.0.0",
	"name":"arrhythmias, overview (HF)"
},
{
	"jumpto":"ENAS5329_9.3.0.0",
	"name":"Arrhythmias and conduction disturbances (STEMI)"
},
{
	"jumpto":"ENAS5531_10.1.0.0",
	"name":"Arrhythmias [CVD Preg]"
},
{
	"jumpto":"ENAS5530_4.1.0.0",
	"name":"Arrhythmia [Sync]"
},
{
	"jumpto":"ENAS5083_13.3.1.0",
	"name":"Arrhythmic risk, during pregnancy"
},
{
	"jumpto":"ENAS5083_13.2.1.0",
	"name":"Arrhythmic risk, in neuromuscular disorders"
},
{
	"jumpto":"ENAS5083_13.1.0.0",
	"name":"Arrhythmic risk, in psychiatric patients"
},
{
	"jumpto":"ENAS5083_13.3.1.0",
	"name":"Arrhythmic risk in pregnancy, management"
},
{
	"jumpto":"ENAS5530_26.4.0.0",
	"name":"Arrhythmogenic right ventricular cardiomyopathy [Sync]"
},
{
	"jumpto":"ENAS5083_8.3.0.0",
	"name":"Arrhythmogenic RV cardiomyopathy (ARVC)"
},
{
	"jumpto":"ENAS5193_3.5.1.0",
	"name":"arterial hypertension, cardiotoxicity"
},
{
	"jumpto":"ENAS261_8.2.0.0",
	"name":"Arterial hypertension in non-cardiac surgery"
},
{
	"jumpto":"ENAS5193_3.5.3.0",
	"name":"arterial hypertension key points, cardiotoxicity"
},
{
	"jumpto":"ENAS5193_3.5.2.0",
	"name":"arterial hypertension mgmt., cardiotoxicity"
},
{
	"jumpto":"ENAS5193_3.6.1.2",
	"name":"arterial thrombosis, cardiotoxicity"
},
{
	"jumpto":"ENAS264_10.2.5.0",
	"name":"Arterial tortuosity syndrome"
},
{
	"jumpto":"ENAS5329_6.3.3.0",
	"name":"Arteriovenous malformation (STEMI)"
},
{
	"jumpto":"ENAS5083_8.3.0.0",
	"name":"ARVC, prevention of SCD"
},
{
	"jumpto":"ENAS264_7.3.3.0",
	"name":"ascending aortic and aortic arch surgery"
},
{
	"jumpto":"ENAS5081_5.1.0.0",
	"name":"Ascites (PH)"
},
{
	"jumpto":"interactive_0001433",
	"name":"AS management &amp; elective non-cardiac surgery (tool)"
},
{
	"jumpto":"ENAS5079_5.3.2.0",
	"name":"Aspergillus spp (IE)"
},
{
	"jumpto":"ENAS5080_5.1.0.0",
	"name":"Aspirin (NSTE-ACS)"
},
{
	"jumpto":"ENAS5329_6.2.3.0",
	"name":"Aspirin (STEMI)"
},
{
	"jumpto":"ENAS5328_12.2.4.0",
	"name":"Aspirin (VHD)"
},
{
	"jumpto":"ENAS5082_3.2.5.0",
	"name":"Aspirin, acute pericarditis"
},
{
	"jumpto":"ENAS5082_3.2.6.0",
	"name":"Aspirin, anti-inflammatory therapy (Pericard.)"
},
{
	"jumpto":"ENAS5326_6.2.0.0",
	"name":"Aspirin, in ACS undergoing CABG (DAPT)"
},
{
	"jumpto":"ENAS5326_7.2.0.0",
	"name":"Aspirin, in ACS with medical management (DAPT)"
},
{
	"jumpto":"ENAS5327_6.2.0.0",
	"name":"Aspirin, in CA stenosis [PAD]"
},
{
	"jumpto":"ENAS5082_6.1.2.0",
	"name":"Aspirin, in paediatric pericardial diseases"
},
{
	"jumpto":"ENAS5326_5.4.0.0",
	"name":"Aspirin, in PCI (DAPT)"
},
{
	"jumpto":"ENAS5082_3.3.2.0",
	"name":"Aspirin, in recurrent pericarditis"
},
{
	"jumpto":"ENAS5326_4.2.2.0",
	"name":"Aspirin, P2Y12 inhibitor selection (DAPT)"
},
{
	"jumpto":"ENAS5194_8.11.2.0",
	"name":"Aspirin after ACS (AFib)"
},
{
	"jumpto":"ENAS5194_8.11.3.0",
	"name":"Aspirin after PCI (AFib)"
},
{
	"jumpto":"interactive_0001432",
	"name":"Assessment of AS severity (tool)"
},
{
	"jumpto":"ENAS5328_6.2.2.0",
	"name":"Assessment of AS severity (VHD)"
},
{
	"jumpto":"ENAS5533_3.2.0.0",
	"name":"Assessment of CVD risk [HTN]"
},
{
	"jumpto":"ENAS5329_11.0.0.0",
	"name":"Assessment of quality of care (STEMI)"
},
{
	"jumpto":"ENAS5327_11.5.0.0",
	"name":"Assessment of the risk of amputation [PAD]"
},
{
	"jumpto":"ENAS5328_6.3.1.0",
	"name":"Asymptomatic patients with severe aortic stenosis, recommendations (VHD)"
},
{
	"jumpto":"ENAS264_11.3.0.0",
	"name":"atherosclerotic aortic occlusion"
},
{
	"jumpto":"ENAS5080_2.0.0.0",
	"name":"Atherosclerotic plaque rupture, type 1 M"
},
{
	"jumpto":"ENAS5194_11.6.0.0",
	"name":"Atrial arrhythmias in CHD (GUCH) (Afib)"
},
{
	"jumpto":"ENAS5196_13.1.0.0",
	"name":"atrial fibrillation (CVD prev)"
},
{
	"jumpto":"ENAS5080_5.4.2.0",
	"name":"Atrial fibrillation, antithrombotic strategies"
},
{
	"jumpto":"ENAS5193_3.4.2.2",
	"name":"atrial fibrillation, cardiotoxicity"
},
{
	"jumpto":"ENAS5329_9.3.0.0",
	"name":"Atrial fibrillation, management (STEMI)"
},
{
	"jumpto":"ENAS257_11.2.0.0",
	"name":"atrial fibrillation, mgmt. in DM"
},
{
	"jumpto":"ENAS5194_10.8.0.0",
	"name":"atrial fibrillation heart team"
},
{
	"jumpto":"ENAS5531_10.1.0.0",
	"name":"Atrial fibrillation [CVD Preg]"
},
{
	"jumpto":"ENAS5194_11.7.0.0",
	"name":"atrial flutter, management"
},
{
	"jumpto":"ENAS5531_10.1.0.0",
	"name":"Atrial flutter [CVD Preg]"
},
{
	"jumpto":"ENAS5194_4.2.0.0",
	"name":"atrial high rate episode, mgmt. (AFib)"
},
{
	"jumpto":"ENAS5530_4.1.0.0",
	"name":"Atrial myxoma [Sync]"
},
{
	"jumpto":"ENAS5531_5.6.0.0",
	"name":"Atrial septal defect [CVD Preg]"
},
{
	"jumpto":"ENAS259_4.3.1.0",
	"name":"atrioventricular block, indication for pacing [Pacing]"
},
{
	"jumpto":"ENAS259_5.3.2.0",
	"name":"atrioventricular junction ablation, indications"
},
{
	"jumpto":"ENAS5531_5.8.0.0",
	"name":"Atrioventricular septal defect [CVD Preg]"
},
{
	"jumpto":"ENAS258_7.2.0.0",
	"name":"atypical angina, definition [SCAD]"
},
{
	"jumpto":"ENAS5329_5.1.0.0",
	"name":"Atypical electrocardiographic presentations (STEMI)"
},
{
	"jumpto":"ENAS5196_9.10.3.0",
	"name":"autoimmune disease (CVD prev)"
},
{
	"jumpto":"ENAS5193_3.9.3.0",
	"name":"autonomic dysfunction, cardiotoxicity"
},
{
	"jumpto":"ENAS5530_12.0.0.0",
	"name":"Autonomic function tests [Sync]"
},
{
	"jumpto":"ENAS259_4.2.3.0",
	"name":"AV block, pacing mode"
},
{
	"jumpto":"ENAS5082_3.3.4.0",
	"name":"Azathioprine, in recurrent pericarditis"
},
{
	"jumpto":"ENAS5329_6.2.1.0",
	"name":"Balloon angioplasty (STEMI)"
},
{
	"jumpto":"ENAS5328_6.3.1.0",
	"name":"Balloon aortic valvotomy (VHD)"
},
{
	"jumpto":"ENAS5081_10.3.0.0",
	"name":"Balloon pulmonary angioplasty (BPA)"
},
{
	"jumpto":"ENAS5326_5.4.0.0",
	"name":"Bare-metal stent (DAPT)"
},
{
	"jumpto":"ENAS5079_5.3.2.0",
	"name":"Bartonella henselea (IE)"
},
{
	"jumpto":"ENAS5079_5.3.2.0",
	"name":"Bartonella Quintana (IE)"
},
{
	"jumpto":"ENAS5081_6.1.1.0",
	"name":"Basic lab (PH)"
},
{
	"jumpto":"ENAS5193_3.1.1.6",
	"name":"BCR-ABL kinase, cardiotoxicity"
},
{
	"jumpto":"ENAS5329_8.1.0.0",
	"name":"Behavioural aspects after STEMI"
},
{
	"jumpto":"ENAS5196_11.1.0.0",
	"name":"behaviour change (CVD prev)"
},
{
	"jumpto":"ENAS5082_2.0.0.0",
	"name":"Behcet syndrome"
},
{
	"jumpto":"ENAS5196_9.1.0.0",
	"name":"benefit, CVD prevention"
},
{
	"jumpto":"ENAS5081_6.2.3.2",
	"name":"Beraprost, PAH monotherapy"
},
{
	"jumpto":"ENAS5081_6.2.3.2",
	"name":"Beraprost, Prostanoids"
},
{
	"jumpto":"ENAS5195_7.0.0.0",
	"name":"beta-blocker (HF)"
},
{
	"jumpto":"ENAS5081_6.2.2.2",
	"name":"Beta-blockers (PH)"
},
{
	"jumpto":"ENAS5329_8.3.0.0",
	"name":"Beta-blockers (STEMI)"
},
{
	"jumpto":"ENAS261_7.1.0.0",
	"name":"beta-blockers, risk reduction in non-cardiac surgery"
},
{
	"jumpto":"ENAS5328_5.4.0.0",
	"name":"Beta blocker (VHD)"
},
{
	"jumpto":"ENAS5530_23.0.0.0",
	"name":"Bifascicular BBB and syncope"
},
{
	"jumpto":"ENAS5197_8.2.0.0",
	"name":"bile acid sequestrants, hypercholesterolaemia (Dyslip)"
},
{
	"jumpto":"ENAS5524_19.0.0.0",
	"name":"Biochemical approach, diagnosis of MI & myocard. injury [UDMI]"
},
{
	"jumpto":"ENAS5524_19.0.0.0",
	"name":"biochemical approach in diagnosis of MI [UDMI]"
},
{
	"jumpto":"ENAS5328_12.1.0.0",
	"name":"Biological valve (VHD)"
},
{
	"jumpto":"ENAS5524_6.0.0.0",
	"name":"Biomarker detection of myocardial injury & infarction [UDMI]"
},
{
	"jumpto":"ENAS5196_9.8.0.0",
	"name":"biomarkers (CVD prev)"
},
{
	"jumpto":"ENAS5328_4.2.1.0",
	"name":"Biomarkers, non-invasive investigation (VHD)"
},
{
	"jumpto":"ENAS5328_12.1.0.0",
	"name":"Bioprosthesis (VHD)"
},
{
	"jumpto":"ENAS5328_12.2.6.1",
	"name":"Bioprosthetic failure (VHD)"
},
{
	"jumpto":"ENAS5328_12.2.6.1",
	"name":"Bioprosthetic thrombosis (VHD)"
},
{
	"jumpto":"ENAS5326_5.2.0.0",
	"name":"Bioresorbable vascular scaffolds (DAPT)"
},
{
	"jumpto":"ENAS5194_9.4.0.0",
	"name":"Bisoprolo (AFib)"
},
{
	"jumpto":"ENAS5080_5.1.0.0",
	"name":"Bivalirudin (NSTE-ACS)"
},
{
	"jumpto":"ENAS5329_6.2.2.0",
	"name":"Bivalirudin (STEMI)"
},
{
	"jumpto":"ENAS5080_5.3.1.0",
	"name":"Bivalirudin, dosing (NSTE-ACS)"
},
{
	"jumpto":"interactive_0001440",
	"name":"Bleeding mgmt. with or without OAC (tool)"
},
{
	"jumpto":"ENAS5326_10.1.0.0",
	"name":"Bleeding mgmt. with or without OAC, gender and special populations (DAPT)"
},
{
	"jumpto":"ENAS5326_8.5.0.0",
	"name":"Bleeding risk (DAPT)"
},
{
	"jumpto":"ENAS5194_8.4.0.0",
	"name":"Bleeding risk factors in anticoag. pts. (AFib)"
},
{
	"jumpto":"ENAS5079_5.4.2.0",
	"name":"Blood culture, positive for IE"
},
{
	"jumpto":"ENAS5079_5.3.1.0",
	"name":"Blood cultures in IE"
},
{
	"jumpto":"ENAS5081_6.1.1.0",
	"name":"Blood gas analysis (PH)"
},
{
	"jumpto":"ENAS5196_5.0.0.0",
	"name":"blood pressure (CVD prev)"
},
{
	"jumpto":"ENAS5533_3.3.0.0",
	"name":"Blood pressure measurement [HTN]"
},
{
	"jumpto":"ENAS5326_5.4.0.0",
	"name":"BMS (DAPT)"
},
{
	"jumpto":"ENAS5196_11.5.0.0",
	"name":"body weight (CVD prev)"
},
{
	"jumpto":"ENAS5196_5.0.0.0",
	"name":"body weight (CVD prev)"
},
{
	"jumpto":"ENAS5081_6.1.1.0",
	"name":"Borg dyspnoea score (PH)"
},
{
	"jumpto":"ENAS5081_6.2.3.3",
	"name":"Bosentan + i.v.epoprostenol, PAH combination therapy"
},
{
	"jumpto":"ENAS5081_6.2.3.3",
	"name":"Bosentan + sildenafil + i.v. epoprostenol, PAH combination therapy"
},
{
	"jumpto":"ENAS5081_6.2.3.2",
	"name":"Bosentan, PAH monotherapy"
},
{
	"jumpto":"ENAS5081_6.2.3.4",
	"name":"Bosentan added to epoprostenol, PH"
},
{
	"jumpto":"ENAS5081_6.2.3.4",
	"name":"Bosentan added to sildenafil, PH"
},
{
	"jumpto":"ENAS5533_5.2.0.0",
	"name":"BP-lowering treatment [HTN]"
},
{
	"jumpto":"ENAS5533_5.2.0.0",
	"name":"BP thresholds for treatment [HTN]"
},
{
	"jumpto":"ENAS5533_5.3.0.0",
	"name":"BP treatment targets [HTN]"
},
{
	"jumpto":"ENAS259_4.1.2.0",
	"name":"bradyarrhythmia, classification [Pacing]"
},
{
	"jumpto":"ENAS259_4.1.2.0",
	"name":"bradyarrhythmia, clinical presentation [Pacing]"
},
{
	"jumpto":"ENAS259_4.1.3.0",
	"name":"bradyarrhythmia, diagnosis [Pacing]"
},
{
	"jumpto":"ENAS259_4.1.3.0",
	"name":"bradyarrhythmia, ECG monitoring [Pacing]"
},
{
	"jumpto":"ENAS259_4.1.1.0",
	"name":"bradyarrhythmia, epidemiology [Pacing]"
},
{
	"jumpto":"ENAS5083_13.4.0.0",
	"name":"Bradyarrhythmia, in sleep apnea"
},
{
	"jumpto":"ENAS259_4.1.3.0",
	"name":"bradyarrhythmia, symptoms"
},
{
	"jumpto":"ENAS5531_10.3.0.0",
	"name":"Bradyarrhythmias [CVD Preg]"
},
{
	"jumpto":"ENAS259_4.1.3.0",
	"name":"bradyarrhythmic syncope, diagnosis"
},
{
	"jumpto":"ENAS259_4.3.1.0",
	"name":"bradycardia, intermittent (documented)"
},
{
	"jumpto":"ENAS5195_11.6.0.0",
	"name":"bradycardia, management (HF)"
},
{
	"jumpto":"ENAS259_4.2.1.0",
	"name":"bradycardia, persistent"
},
{
	"jumpto":"ENAS259_4.1.3.0",
	"name":"bradycardia, symptoms"
},
{
	"jumpto":"ENAS5193_3.4.2.3",
	"name":"bradycardia and atrioventricular block, cardiotoxicity"
},
{
	"jumpto":"ENAS5328_12.2.5.0",
	"name":"Bridging steps for an intervention requiring"
},
{
	"jumpto":"ENAS5079_5.3.2.0",
	"name":"Brucella spp (IE)"
},
{
	"jumpto":"ENAS5083_9.4.1.0",
	"name":"Brugada syndrome, diagnosis"
},
{
	"jumpto":"ENAS5083_9.4.2.0",
	"name":"Brugada syndrome, risk stratification and management"
},
{
	"jumpto":"ENAS5530_26.6.0.0",
	"name":"Brugada syndrome [Sync]"
},
{
	"jumpto":"ENAS5083_4.3.3.0",
	"name":"Bundle-branch re-entrant tachycardia (VA and SCD)"
},
{
	"jumpto":"ENAS259_4.4.1.0",
	"name":"bundle branch block, clinical perspectives"
},
{
	"jumpto":"ENAS5329_5.1.0.0",
	"name":"Bundle branch block, ECG presentation (STEMI)"
},
{
	"jumpto":"ENAS259_4.4.1.0",
	"name":"bundle branch block, indications for cardiac pacing"
},
{
	"jumpto":"ENAS259_4.4.1.0",
	"name":"bundle branch block, therapeutic algorithm"
},
{
	"jumpto":"ENAS5083_7.4.3.0",
	"name":"Bundle branch re-entrant tachycardia"
},
{
	"jumpto":"ENAS5326_6.1.0.0",
	"name":"CABG (DAPT)"
},
{
	"jumpto":"ENAS5195_12.2.0.0",
	"name":"CABG (HF)"
},
{
	"jumpto":"ENAS5532_16.0.0.0",
	"name":"CABG, procedural aspects [MR]"
},
{
	"jumpto":"ENAS5532_16.0.0.0",
	"name":"CABG, technical aspects [MR]"
},
{
	"jumpto":"ENAS5195_12.3.0.0",
	"name":"cachexia and sarcopenia (HF)"
},
{
	"jumpto":"ENAS5327_7.1.4.0",
	"name":"CAD asymptomatic, management of [PAD]"
},
{
	"jumpto":"ENAS5533_4.1.2.0",
	"name":"Café-au-lait patches [HTN]"
},
{
	"jumpto":"ENAS264_11.4.0.0",
	"name":"calcified aorta"
},
{
	"jumpto":"ENAS5328_6.2.2.0",
	"name":"Calcium score CT (VHD)"
},
{
	"jumpto":"ENAS5328_6.2.3.0",
	"name":"Calcium score MSCT (VHD)"
},
{
	"jumpto":"ENAS5195_12.4.0.0",
	"name":"cancer (HF)"
},
{
	"jumpto":"ENAS262_10.2.0.0",
	"name":"cancer, pulmonary embolism"
},
{
	"jumpto":"ENAS5193_4.2.0.0",
	"name":"cancer, thromboembolic events, prevention"
},
{
	"jumpto":"ENAS5193_5.1.0.0",
	"name":"cancer patients, long-term surveillance"
},
{
	"jumpto":"ENAS5196_9.10.2.0",
	"name":"cancer treated patients (CVD prev)"
},
{
	"jumpto":"ENAS5193_3.1.1.1",
	"name":"cancer treatment, heart failure"
},
{
	"jumpto":"ENAS5193_3.1.1.1",
	"name":"cancer treatment, LV dysfunction"
},
{
	"jumpto":"ENAS5080_5.1.0.0",
	"name":"Cangrelor (NSTE-ACS)"
},
{
	"jumpto":"ENAS5329_6.2.2.0",
	"name":"Cangrelor (STEMI)"
},
{
	"jumpto":"ENAS5080_5.2.1.0",
	"name":"Cangrelor, P2Y12 inhibitor (NSTE-ACS)"
},
{
	"jumpto":"ENAS5329_5.3.0.0",
	"name":"Cardiac arrest (STEMI)"
},
{
	"jumpto":"ENAS5327_13.1.0.0",
	"name":"Cardiac conditions in PAD"
},
{
	"jumpto":"ENAS5195_6.1.0.0",
	"name":"cardiac imaging, overview (HF)"
},
{
	"jumpto":"ENAS5195_6.2.0.0",
	"name":"cardiac imaging, suspected or established heart failure"
},
{
	"jumpto":"ENAS5081_5.2.0.0",
	"name":"Cardiac magnetic resonance (PH)"
},
{
	"jumpto":"ENAS5195_6.2.0.0",
	"name":"cardiac magnetic resonance, CMR (HF)"
},
{
	"jumpto":"ENAS5524_23.3.0.0",
	"name":"Cardiac magnetic resonance imaging [UDMI]"
},
{
	"jumpto":"ENAS5530_21.0.0.0",
	"name":"Cardiac pacing in reflex syncope [Sync]"
},
{
	"jumpto":"ENAS259_5.1.0.0",
	"name":"cardiac resynchronization therapy (CRT)"
},
{
	"jumpto":"ENAS5195_9.2.0.0",
	"name":"cardiac resynchronization therapy (HF)"
},
{
	"jumpto":"ENAS259_5.1.0.0",
	"name":"cardiac resynchronization therapy, implantation rate of devices"
},
{
	"jumpto":"ENAS259_6.2.0.0",
	"name":"cardiac surgery, pacing [Pacing]"
},
{
	"jumpto":"ENAS5326_6.1.0.0",
	"name":"Cardiac surgery with stable or unstable CAD, recommendations (DAPT)"
},
{
	"jumpto":"ENAS5530_4.1.0.0",
	"name":"Cardiac syncope"
},
{
	"jumpto":"ENAS5530_5.3.0.0",
	"name":"Cardiac syncope, clinical features"
},
{
	"jumpto":"ENAS5530_24.0.0.0",
	"name":"Cardiac tachyarrhythmia syncope, treatment"
},
{
	"jumpto":"ENAS5082_3.6.2.0",
	"name":"Cardiac tamponade (Pericard.)"
},
{
	"jumpto":"ENAS5082_3.7.2.0",
	"name":"Cardiac tamponade, causes"
},
{
	"jumpto":"ENAS5082_3.7.1.0",
	"name":"Cardiac tamponade, definition"
},
{
	"jumpto":"ENAS5082_3.7.3.0",
	"name":"Cardiac tamponade, treatment"
},
{
	"jumpto":"ENAS5524_20.0.0.0",
	"name":"Cardiac troponins, analytical issues [UDMI]"
},
{
	"jumpto":"ENAS5195_13.8.4.0",
	"name":"cardiogenic shock, management (HF)"
},
{
	"jumpto":"ENAS5329_9.2.0.0",
	"name":"Cardiogenic shock, mgmt. (STEMI)"
},
{
	"jumpto":"interactive_0001863",
	"name":"Cardiogenic shock, mgmt. (tool)"
},
{
	"jumpto":"ENAS5532_9.0.0.0",
	"name":"Cardiogenic shock management [MR]"
},
{
	"jumpto":"ENAS5530_4.2.0.0",
	"name":"Cardioinhibition [Sync]"
},
{
	"jumpto":"ENAS5080_3.1.0.0",
	"name":"Cardiomyocyte injury, biomarker"
},
{
	"jumpto":"ENAS5531_9.1.0.0",
	"name":"Cardiomyopathies and heart failure [CVD Preg]"
},
{
	"jumpto":"ENAS5083_8.4.3.0",
	"name":"Cardiomyopathy, Chagas’"
},
{
	"jumpto":"ENAS5083_8.1.1.0",
	"name":"Cardiomyopathy, dilated (VA and SCD)"
},
{
	"jumpto":"ENAS259_6.4.0.0",
	"name":"cardiomyopathy, hypertrophic, pacing therapy [Pacing]"
},
{
	"jumpto":"ENAS5083_8.4.1.0",
	"name":"Cardiomyopathy, infiltrative (VA and SCD)"
},
{
	"jumpto":"ENAS5083_8.4.2.0",
	"name":"Cardiomyopathy, restrictive (VA and SCD)"
},
{
	"jumpto":"ENAS5193_4.1.6.0",
	"name":"cardioprotective interventions, non-pharmacological"
},
{
	"jumpto":"ENAS5195_6.3.0.0",
	"name":"cardiopulmonary exercise testing (HF)"
},
{
	"jumpto":"ENAS5081_6.1.2.0",
	"name":"Cardiopulmonary exercise testing (PH)"
},
{
	"jumpto":"ENAS5081_6.1.1.0",
	"name":"Cardiopulmonary exercise testing (PH)"
},
{
	"jumpto":"ENAS5193_6.0.0.0",
	"name":"cardiotixicity, future perspective"
},
{
	"jumpto":"ENAS5195_12.4.0.0",
	"name":"cardiotoxic cytotoxics (HF)"
},
{
	"jumpto":"ENAS5193_3.1.1.2",
	"name":"cardiotoxicity, anthracyclines"
},
{
	"jumpto":"ENAS5193_4.3.1.0",
	"name":"cardiotoxicity, anthracyclines prevention"
},
{
	"jumpto":"ENAS5193_3.4.1.1",
	"name":"cardiotoxicity, arrhythmias"
},
{
	"jumpto":"ENAS5193_3.5.1.0",
	"name":"cardiotoxicity, arterial hypertension"
},
{
	"jumpto":"ENAS5193_3.5.3.0",
	"name":"cardiotoxicity, arterial hypertension key points"
},
{
	"jumpto":"ENAS5193_3.5.2.0",
	"name":"cardiotoxicity, arterial hypertension mgmt."
},
{
	"jumpto":"ENAS5193_3.6.1.2",
	"name":"cardiotoxicity, arterial thrombosis"
},
{
	"jumpto":"ENAS5193_3.4.2.2",
	"name":"cardiotoxicity, atrial fibrillation"
},
{
	"jumpto":"ENAS5193_3.9.3.0",
	"name":"cardiotoxicity, autonomic dysfunction"
},
{
	"jumpto":"ENAS5193_3.1.1.6",
	"name":"cardiotoxicity, BCR-ABL kinase"
},
{
	"jumpto":"ENAS5193_3.4.2.3",
	"name":"cardiotoxicity, bradycardia and atrioventricular block"
},
{
	"jumpto":"ENAS5193_3.1.1.3",
	"name":"cardiotoxicity, chemotherapies"
},
{
	"jumpto":"ENAS5193_3.4.1.5",
	"name":"cardiotoxicity, conduction defects"
},
{
	"jumpto":"ENAS5193_3.2.1.1",
	"name":"cardiotoxicity, CVD"
},
{
	"jumpto":"ENAS5193_3.1.2.2",
	"name":"cardiotoxicity, CV management anthracyclines"
},
{
	"jumpto":"ENAS5193_3.1.2.3",
	"name":"cardiotoxicity, CV management anti-HER2"
},
{
	"jumpto":"ENAS5193_3.1.2.4",
	"name":"cardiotoxicity, CV management VEGF inhibitors"
},
{
	"jumpto":"ENAS5193_3.1.2.2",
	"name":"cardiotoxicity, CV mgmt. anthracyclines"
},
{
	"jumpto":"ENAS5193_3.1.2.3",
	"name":"cardiotoxicity, CV mgmt. anti-HER2"
},
{
	"jumpto":"ENAS5193_3.1.2.4",
	"name":"cardiotoxicity, CV mgmt. VEGF inhibitors"
},
{
	"jumpto":"ENAS5193_3.1.2.6",
	"name":"cardiotoxicity, diagnostic tools"
},
{
	"jumpto":"ENAS5193_3.1.2.1",
	"name":"cardiotoxicity, early detection strategies"
},
{
	"jumpto":"ENAS5193_3.10.2.0",
	"name":"cardiotoxicity, elderly patients"
},
{
	"jumpto":"ENAS5193_3.2.1.2",
	"name":"cardiotoxicity, fluoropyrimidines"
},
{
	"jumpto":"ENAS5193_4.1.4.0",
	"name":"cardiotoxicity, global longitudinal strain reduction"
},
{
	"jumpto":"ENAS5193_4.1.5.0",
	"name":"cardiotoxicity, heart failure"
},
{
	"jumpto":"ENAS5193_4.3.2.0",
	"name":"cardiotoxicity, HER-2 targeted therapy prevention"
},
{
	"jumpto":"ENAS5193_3.1.1.4",
	"name":"cardiotoxicity, immunotherapies"
},
{
	"jumpto":"ENAS5193_3.1.3.0",
	"name":"cardiotoxicity, key points"
},
{
	"jumpto":"ENAS5193_4.1.3.0",
	"name":"cardiotoxicity, LVEF reduction"
},
{
	"jumpto":"ENAS5193_3.1.2.2",
	"name":"cardiotoxicity, mgmt. of patients treated with anthracyclines"
},
{
	"jumpto":"ENAS5193_3.1.2.3",
	"name":"cardiotoxicity, mgmt. of patients treated with anti-HER2"
},
{
	"jumpto":"ENAS5193_3.1.2.4",
	"name":"cardiotoxicity, mgmt. of patients treated with VEGF inhibitors"
},
{
	"jumpto":"ENAS5193_3.10.1.0",
	"name":"cardiotoxicity, paediatric population"
},
{
	"jumpto":"ENAS5193_3.7.1.1",
	"name":"cardiotoxicity, peripheral vascular disease"
},
{
	"jumpto":"ENAS5193_3.7.2.0",
	"name":"cardiotoxicity, peripheral vascular disease mgmt."
},
{
	"jumpto":"ENAS5193_3.9.2.0",
	"name":"cardiotoxicity, pleural effusion"
},
{
	"jumpto":"ENAS5193_3.10.3.0",
	"name":"cardiotoxicity, pregnant women"
},
{
	"jumpto":"ENAS5193_4.1.1.0",
	"name":"cardiotoxicity, prevention"
},
{
	"jumpto":"ENAS5193_3.1.1.7",
	"name":"cardiotoxicity, proteasome inhibitors"
},
{
	"jumpto":"ENAS5193_3.8.1.0",
	"name":"cardiotoxicity, pulmonary hypertension"
},
{
	"jumpto":"ENAS5193_3.8.2.0",
	"name":"cardiotoxicity, pulmonary hypertension mgmt."
},
{
	"jumpto":"ENAS5193_4.3.3.0",
	"name":"cardiotoxicity, pyrimidine analogues prevention"
},
{
	"jumpto":"ENAS5193_3.4.1.2",
	"name":"cardiotoxicity, QT prolongation"
},
{
	"jumpto":"ENAS5193_3.4.2.1",
	"name":"cardiotoxicity, QT prolongation, risk factors"
},
{
	"jumpto":"ENAS5193_3.1.1.8",
	"name":"cardiotoxicity, radiotherapy"
},
{
	"jumpto":"ENAS5193_3.2.3.0",
	"name":"cardiotoxicity, radiotherapy, key points"
},
{
	"jumpto":"ENAS5193_3.2.2.0",
	"name":"cardiotoxicity, radiotherapy, mgmt."
},
{
	"jumpto":"ENAS5193_4.3.5.0",
	"name":"cardiotoxicity, radiotherapy prevention"
},
{
	"jumpto":"ENAS5193_3.1.2.1",
	"name":"cardiotoxicity, risk factors"
},
{
	"jumpto":"ENAS5193_3.1.2.1",
	"name":"cardiotoxicity, risk stratification"
},
{
	"jumpto":"ENAS5193_3.1.2.5",
	"name":"cardiotoxicity, screening"
},
{
	"jumpto":"ENAS5193_3.1.2.1",
	"name":"cardiotoxicity, screening"
},
{
	"jumpto":"ENAS5193_3.4.1.5",
	"name":"cardiotoxicity, sinus node dysfunction"
},
{
	"jumpto":"ENAS5193_3.7.1.2",
	"name":"cardiotoxicity, stroke"
},
{
	"jumpto":"ENAS5193_3.7.2.0",
	"name":"cardiotoxicity, stroke mgmt."
},
{
	"jumpto":"ENAS5193_3.4.1.3",
	"name":"cardiotoxicity, supraventricular arrhythmia"
},
{
	"jumpto":"ENAS5193_3.1.1.4",
	"name":"cardiotoxicity, targeted therapies"
},
{
	"jumpto":"ENAS5193_3.6.1.1",
	"name":"cardiotoxicity, thrombembolic disease"
},
{
	"jumpto":"ENAS5193_3.6.2.0",
	"name":"cardiotoxicity, thrombembolic disease mgmt."
},
{
	"jumpto":"ENAS5193_4.1.1.0",
	"name":"cardiotoxicity, treatment options"
},
{
	"jumpto":"ENAS5193_4.1.2.0",
	"name":"cardiotoxicity, troponin elevation"
},
{
	"jumpto":"ENAS5193_3.3.1.0",
	"name":"cardiotoxicity, valvular disease"
},
{
	"jumpto":"ENAS5193_3.1.1.5",
	"name":"cardiotoxicity, VEGF inhibitors"
},
{
	"jumpto":"ENAS5193_4.3.4.0",
	"name":"cardiotoxicity, VEGF inhibitors prevention"
},
{
	"jumpto":"ENAS5193_3.6.1.3",
	"name":"cardiotoxicity, venous thrombosis"
},
{
	"jumpto":"ENAS5193_3.4.1.4",
	"name":"cardiotoxicity, ventricular arrhythmias"
},
{
	"jumpto":"ENAS5193_3.3.2.0",
	"name":"cardiotoxicity, VHD mgmt."
},
{
	"jumpto":"ENAS257_6.0.0.0",
	"name":"cardiovascular continuum [DM]"
},
{
	"jumpto":"ENAS257_4.1.0.0",
	"name":"cardiovascular disease in diabetes mellitus"
},
{
	"jumpto":"ENAS5533_3.2.0.0",
	"name":"Cardiovascular risk categories [HTN]"
},
{
	"jumpto":"ENAS5329_9.3.0.0",
	"name":"Cardioversion (STEMI)"
},
{
	"jumpto":"ENAS5083_5.2.4.0",
	"name":"Cardioverter defibrillator, public access"
},
{
	"jumpto":"ENAS5083_5.2.2.0",
	"name":"Cardioverter defibrillator, subcutaneous"
},
{
	"jumpto":"ENAS5083_5.2.3.0",
	"name":"Cardioverter defibrillator, wearable"
},
{
	"jumpto":"ENAS257_12.3.0.0",
	"name":"carotid artery disease, extra cranial"
},
{
	"jumpto":"ENAS257_12.3.0.0",
	"name":"carotid artery disease [DM]"
},
{
	"jumpto":"ENAS5532_13.0.0.0",
	"name":"Carotid artery revascularization [MR]"
},
{
	"jumpto":"ENAS5327_12.2.2.0",
	"name":"Carotid disease screening, in CABG [PAD]"
},
{
	"jumpto":"ENAS5327_7.1.4.0",
	"name":"Carotid endarterectomy, in asymptomatic CAD [PAD]"
},
{
	"jumpto":"ENAS5530_9.0.0.0",
	"name":"Carotid sinus massage [Sync]"
},
{
	"jumpto":"ENAS5532_13.0.0.0",
	"name":"Carotid stenosis, management [MR]"
},
{
	"jumpto":"ENAS5327_12.2.2.0",
	"name":"Carotid stenosis management, in CABG [PAD]"
},
{
	"jumpto":"ENAS5530_4.3.0.0",
	"name":"Carotid TIA [Sync]"
},
{
	"jumpto":"ENAS5328_7.2.2.0",
	"name":"Carpentier classification (VHD)"
},
{
	"jumpto":"ENAS5194_9.4.0.0",
	"name":"Carvedilol (AFib)"
},
{
	"jumpto":"ENAS5530_29.4.0.0",
	"name":"Cataplexy [Sync]"
},
{
	"jumpto":"ENAS5530_4.3.0.0",
	"name":"Cataplexy [Sync]"
},
{
	"jumpto":"ENAS5195_11.2.0.0",
	"name":"catheter ablation (HF)"
},
{
	"jumpto":"ENAS5194_10.4.0.0",
	"name":"Catheter ablation, complications (AFib)"
},
{
	"jumpto":"ENAS5533_6.2.0.0",
	"name":"Causes of pseudo-resistant hypertension"
},
{
	"jumpto":"ENAS5533_7.3.0.0",
	"name":"Causes of secondary HTN"
},
{
	"jumpto":"interactive_0001877",
	"name":"Causes of secondary hypertension (tool)"
},
{
	"jumpto":"ENAS5081_6.2.3.1",
	"name":"CCB in DPAH"
},
{
	"jumpto":"ENAS5081_6.2.3.1",
	"name":"CCB in HPAH"
},
{
	"jumpto":"ENAS261_7.4.0.0",
	"name":"CCBs, risk reduction in non-cardiac surgery"
},
{
	"jumpto":"ENAS5081_6.2.3.1",
	"name":"CCBs in IPAH"
},
{
	"jumpto":"ENAS5081_6.2.3.1",
	"name":"CCB therapy in PAH"
},
{
	"jumpto":"ENAS5081_6.2.3.1",
	"name":"CCB therapy in PAH, contraindication"
},
{
	"jumpto":"ENAS5079_10.0.0.0",
	"name":"CDRIE, diagnosis"
},
{
	"jumpto":"ENAS5079_10.0.0.0",
	"name":"CDRIE, mode of device removal"
},
{
	"jumpto":"ENAS5079_10.0.0.0",
	"name":"CDRIE, principles of treatment"
},
{
	"jumpto":"ENAS5079_10.0.0.0",
	"name":"CDRIE, prophylaxis"
},
{
	"jumpto":"ENAS5079_10.0.0.0",
	"name":"CDRIE, reimplantation"
},
{
	"jumpto":"ENAS5195_12.5.0.0",
	"name":"central nervous system (HF)"
},
{
	"jumpto":"ENAS5196_13.4.0.0",
	"name":"cerebrovascular disease (CVD prev)"
},
{
	"jumpto":"ENAS261_8.6.0.0",
	"name":"cerebrovascular disease in non-cardiac surgery"
},
{
	"jumpto":"ENAS5530_29.2.0.0",
	"name":"Cerebrovascular disorders [Sync]"
},
{
	"jumpto":"ENAS5194_8.2.0.0",
	"name":"CHA2DS2-VASc score (AFib)"
},
{
	"jumpto":"ENAS5195_13.5.0.0",
	"name":"CHAMP (HF)"
},
{
	"jumpto":"ENAS5195_15.1.1.0",
	"name":"charateristics and components, multidisciplinary team management"
},
{
	"jumpto":"ENAS5193_3.1.1.3",
	"name":"chemotherapies, cardiotoxicity"
},
{
	"jumpto":"ENAS258_7.3.4.0",
	"name":"chest pain, pre-test clinical probabilities"
},
{
	"jumpto":"ENAS258_7.3.2.0",
	"name":"chest X-ray [SCAD]"
},
{
	"jumpto":"ENAS5197_11.2.0.0",
	"name":"children, dyslipidaemias"
},
{
	"jumpto":"ENAS5328_12.1.0.0",
	"name":"Choice of prosthetic valve (VHD)"
},
{
	"jumpto":"ENAS5197_8.3.0.0",
	"name":"cholesterol absorption inhibitors, hypercholesterolaemia (Dyslip)"
},
{
	"jumpto":"ENAS264_14.2.0.0",
	"name":"chronic aortic dissection"
},
{
	"jumpto":"ENAS5196_13.3.0.0",
	"name":"chronic heart failure (CVD prev)"
},
{
	"jumpto":"ENAS261_8.1.0.0",
	"name":"Chronic heart failure in non-cardiac surgery"
},
{
	"jumpto":"ENAS5197_11.8.0.0",
	"name":"chronic kidney disease, dyslipidaemias"
},
{
	"jumpto":"ENAS5327_11.5.0.0",
	"name":"Chronic limb-threatening ischaemia, management [PAD]"
},
{
	"jumpto":"ENAS5327_9.2.0.0",
	"name":"Chronic mesenteric artery disease [PAD]"
},
{
	"jumpto":"ENAS5082_3.2.1.0",
	"name":"Chronic pericarditis, definition"
},
{
	"jumpto":"ENAS5081_10.1.0.0",
	"name":"Chronic thromboembolic pulmonary hypertension (CTEPH)"
},
{
	"jumpto":"ENAS262_9.1.0.0",
	"name":"chronic thromboembolic pulmonary hypertension, diagnosis"
},
{
	"jumpto":"ENAS262_9.2.0.0",
	"name":"chronic thromboembolic pulmonary hypertension, treatment"
},
{
	"jumpto":"ENAS5082_2.0.0.0",
	"name":"Churg-Strauss syndrome (Pericard.)"
},
{
	"jumpto":"ENAS5082_5.8.2.0",
	"name":"Chylopericardium"
},
{
	"jumpto":"ENAS5082_5.8.2.0",
	"name":"Chylopericardium, diagnosis"
},
{
	"jumpto":"ENAS5082_5.8.2.0",
	"name":"Chylothorax"
},
{
	"jumpto":"ENAS5196_9.8.0.0",
	"name":"circulating and urinary biomarkers (CVD prev)"
},
{
	"jumpto":"ENAS5196_2.0.0.0",
	"name":"classes of recommendation (CVD prev)"
},
{
	"jumpto":"ENAS5081_2.0.0.0",
	"name":"Classes of recommendations (PH)"
},
{
	"jumpto":"ENAS5083_2.0.0.0",
	"name":"Classes of recommendations (VA and SCD)"
},
{
	"jumpto":"ENAS5195_4.0.0.0",
	"name":"classification (HF)"
},
{
	"jumpto":"ENAS5194_5.1.0.0",
	"name":"classification, AF"
},
{
	"jumpto":"ENAS5533_3.1.0.0",
	"name":"Classification of BP & definition of HTN"
},
{
	"jumpto":"ENAS5533_3.2.0.0",
	"name":"Classification of hypertension stages [HTN]"
},
{
	"jumpto":"ENAS5079_3.2.0.0",
	"name":"Clindamycin, dental procedure prophylaxis"
},
{
	"jumpto":"interactive_0001456",
	"name":"Clinical categories of acute limb ischaemia (tool)"
},
{
	"jumpto":"ENAS5327_11.6.0.0",
	"name":"Clinical categories of acute limb ischaemia [PAD]"
},
{
	"jumpto":"ENAS5533_4.1.8.0",
	"name":"Clinical evaluation & HMOD assessment [HTN]"
},
{
	"jumpto":"ENAS5530_5.3.0.0",
	"name":"Clinical features that can suggest a diagnosis on initial evaluation [Sync]"
},
{
	"jumpto":"ENAS5327_5.2.0.0",
	"name":"Clinical history"
},
{
	"jumpto":"ENAS5533_3.7.0.0",
	"name":"Clinical indications for BP monitoring"
},
{
	"jumpto":"ENAS5195_13.8.6.0",
	"name":"clinical monitoring, AHF"
},
{
	"jumpto":"ENAS5195_13.8.6.0",
	"name":"clinical monitoring, hospitalized patients (HF)"
},
{
	"jumpto":"ENAS5082_4.2.2.0",
	"name":"Clinical predictors, major (Pericard.)"
},
{
	"jumpto":"ENAS5082_4.2.2.0",
	"name":"Clinical predictors, minor (Pericard.)"
},
{
	"jumpto":"ENAS5524_7.1.0.0",
	"name":"Clinical presentation & classification of MI [UDMI]"
},
{
	"jumpto":"ENAS5195_13.3.0.0",
	"name":"clinical profiles, acute HF patients"
},
{
	"jumpto":"ENAS5329_7.3.1.0",
	"name":"Clinical risk assessment (STEMI)"
},
{
	"jumpto":"ENAS5081_6.1.2.0",
	"name":"Clinical signs of right heart failure (PH)"
},
{
	"jumpto":"interactive_0001457",
	"name":"Clinical stages of LEAD (tool)"
},
{
	"jumpto":"ENAS5080_5.1.0.0",
	"name":"Clopidogrel (NSTE-ACS)"
},
{
	"jumpto":"ENAS5329_6.2.2.0",
	"name":"Clopidogrel (STEMI)"
},
{
	"jumpto":"ENAS5328_12.2.4.0",
	"name":"Clopidogrel (VHD)"
},
{
	"jumpto":"ENAS5326_6.2.0.0",
	"name":"Clopidogrel, in ACS undergoing CABG (DAPT)"
},
{
	"jumpto":"ENAS5326_7.2.0.0",
	"name":"Clopidogrel, in ACS with medical management (DAPT)"
},
{
	"jumpto":"ENAS5327_6.2.0.0",
	"name":"Clopidogrel, in CA stenosis [PAD]"
},
{
	"jumpto":"ENAS5326_5.4.0.0",
	"name":"Clopidogrel, in PCI (DAPT)"
},
{
	"jumpto":"ENAS5080_5.2.1.0",
	"name":"Clopidogrel, P2Y12 inhibitor (NSTE-ACS)"
},
{
	"jumpto":"ENAS5326_4.2.2.0",
	"name":"Clopidogrel, P2Y12 inhibitor selection (DAPT)"
},
{
	"jumpto":"ENAS5326_4.3.0.0",
	"name":"Clopidogrel LD (DAPT)"
},
{
	"jumpto":"ENAS5326_4.3.0.0",
	"name":"Clopidogrel MD (DAPT)"
},
{
	"jumpto":"ENAS5328_6.2.4.0",
	"name":"CMR (VHD)"
},
{
	"jumpto":"ENAS5328_4.2.1.0",
	"name":"CMR, non-invasive investigation (VHD)"
},
{
	"jumpto":"ENAS5524_23.3.0.0",
	"name":"CMR [UDMI]"
},
{
	"jumpto":"ENAS5195_12.1.0.0",
	"name":"co-morbidities, overview (HF)"
},
{
	"jumpto":"ENAS5329_6.3.2.0",
	"name":"Co-therapies, doses (STEMI)"
},
{
	"jumpto":"ENAS264_10.4.0.0",
	"name":"coarctation of the aorta"
},
{
	"jumpto":"ENAS5531_5.9.0.0",
	"name":"Coarctation of the aorta [CVD Preg]"
},
{
	"jumpto":"ENAS5082_3.2.6.0",
	"name":"Colchicine, anti-inflammatory therapy (Pericard.)"
},
{
	"jumpto":"ENAS5082_3.3.2.0",
	"name":"Colchicine, in recurrent pericarditis"
},
{
	"jumpto":"ENAS5530_12.0.0.0",
	"name":"Cold pressure test [Sync]"
},
{
	"jumpto":"ENAS5194_8.11.4.0",
	"name":"combination therapy with OAC and antiplatelets (AFib)"
},
{
	"jumpto":"ENAS5328_11.0.0.0",
	"name":"Combined and multiple valve diseases (VHD)"
},
{
	"jumpto":"ENAS5081_4.1.2.0",
	"name":"Combined post-capillary PH"
},
{
	"jumpto":"ENAS5081_9.0.0.0",
	"name":"Combined pulmonary fibrosis and emphysema (CPEE)"
},
{
	"jumpto":"ENAS5079_4.1.0.0",
	"name":"Complicated infective endocarditis"
},
{
	"jumpto":"ENAS5329_9.1.0.0",
	"name":"Complications, STEMI"
},
{
	"jumpto":"ENAS5329_6.1.5.0",
	"name":"Components of ischaemic time (STEMI)"
},
{
	"jumpto":"ENAS258_7.3.8.0",
	"name":"computed tomography angiography [SCAD]"
},
{
	"jumpto":"ENAS5328_4.7.0.0",
	"name":"Concept of the Heart Team and heart valve centres (VHD)"
},
{
	"jumpto":"interactive_0001860",
	"name":"Conceptual model for interpreting myocardial injury (tool)"
},
{
	"jumpto":"ENAS5328_6.3.1.0",
	"name":"Concomitant aortic valve surgery at the time of other cardiac/ascending aorta surgery (VHD)"
},
{
	"jumpto":"ENAS5195_11.1.0.0",
	"name":"conductance disturbance, overview (HF)"
},
{
	"jumpto":"ENAS5193_3.4.1.5",
	"name":"conduction defects, cardiotoxicity"
},
{
	"jumpto":"ENAS5329_9.3.0.0",
	"name":"Conduction disturbances (STEMI)"
},
{
	"jumpto":"ENAS5533_3.7.0.0",
	"name":"Confirming the diagnosis of HTN"
},
{
	"jumpto":"ENAS259_6.3.1.0",
	"name":"congenital heart disease, indications for pacing"
},
{
	"jumpto":"ENAS5531_5.1.0.0",
	"name":"Congenital heart disease and pulmonary hypertension [CVD Preg]"
},
{
	"jumpto":"ENAS261_8.9.0.0",
	"name":"congenital heart disease in non-cardiac surgery"
},
{
	"jumpto":"ENAS5531_5.17.0.0",
	"name":"Congenital heart disease [CVD Preg]"
},
{
	"jumpto":"ENAS5531_5.14.0.0",
	"name":"Congenitally corrected transposition of the great arteries [CVD Preg]"
},
{
	"jumpto":"ENAS5082_3.8.5.0",
	"name":"Constrictive pericardial syndromes"
},
{
	"jumpto":"ENAS5082_3.8.5.0",
	"name":"Constrictive pericarditis, chronic constriction"
},
{
	"jumpto":"ENAS5082_3.8.3.0",
	"name":"Constrictive pericarditis, diagnosis"
},
{
	"jumpto":"ENAS5082_3.8.2.0",
	"name":"Constrictive pericarditis, differential diagnoses"
},
{
	"jumpto":"ENAS5082_3.8.5.0",
	"name":"Constrictive pericarditis, effusive"
},
{
	"jumpto":"ENAS5082_3.8.1.0",
	"name":"Constrictive pericarditis, overview"
},
{
	"jumpto":"ENAS5082_3.8.6.0",
	"name":"Constrictive pericarditis, therapy"
},
{
	"jumpto":"ENAS5082_3.8.4.0",
	"name":"Constrictive pericarditis, therapy overview"
},
{
	"jumpto":"ENAS5082_3.8.5.0",
	"name":"Constrictive pericarditis, transient constriction"
},
{
	"jumpto":"ENAS5082_5.2.2.3",
	"name":"Constrictive pericarditis, tuberculor"
},
{
	"jumpto":"ENAS5082_5.2.2.3",
	"name":"Constrictive tuberculous pericarditis, management"
},
{
	"jumpto":"ENAS5080_4.3.3.0",
	"name":"Continuous rhythm monitoring (NSTE-ACS)"
},
{
	"jumpto":"ENAS5329_6.3.3.0",
	"name":"Contra-indications, fibrinolytic therapy (STEMI)"
},
{
	"jumpto":"ENAS5328_8.3.3.0",
	"name":"Contra-indications for PMC (VHD)"
},
{
	"jumpto":"ENAS5531_4.2.10.0",
	"name":"Contraception and assisted reproductive therapy [CVD Preg]"
},
{
	"jumpto":"ENAS5081_5.1.0.0",
	"name":"Cool extremities (PH)"
},
{
	"jumpto":"ENAS264_11.5.0.0",
	"name":"coral reef aorta"
},
{
	"jumpto":"ENAS5328_8.3.4.0",
	"name":"Cormier score, assessment of mitral valve anatomy (VHD)"
},
{
	"jumpto":"ENAS5328_4.2.1.0",
	"name":"Coronary angiography, invasive investigation (VHD)"
},
{
	"jumpto":"ENAS258_7.4.0.0",
	"name":"coronary angiography, invasive [SCAD]"
},
{
	"jumpto":"ENAS5083_4.3.2.0",
	"name":"Coronary angiography, VA screening"
},
{
	"jumpto":"ENAS5530_18.0.0.0",
	"name":"Coronary angiography [Sync]"
},
{
	"jumpto":"ENAS5326_6.1.0.0",
	"name":"Coronary artery bypass graft surgery (DAPT)"
},
{
	"jumpto":"ENAS258_7.3.4.0",
	"name":"coronary artery disease, commonly used tests [SCAD]"
},
{
	"jumpto":"ENAS257_9.1.0.0",
	"name":"coronary artery disease, mgmt. [DM]"
},
{
	"jumpto":"ENAS5531_8.0.0.0",
	"name":"Coronary artery disease [CVD Preg]"
},
{
	"jumpto":"ENAS5329_6.4.0.0",
	"name":"Coronary bypass surgery (STEMI)"
},
{
	"jumpto":"ENAS5080_4.2.0.0",
	"name":"Coronary care unit (NSTE-ACS)"
},
{
	"jumpto":"ENAS5196_13.2.0.0",
	"name":"coronary disease (CVD prev)"
},
{
	"jumpto":"ENAS258_7.8.1.0",
	"name":"coronary microvascular disease [SCAD]"
},
{
	"jumpto":"ENAS5524_8.0.0.0",
	"name":"Coronary procedure-related myocardial injury [UDMI]"
},
{
	"jumpto":"ENAS257_9.2.0.0",
	"name":"coronary revascularization [DM]"
},
{
	"jumpto":"ENAS5080_5.4.4.0",
	"name":"Coronary stenting, anticoagulation (NSTE-ACS)"
},
{
	"jumpto":"ENAS5080_5.4.4.0",
	"name":"Coronary stenting, antiplatelet treatment (NSTE-ACS)"
},
{
	"jumpto":"ENAS5080_5.4.4.0",
	"name":"Coronary stenting, medically-managed patients (NSTE-ACS)"
},
{
	"jumpto":"ENAS5080_5.4.4.0",
	"name":"Coronary stenting, vascular access (NSTE-ACS)"
},
{
	"jumpto":"ENAS5081_7.2.0.0",
	"name":"Correction of CHD with PAH"
},
{
	"jumpto":"ENAS5195_12.15.0.0",
	"name":"corticosteroids (HF)"
},
{
	"jumpto":"ENAS5196_8.0.0.0",
	"name":"cost-effectiveness, CVD prevention"
},
{
	"jumpto":"ENAS5197_3.2.0.0",
	"name":"cost-effectiveness of CVD prevention, key messages (Dyslip)"
},
{
	"jumpto":"ENAS5195_8.5.0.0",
	"name":"COX-2 inhibitors (HF)"
},
{
	"jumpto":"ENAS5079_5.3.2.0",
	"name":"Coxiella burnettii (IE)"
},
{
	"jumpto":"ENAS5081_6.1.1.0",
	"name":"CPET (PH)"
},
{
	"jumpto":"ENAS5083_9.5.1.0",
	"name":"CPVT, diagnosis"
},
{
	"jumpto":"ENAS5083_9.5.2.0",
	"name":"CPVT, risk stratification and management"
},
{
	"jumpto":"ENAS5524_2.0.0.0",
	"name":"Criteria for acute MI [UDMI]"
},
{
	"jumpto":"ENAS5195_13.9.0.0",
	"name":"criteria for discharge (HF)"
},
{
	"jumpto":"ENAS5328_6.2.3.0",
	"name":"Criteria that increase the likelihood of severe AS in the presence of low gradient (VHD)"
},
{
	"jumpto":"ENAS5080_3.3.0.0",
	"name":"Critical illness, troponin elevation (NSTE-ACS)"
},
{
	"jumpto":"ENAS5195_9.2.0.0",
	"name":"CRT (HF)"
},
{
	"jumpto":"ENAS259_7.1.0.0",
	"name":"CRT, complications"
},
{
	"jumpto":"ENAS259_5.3.1.0",
	"name":"CRT, in atrial fibrillation [Pacing]"
},
{
	"jumpto":"ENAS259_5.4.1.0",
	"name":"CRT, indications for upgrade"
},
{
	"jumpto":"ENAS259_5.2.2.0",
	"name":"CRT, indications in patients with sinus rhythm"
},
{
	"jumpto":"ENAS259_5.3.3.0",
	"name":"CRT, in permanent atrial fibrillation, indications"
},
{
	"jumpto":"ENAS259_5.2.3.0",
	"name":"CRT, patients with sinus rhythm, choice of pacing"
},
{
	"jumpto":"ENAS259_5.2.3.0",
	"name":"CRT, patients with sinus rhythm, clinical perspective"
},
{
	"jumpto":"ENAS259_5.2.4.0",
	"name":"CRT, patient with sinus rhythm, summary"
},
{
	"jumpto":"ENAS259_5.2.1.0",
	"name":"CRT, sinus rhythm [Pacing]"
},
{
	"jumpto":"ENAS259_5.5.2.0",
	"name":"CRT and defibrillator vs. CRT and pacemaker"
},
{
	"jumpto":"ENAS5083_7.2.1.0",
	"name":"CRT in primary prevention of SCD"
},
{
	"jumpto":"ENAS5080_4.1.0.0",
	"name":"CRUSADE risk score (NSTE-ACS)"
},
{
	"jumpto":"ENAS5081_4.2.1.0",
	"name":"CTEPH, clinical classification"
},
{
	"jumpto":"ENAS5081_10.2.0.0",
	"name":"CTEPH, treatment algorithm"
},
{
	"jumpto":"ENAS5081_10.1.0.0",
	"name":"CTEPH diagnostic algorithm"
},
{
	"jumpto":"ENAS5081_10.3.0.0",
	"name":"CTEPH strategy"
},
{
	"jumpto":"ENAS5193_3.9.1.0",
	"name":"CV complications, cardiotoxicity"
},
{
	"jumpto":"ENAS5193_3.2.1.1",
	"name":"CVD, cardiotoxicity"
},
{
	"jumpto":"ENAS5197_3.1.0.0",
	"name":"CVD definition and rationale"
},
{
	"jumpto":"ENAS5531_4.2.5.0",
	"name":"CVD in pregnancy, diagnosis"
},
{
	"jumpto":"ENAS5196_15.2.0.0",
	"name":"CVD prevention, acute hospital admission"
},
{
	"jumpto":"ENAS5196_9.1.0.0",
	"name":"CVD prevention, benfit"
},
{
	"jumpto":"ENAS5196_8.0.0.0",
	"name":"CVD prevention, cost-effectiveness"
},
{
	"jumpto":"ENAS5196_15.4.0.0",
	"name":"CVD prevention, monitoring preventive activities"
},
{
	"jumpto":"ENAS5196_15.5.0.0",
	"name":"CVD prevention, performance measurements"
},
{
	"jumpto":"ENAS5196_15.1.0.0",
	"name":"CVD prevention, primary care"
},
{
	"jumpto":"ENAS5196_7.0.0.0",
	"name":"CVD prevention, relevance"
},
{
	"jumpto":"ENAS5196_15.3.0.0",
	"name":"CVD prevention, specialized programmes"
},
{
	"jumpto":"ENAS5196_9.2.0.0",
	"name":"CVD prevention, total CV risk assessment"
},
{
	"jumpto":"ENAS5533_3.2.0.0",
	"name":"CVD risk assessment [HTN]"
},
{
	"jumpto":"ENAS5531_4.2.7.0",
	"name":"CV interventions during pregnancy [CVD Preg]"
},
{
	"jumpto":"ENAS257_7.0.0.0",
	"name":"CV risk assessment: in DM"
},
{
	"jumpto":"ENAS5531_4.2.2.0",
	"name":"CV risk classification, mWHO [CVD Preg]"
},
{
	"jumpto":"ENAS5531_5.4.0.0",
	"name":"Cyanotic heart disease without pulmonary hypertension [CVD Preg]"
},
{
	"jumpto":"ENAS5326_8.1.0.0",
	"name":"Dabigatran (DAPT)"
},
{
	"jumpto":"ENAS5326_5.2.0.0",
	"name":"DAPT & stent choices in stable CAD with PCI, recom. (DAPT)"
},
{
	"jumpto":"ENAS5327_6.2.0.0",
	"name":"DAPT, in CA stenosis [PAD]"
},
{
	"jumpto":"ENAS5326_5.1.0.0",
	"name":"DAPT and percutaneous coronary intervention, overview (DAPT)"
},
{
	"jumpto":"ENAS5532_18.9.0.0",
	"name":"DAPT duration in Pts. with indication for OAC [MR]"
},
{
	"jumpto":"ENAS5326_5.3.0.0",
	"name":"DAPT in ACS treated with PCI (DAPT)"
},
{
	"jumpto":"ENAS5326_9.1.0.0",
	"name":"DAPT in elective non-cardiac surgery, recommendations(DAPT)"
},
{
	"jumpto":"ENAS5326_7.1.0.0",
	"name":"DAPT in medically managed ACS, recommendations (DAPT)"
},
{
	"jumpto":"ENAS5532_18.7.0.0",
	"name":"DAPT in patients undergoing cardiac surgery [MR]"
},
{
	"jumpto":"interactive_0001878",
	"name":"DAPT in Pts. undergoing PCI (tool)"
},
{
	"jumpto":"ENAS5326_4.1.0.0",
	"name":"DAPT score"
},
{
	"jumpto":"interactive_0001454",
	"name":"DAPT score (tool)"
},
{
	"jumpto":"ENAS5326_8.1.0.0",
	"name":"DAPT with indication for OAC (DAPT)"
},
{
	"jumpto":"ENAS5326_5.4.0.0",
	"name":"DCB (DAPT)"
},
{
	"jumpto":"interactive_0001458",
	"name":"DDx in upper limbs artery disease (tool)"
},
{
	"jumpto":"ENAS5532_6.2.0.0",
	"name":"Decision-making and patient information in the elective setting [MR]"
},
{
	"jumpto":"ENAS5532_5.0.0.0",
	"name":"Decision making and patient information process [MR]"
},
{
	"jumpto":"interactive_0001872",
	"name":"Decision pathway for pacing in patients with reflex syncope (tool)"
},
{
	"jumpto":"interactive_0001857",
	"name":"Decision pathway for the first-line mgmt. of reflex syncope (tool)"
},
{
	"jumpto":"ENAS5530_12.0.0.0",
	"name":"Deep breathing test [Sync]"
},
{
	"jumpto":"ENAS5081_10.3.0.0",
	"name":"Deep hypothermia circulatory arrest, CTEPH"
},
{
	"jumpto":"ENAS5329_6.2.1.0",
	"name":"Deferred stenting (STEMI)"
},
{
	"jumpto":"ENAS5533_9.1.0.0",
	"name":"Definition & classification of HTN in pregnancy"
},
{
	"jumpto":"ENAS5196_4.0.0.0",
	"name":"definition (CVD prev)"
},
{
	"jumpto":"ENAS5195_4.0.0.0",
	"name":"definition (HF)"
},
{
	"jumpto":"ENAS5329_3.2.0.0",
	"name":"Definition, acute myocardial infarction (STEMI)"
},
{
	"jumpto":"ENAS5530_30.2.0.0",
	"name":"Definition, syncope specialist"
},
{
	"jumpto":"ENAS5530_30.1.0.0",
	"name":"Definition, syncope unit"
},
{
	"jumpto":"ENAS5326_3.0.0.0",
	"name":"Definition and classification (DAPT)"
},
{
	"jumpto":"ENAS5197_3.1.0.0",
	"name":"definition and rationale CVD"
},
{
	"jumpto":"ENAS5195_4.0.0.0",
	"name":"definition of HFmrEF"
},
{
	"jumpto":"ENAS5195_4.0.0.0",
	"name":"definition of HFpEF"
},
{
	"jumpto":"ENAS5195_4.0.0.0",
	"name":"definition of HFrEF"
},
{
	"jumpto":"interactive_0001883",
	"name":"Definition of MI (tool)"
},
{
	"jumpto":"ENAS5533_4.1.5.0",
	"name":"Definitions of electrocardiogram LVH [HTN]"
},
{
	"jumpto":"ENAS5082_7.1.0.0",
	"name":"Delayed tamponade"
},
{
	"jumpto":"ENAS5531_11.6.0.0",
	"name":"Delivery, breastfeeding and prognosis after pregnancy [CVD Preg]"
},
{
	"jumpto":"ENAS5531_9.5.0.0",
	"name":"Delivery and breastfeeding [CVD Preg]"
},
{
	"jumpto":"ENAS5531_4.2.8.0",
	"name":"Delivery [CVD Preg]"
},
{
	"jumpto":"ENAS5531_9.7.0.0",
	"name":"Delivery [CVD Preg]"
},
{
	"jumpto":"ENAS5326_5.2.0.0",
	"name":"DES (DAPT)"
},
{
	"jumpto":"ENAS5533_5.7.0.0",
	"name":"Device-based HTN treatment"
},
{
	"jumpto":"ENAS5083_5.2.1.0",
	"name":"Device therapy in VA, ICD implantation"
},
{
	"jumpto":"ENAS5083_5.2.4.0",
	"name":"Device therapy in VA, public access defibrillator"
},
{
	"jumpto":"ENAS5083_5.2.2.0",
	"name":"Device therapy in VA, subcut. cardioverter defibrillator"
},
{
	"jumpto":"ENAS5083_5.2.3.0",
	"name":"Device therapy in VA, wearable cardioverter defibrillator"
},
{
	"jumpto":"ENAS5195_12.6.0.0",
	"name":"diabetes (HF)"
},
{
	"jumpto":"ENAS5197_11.5.0.0",
	"name":"diabetes, dyslipidaemias"
},
{
	"jumpto":"ENAS5196_5.0.0.0",
	"name":"diabetes mellitus (CVD prev)"
},
{
	"jumpto":"ENAS257_8.5.0.0",
	"name":"diabetes mellitus, antiplatelet therapy"
},
{
	"jumpto":"ENAS257_8.3.0.0",
	"name":"diabetes mellitus, BP control"
},
{
	"jumpto":"ENAS257_4.1.0.0",
	"name":"diabetes mellitus, cardiovascular disease"
},
{
	"jumpto":"ENAS257_7.0.0.0",
	"name":"diabetes mellitus, cardiovascular risk assessment"
},
{
	"jumpto":"ENAS257_9.2.0.0",
	"name":"diabetes mellitus, coronary revascularization"
},
{
	"jumpto":"ENAS257_5.2.0.0",
	"name":"diabetes mellitus, diagnostic criteria"
},
{
	"jumpto":"ENAS257_8.4.0.0",
	"name":"diabetes mellitus, dyslipidaemia mgmt."
},
{
	"jumpto":"ENAS257_5.3.2.0",
	"name":"diabetes mellitus, FINDRISC [DM]"
},
{
	"jumpto":"ENAS257_8.2.1.0",
	"name":"diabetes mellitus, glycaemic control recommendations"
},
{
	"jumpto":"ENAS257_8.2.2.0",
	"name":"diabetes mellitus, glycaemic targets"
},
{
	"jumpto":"ENAS257_8.1.1.0",
	"name":"diabetes mellitus, lifestyle modifications"
},
{
	"jumpto":"ENAS257_13.1.0.0",
	"name":"diabetes mellitus, microvascular disease mgmt."
},
{
	"jumpto":"ENAS257_8.6.0.0",
	"name":"diabetes mellitus, multifactorial risk mgmt."
},
{
	"jumpto":"ENAS257_14.0.0.0",
	"name":"diabetes mellitus, patient-centred care"
},
{
	"jumpto":"ENAS257_8.2.3.0",
	"name":"diabetes mellitus, pharmacological treatment"
},
{
	"jumpto":"ENAS257_5.4.0.0",
	"name":"diabetes mellitus, prevention of T2DM"
},
{
	"jumpto":"ENAS257_5.3.1.0",
	"name":"diabetes mellitus, risk scores: overview"
},
{
	"jumpto":"ENAS257_11.3.0.0",
	"name":"diabetes mellitus, sudden cardiac death"
},
{
	"jumpto":"ENAS5196_12.2.1.0",
	"name":"diabetes type 1 (CVD prev)"
},
{
	"jumpto":"ENAS5196_12.1.0.0",
	"name":"diabetes type 2 (CVD prev)"
},
{
	"jumpto":"ENAS5531_4.2.5.0",
	"name":"Diagnosis, CVD in pregnancy"
},
{
	"jumpto":"ENAS5194_4.1.0.0",
	"name":"diagnosis of AF"
},
{
	"jumpto":"ENAS5328_4.2.3.0",
	"name":"Diagnosis of CAD (VHD)"
},
{
	"jumpto":"ENAS5195_5.2.0.0",
	"name":"diagnosis of heart failure"
},
{
	"jumpto":"ENAS5533_3.7.0.0",
	"name":"Diagnosis of HTN, confirmation"
},
{
	"jumpto":"ENAS5079_5.2.1.0",
	"name":"Diagnosis of IE, role of echocardiography"
},
{
	"jumpto":"ENAS5524_19.0.0.0",
	"name":"Diagnosis of MI, biochemical approach [UDMI]"
},
{
	"jumpto":"interactive_0000595",
	"name":"Diagnosis of non-acute HF (interactive algorithm)"
},
{
	"jumpto":"ENAS5533_3.1.0.0",
	"name":"Diagnostic aspects [HTN]"
},
{
	"jumpto":"interactive_0000278",
	"name":"Diagnostic criteria for FH (interactive score)"
},
{
	"jumpto":"ENAS5329_10.0.0.0",
	"name":"Diagnostic criteria for MINOCA (STEMI)"
},
{
	"jumpto":"ENAS5530_5.2.0.0",
	"name":"Diagnostic criteria with initial evaluation [Sync]"
},
{
	"jumpto":"ENAS5327_10.0.0.0",
	"name":"Diagnostic strategies for RAD [PAD]"
},
{
	"jumpto":"interactive_0001869",
	"name":"Diagnostic strategy after unclear initial eval. (tool)"
},
{
	"jumpto":"ENAS5530_8.0.0.0",
	"name":"Diagnostic strategy when diagnosis is unclear [Sync]"
},
{
	"jumpto":"ENAS5329_10.0.0.0",
	"name":"Diagnostic test flow chart in MINOCA (STEMI)"
},
{
	"jumpto":"interactive_0001447",
	"name":"Diagnostic test flow chart in MINOCA (tool)"
},
{
	"jumpto":"ENAS5195_6.3.0.0",
	"name":"diagnostic tests, recommendations (HF)"
},
{
	"jumpto":"ENAS5193_3.1.2.6",
	"name":"diagnostic tools, cardiotoxicity"
},
{
	"jumpto":"ENAS5533_8.0.0.0",
	"name":"Diagnostic work-up for suspected HTN emergency"
},
{
	"jumpto":"interactive_0001876",
	"name":"Diagnostic work-up of cardiovascular autonomic failure (tool)"
},
{
	"jumpto":"ENAS5530_29.7.0.0",
	"name":"Diagnostic work-up of cardiovascular autonomic failure [Sync]"
},
{
	"jumpto":"ENAS5195_13.4.0.0",
	"name":"diagnostic workup (HF)"
},
{
	"jumpto":"ENAS5083_8.1.1.0",
	"name":"Dialted cardiomyopathy, definition"
},
{
	"jumpto":"ENAS5081_5.1.0.0",
	"name":"Diastolic murmur, of pulmonary regurgitation"
},
{
	"jumpto":"ENAS5081_4.1.2.0",
	"name":"Diastolic pressure gradient (DPG)"
},
{
	"jumpto":"ENAS5196_5.0.0.0",
	"name":"diet (CVD prev)"
},
{
	"jumpto":"ENAS5196_14.1.0.0",
	"name":"diet, population-based approach (CVD prev)"
},
{
	"jumpto":"ENAS5197_7.4.0.0",
	"name":"dietary supplements (Dyslip)"
},
{
	"jumpto":"ENAS5197_7.5.0.0",
	"name":"diet in CVD prevention (Dyslip)"
},
{
	"jumpto":"ENAS5327_8.0.0.0",
	"name":"Differential diagnosis, UEAD [PAD]"
},
{
	"jumpto":"ENAS5530_4.3.0.0",
	"name":"Differential diagnosis of syncope"
},
{
	"jumpto":"ENAS5194_9.4.0.0",
	"name":"Digitoxin (AFib)"
},
{
	"jumpto":"ENAS5194_9.4.0.0",
	"name":"Digoxin (AFib)"
},
{
	"jumpto":"ENAS5083_8.1.2.0",
	"name":"Dilated cardiomyopathy, management"
},
{
	"jumpto":"ENAS5083_8.1.2.0",
	"name":"Dilated cardiomyopathy, prevention of SCD"
},
{
	"jumpto":"ENAS5083_8.1.2.0",
	"name":"Dilated cardiomyopathy, risk stratification"
},
{
	"jumpto":"ENAS5531_9.3.0.0",
	"name":"Dilated cardiomyopathy and congestive HF [CVD Preg]"
},
{
	"jumpto":"ENAS5194_9.4.0.0",
	"name":"Diltiazem (AFib)"
},
{
	"jumpto":"ENAS5195_8.5.0.0",
	"name":"diltiazem (HF)"
},
{
	"jumpto":"ENAS5082_3.8.2.0",
	"name":"Dip and plateau sign"
},
{
	"jumpto":"ENAS5532_14.0.0.0",
	"name":"Disease progression & late graft failure [MR]"
},
{
	"jumpto":"ENAS257_5.1.0.0",
	"name":"disorders of glucose metabolism, diagnosis"
},
{
	"jumpto":"ENAS5081_6.2.2.2",
	"name":"Diuretics, PAH supportive therapy"
},
{
	"jumpto":"ENAS257_4.2.0.0",
	"name":"DM and coronary artery disease: treatment targets"
},
{
	"jumpto":"ENAS257_4.2.0.0",
	"name":"DM with CAD: treatment targets"
},
{
	"jumpto":"ENAS5195_13.8.2.0",
	"name":"dobutamine (HF)"
},
{
	"jumpto":"ENAS5328_6.2.2.0",
	"name":"Dobutamine, in echocardiography (VHD)"
},
{
	"jumpto":"ENAS5195_8.4.0.0",
	"name":"dogoxin (HF)"
},
{
	"jumpto":"ENAS5195_13.8.2.0",
	"name":"dopamine (HF)"
},
{
	"jumpto":"ENAS5329_9.2.0.0",
	"name":"Doppler echocardiography (STEMI)"
},
{
	"jumpto":"ENAS5195_6.2.0.0",
	"name":"Doppler velocities (HF)"
},
{
	"jumpto":"ENAS5327_11.2.0.0",
	"name":"Doppler waveform analysis [PAD]"
},
{
	"jumpto":"ENAS5329_6.2.3.0",
	"name":"Doses of anticoagulant (STEMI)"
},
{
	"jumpto":"ENAS5329_6.3.2.0",
	"name":"Doses of anticoagulant co-therapies (STEMI)"
},
{
	"jumpto":"ENAS5329_6.2.3.0",
	"name":"Doses of antiplatelet (STEMI)"
},
{
	"jumpto":"ENAS5329_6.3.2.0",
	"name":"Doses of antiplatelet co-therapies (STEMI)"
},
{
	"jumpto":"interactive_0001459",
	"name":"Doses of antithromb. agents (tool)"
},
{
	"jumpto":"ENAS5329_6.3.2.0",
	"name":"Doses of co-therapies (STEMI)"
},
{
	"jumpto":"interactive_0001461",
	"name":"Doses of co-therapies (tool)"
},
{
	"jumpto":"interactive_0001462",
	"name":"Doses of co-therapies in PCI (tool)"
},
{
	"jumpto":"ENAS5329_6.3.2.0",
	"name":"Doses of fibrinolytic therapy (STEMI)"
},
{
	"jumpto":"ENAS5326_8.1.0.0",
	"name":"Dronedarone (DAPT)"
},
{
	"jumpto":"ENAS5195_11.3.0.0",
	"name":"dronedarone (HF)"
},
{
	"jumpto":"ENAS5530_29.5.0.0",
	"name":"Drop attacks [Sync]"
},
{
	"jumpto":"ENAS5326_5.2.0.0",
	"name":"Drug-eluting stent (DAPT)"
},
{
	"jumpto":"ENAS5533_5.6.5.0",
	"name":"Drug-treatment for HTN & HFrEF"
},
{
	"jumpto":"ENAS5533_5.6.3.0",
	"name":"Drug-treatment strategy for HTN & CAD"
},
{
	"jumpto":"ENAS5533_5.6.4.0",
	"name":"Drug-treatment strategy for HTN & CKD"
},
{
	"jumpto":"ENAS5081_6.2.3.2",
	"name":"Drug monotherapy, group I PAH"
},
{
	"jumpto":"ENAS5081_8.2.0.0",
	"name":"Drugs approved for PAH"
},
{
	"jumpto":"ENAS5081_9.0.0.0",
	"name":"Drugs approved for PAH"
},
{
	"jumpto":"ENAS5531_13.0.0.0",
	"name":"Drugs during pregnancy and breastfeeding [CVD Preg]"
},
{
	"jumpto":"ENAS5533_5.6.1.0",
	"name":"Drug treatment algorithm for hypertension [HTN]"
},
{
	"jumpto":"ENAS5533_5.6.2.0",
	"name":"Drug treatment strategy for hypertension [HTN]"
},
{
	"jumpto":"ENAS5326_3.0.0.0",
	"name":"Dual antiplatelet therapy (DAPT)"
},
{
	"jumpto":"ENAS5326_8.1.0.0",
	"name":"Dual therapy (DAPT)"
},
{
	"jumpto":"ENAS5194_8.11.2.0",
	"name":"dual therapy after ACS (AFib)"
},
{
	"jumpto":"ENAS5194_8.11.3.0",
	"name":"dual therapy after PCI (AFib)"
},
{
	"jumpto":"ENAS5079_5.4.1.0",
	"name":"Duke criteria (IE)"
},
{
	"jumpto":"ENAS5197_7.5.0.0",
	"name":"dyslipidaemia, diet in CVD prevention"
},
{
	"jumpto":"ENAS5197_11.6.0.0",
	"name":"dyslipidaemias, ACS and undergoing PCI"
},
{
	"jumpto":"ENAS5197_8.2.0.0",
	"name":"dyslipidaemias, bile acid sequestrants, hypercholesterolaemia"
},
{
	"jumpto":"ENAS5197_11.2.0.0",
	"name":"dyslipidaemias, children"
},
{
	"jumpto":"ENAS5197_8.3.0.0",
	"name":"dyslipidaemias, cholesterol absorption inhibitors, hypercholesterolaemia"
},
{
	"jumpto":"ENAS5197_11.8.0.0",
	"name":"dyslipidaemias, chronic kidney disease"
},
{
	"jumpto":"ENAS5197_11.5.0.0",
	"name":"dyslipidaemias, diabetes"
},
{
	"jumpto":"ENAS5197_7.4.0.0",
	"name":"dyslipidaemias, dietary supplements"
},
{
	"jumpto":"ENAS5197_11.1.0.0",
	"name":"dyslipidaemias, familial"
},
{
	"jumpto":"ENAS5197_10.0.0.0",
	"name":"dyslipidaemias, HDL-cholesterol"
},
{
	"jumpto":"ENAS5197_11.7.0.0",
	"name":"dyslipidaemias, heart failure"
},
{
	"jumpto":"ENAS5197_11.12.0.0",
	"name":"dyslipidaemias, HIV patients"
},
{
	"jumpto":"ENAS5197_4.1.5.0",
	"name":"dyslipidaemias, Illustration of the risk age concept"
},
{
	"jumpto":"ENAS5197_4.2.2.0",
	"name":"dyslipidaemias, key messages"
},
{
	"jumpto":"ENAS5197_7.2.0.0",
	"name":"dyslipidaemias, lifestyle changes LDL"
},
{
	"jumpto":"ENAS5197_7.1.0.0",
	"name":"dyslipidaemias, lifestyle changes lipids"
},
{
	"jumpto":"ENAS5197_11.13.0.0",
	"name":"dyslipidaemias, mental disorders"
},
{
	"jumpto":"ENAS5197_12.1.0.0",
	"name":"dyslipidaemias, monitoring lipids/enzymes"
},
{
	"jumpto":"ENAS5197_12.2.0.0",
	"name":"dyslipidaemias, muscular symptoms"
},
{
	"jumpto":"ENAS5197_8.5.0.0",
	"name":"dyslipidaemias, nicotinic acid, hypercholesterolaemia"
},
{
	"jumpto":"ENAS5197_11.4.0.0",
	"name":"dyslipidaemias, older persons"
},
{
	"jumpto":"ENAS5197_7.3.0.0",
	"name":"dyslipidaemias, overweight"
},
{
	"jumpto":"ENAS5197_8.4.0.0",
	"name":"dyslipidaemias, PCSK9 inhibitors, hypercholesterolaemia"
},
{
	"jumpto":"ENAS5197_11.10.0.0",
	"name":"dyslipidaemias, peripheral arterial disease"
},
{
	"jumpto":"ENAS5197_8.6.0.0",
	"name":"dyslipidaemias, pharmacological treatment, hypercholesterolaemia"
},
{
	"jumpto":"ENAS5197_4.1.4.0",
	"name":"dyslipidaemias, relative risk chart for CV mortality"
},
{
	"jumpto":"ENAS5197_4.2.3.0",
	"name":"dyslipidaemias, risk based intervention strategies"
},
{
	"jumpto":"ENAS5197_4.1.9.0",
	"name":"dyslipidaemias, risk charts qualifiers"
},
{
	"jumpto":"ENAS5197_4.2.4.0",
	"name":"dyslipidaemias, risk estimation"
},
{
	"jumpto":"ENAS5197_4.1.8.0",
	"name":"dyslipidaemias, risk estimation charts"
},
{
	"jumpto":"ENAS5197_4.1.2.0",
	"name":"dyslipidaemias, SCORE high risk chart"
},
{
	"jumpto":"ENAS5197_4.1.3.0",
	"name":"dyslipidaemias, SCORE low risk chart"
},
{
	"jumpto":"ENAS5197_8.1.0.0",
	"name":"dyslipidaemias, statin, hypercholesterolaemia"
},
{
	"jumpto":"ENAS5197_11.11.0.0",
	"name":"dyslipidaemias, stroke"
},
{
	"jumpto":"ENAS5197_11.9.0.0",
	"name":"dyslipidaemias, transplantation"
},
{
	"jumpto":"ENAS5197_9.2.0.0",
	"name":"dyslipidaemias, triglycerides"
},
{
	"jumpto":"ENAS5197_6.2.0.0",
	"name":"dyslipidaemias, tx goals LDL-cholesterol"
},
{
	"jumpto":"ENAS5197_6.3.0.0",
	"name":"dyslipidaemias, tx goals secondary targets"
},
{
	"jumpto":"ENAS5197_6.1.0.0",
	"name":"dyslipidaemias, tx targets"
},
{
	"jumpto":"ENAS5197_11.7.0.0",
	"name":"dyslipidaemias, valvular diseases"
},
{
	"jumpto":"ENAS5197_11.3.0.0",
	"name":"dyslipidaemias, women"
},
{
	"jumpto":"ENAS5083_6.2.1.0",
	"name":"Early after MI"
},
{
	"jumpto":"ENAS5193_3.1.2.1",
	"name":"early detection strategies, cardiotoxicity"
},
{
	"jumpto":"ENAS5081_5.4.0.0",
	"name":"Early diagnostic pulmonary regurgitation velocity"
},
{
	"jumpto":"ENAS5081_5.6.0.0",
	"name":"Early diastolic pulmonary regurgitation velocity"
},
{
	"jumpto":"ENAS5080_5.5.2.0",
	"name":"Early invasive strategy, PCI in NSTE-ACS"
},
{
	"jumpto":"ENAS5532_14.0.0.0",
	"name":"Early postoperative ischaemia and graft failure [MR]"
},
{
	"jumpto":"ENAS5531_5.12.0.0",
	"name":"Ebstein’s anomaly [CVD Preg]"
},
{
	"jumpto":"ENAS5081_6.1.1.0",
	"name":"ECG (PH)"
},
{
	"jumpto":"ENAS5524_22.2.0.0",
	"name":"ECG, manifestations of acute ishcemia MI [UDMI]"
},
{
	"jumpto":"ENAS5533_4.1.6.0",
	"name":"ECG definitions [HTN]"
},
{
	"jumpto":"ENAS5524_22.1.0.0",
	"name":"ECG in MI [UDMI]"
},
{
	"jumpto":"ENAS5081_6.1.1.0",
	"name":"ECHO (PH)"
},
{
	"jumpto":"ENAS5328_4.2.2.0",
	"name":"Echocardiographic criteria (VHD)"
},
{
	"jumpto":"ENAS5533_4.1.6.0",
	"name":"Echocardiographic definitions [HTN]"
},
{
	"jumpto":"ENAS5083_4.3.1.0",
	"name":"Echocardiography (VA and SCD)"
},
{
	"jumpto":"ENAS5328_6.2.1.0",
	"name":"Echocardiography (VHD)"
},
{
	"jumpto":"ENAS5328_4.2.1.0",
	"name":"Echocardiography (VHD)"
},
{
	"jumpto":"ENAS5081_9.0.0.0",
	"name":"Echocardiography, group 3 PAH"
},
{
	"jumpto":"ENAS5079_5.2.2.0",
	"name":"Echocardiography in iE, indications"
},
{
	"jumpto":"ENAS5079_5.2.3.0",
	"name":"Echocardiography in IE, recommendations"
},
{
	"jumpto":"ENAS258_7.3.2.0",
	"name":"echocardiography [SCAD]"
},
{
	"jumpto":"ENAS5530_16.0.0.0",
	"name":"Echocardiography [Sync]"
},
{
	"jumpto":"ENAS5524_23.2.0.0",
	"name":"Echocardiography [UDMI]"
},
{
	"jumpto":"ENAS5328_8.3.4.0",
	"name":"Echo scores (VHD)"
},
{
	"jumpto":"ENAS5328_8.3.4.0",
	"name":"Echo Score “Revisited” for immediate outcome prediction (VHD)"
},
{
	"jumpto":"ENAS5326_8.1.0.0",
	"name":"Edoxaban (DAPT)"
},
{
	"jumpto":"interactive_0001856",
	"name":"ED risk stratification flowchart (tool)"
},
{
	"jumpto":"ENAS5530_6.3.0.0",
	"name":"ED risk stratification flowchart [Sync]"
},
{
	"jumpto":"ENAS5081_4.2.2.0",
	"name":"Eisenmenger's syndrome (PH)"
},
{
	"jumpto":"ENAS5531_5.3.0.0",
	"name":"Eisenmenger syndrome [CVD Preg]"
},
{
	"jumpto":"ENAS5196_10.2.0.0",
	"name":"elderly (CVD prev)"
},
{
	"jumpto":"ENAS5193_3.10.2.0",
	"name":"elderly patients, cardiotoxicity"
},
{
	"jumpto":"ENAS5329_7.2.2.0",
	"name":"Elderly patients, mgmt. (STEMI)"
},
{
	"jumpto":"interactive_0001448",
	"name":"Elective non-cardiac surgery timing (tool)"
},
{
	"jumpto":"ENAS5326_9.2.0.0",
	"name":"Elective non-cardiac surgery timing after PCI (DAPT)"
},
{
	"jumpto":"ENAS5081_6.2.2.1",
	"name":"Elective surgery (PH)"
},
{
	"jumpto":"ENAS5195_11.2.0.0",
	"name":"electrical cardioversion (HF)"
},
{
	"jumpto":"ENAS5524_22.1.0.0",
	"name":"Electrocardiographic detection of MI [UDMI]"
},
{
	"jumpto":"ENAS5530_13.0.0.0",
	"name":"Electrocardiographic monitoring [Sync]"
},
{
	"jumpto":"ENAS258_7.3.2.0",
	"name":"electrocardiography (ECG) [SCAD]"
},
{
	"jumpto":"ENAS5083_4.3.2.0",
	"name":"Electrophysiological study, VA screening"
},
{
	"jumpto":"ENAS5530_15.0.0.0",
	"name":"Electrophysiological study [Sync]"
},
{
	"jumpto":"ENAS5327_7.1.8.0",
	"name":"Embolic protection device during CAS [PAD]"
},
{
	"jumpto":"ENAS5329_5.1.0.0",
	"name":"Emergency care, initial diagnosis (STEMI)"
},
{
	"jumpto":"ENAS5083_13.2.2.0",
	"name":"Emerin"
},
{
	"jumpto":"ENAS5083_13.2.1.0",
	"name":"Emery-Dreifuss muscular dystrophy"
},
{
	"jumpto":"ENAS5195_7.0.0.0",
	"name":"empagliflozin (HF)"
},
{
	"jumpto":"ENAS5328_4.5.0.0",
	"name":"Endocarditis prophylaxis (VHD)"
},
{
	"jumpto":"ENAS5079_4.1.0.0",
	"name":"Endocarditis team, characteristics"
},
{
	"jumpto":"ENAS5079_4.1.0.0",
	"name":"Endocarditis team, role"
},
{
	"jumpto":"ENAS5195_6.3.0.0",
	"name":"endomyocardial biopsy, EMB (HF)"
},
{
	"jumpto":"ENAS5329_6.2.2.0",
	"name":"Enoxaparin (STEMI)"
},
{
	"jumpto":"ENAS5080_5.3.1.0",
	"name":"Enoxaparin, dosing (NSTE-ACS)"
},
{
	"jumpto":"ENAS5079_7.4.0.0",
	"name":"Enterococcus spp., infective endocarditis"
},
{
	"jumpto":"ENAS5196_14.5.0.0",
	"name":"environment, population-based approach (CVD prev)"
},
{
	"jumpto":"ENAS5082_7.1.0.0",
	"name":"Epicardial access"
},
{
	"jumpto":"ENAS5327_4.0.0.0",
	"name":"Epidemiology"
},
{
	"jumpto":"ENAS5194_3.0.0.0",
	"name":"epidemiology, AF"
},
{
	"jumpto":"ENAS5329_3.3.0.0",
	"name":"Epidemiology, STEMI"
},
{
	"jumpto":"ENAS5530_29.1.0.0",
	"name":"Epilepsy and ictal asystole [Sync]"
},
{
	"jumpto":"ENAS5530_29.1.0.0",
	"name":"Epileptic aura [Sync]"
},
{
	"jumpto":"ENAS5081_6.2.3.2",
	"name":"Epoprostenol, PAH monotherapy"
},
{
	"jumpto":"ENAS5081_6.2.3.2",
	"name":"Epoprostenol, Prostanoids"
},
{
	"jumpto":"ENAS5081_5.7.0.0",
	"name":"Epoprostenol in vasoreactivity testing"
},
{
	"jumpto":"ENAS5530_15.0.0.0",
	"name":"EPS [Sync]"
},
{
	"jumpto":"ENAS5329_6.2.3.0",
	"name":"Eptifibatide (STEMI)"
},
{
	"jumpto":"ENAS5080_5.2.2.0",
	"name":"Eptifibatide, glycoprotein IIb/IIIa inhibitor (NSTE-ACS)"
},
{
	"jumpto":"ENAS5081_6.2.3.3",
	"name":"ERA + PDE-5i, PAH therapy"
},
{
	"jumpto":"ENAS5196_9.10.5.0",
	"name":"erectile dysfunction (CVD prev)"
},
{
	"jumpto":"ENAS5195_12.7.0.0",
	"name":"erectile dysfunction (HF)"
},
{
	"jumpto":"ENAS5079_5.4.2.0",
	"name":"ESC 2015 modified criteria, major (IE)"
},
{
	"jumpto":"ENAS5079_5.4.2.0",
	"name":"ESC 2015 modified criteria, minor (IE)"
},
{
	"jumpto":"ENAS5194_9.4.0.0",
	"name":"Esmolol (AFib)"
},
{
	"jumpto":"ENAS5082_5.2.2.3",
	"name":"Ethambutol, in tubercular pericarditis"
},
{
	"jumpto":"ENAS5196_10.4.0.0",
	"name":"ethnic minorities (CVD prev)"
},
{
	"jumpto":"ENAS5532_6.3.0.0",
	"name":"EuroSCORE CABG [MR]"
},
{
	"jumpto":"ENAS5532_6.3.0.0",
	"name":"EuroSCORE PCI [MR]"
},
{
	"jumpto":"ENAS5532_6.3.0.0",
	"name":"EuroSCOREs [MR]"
},
{
	"jumpto":"ENAS5195_11.2.0.0",
	"name":"euvolaemic"
},
{
	"jumpto":"ENAS5197_5.1.0.0",
	"name":"evaluation of lipid and apolipoprotein parameters (Dyslip)"
},
{
	"jumpto":"ENAS5328_4.1.0.0",
	"name":"Evaluation of patients for valvular intervention (VHD)"
},
{
	"jumpto":"ENAS5195_15.1.2.0",
	"name":"exercise (HF)"
},
{
	"jumpto":"ENAS5082_3.2.7.0",
	"name":"Exercise restriction, , acute pericarditis therapy"
},
{
	"jumpto":"ENAS5083_4.3.1.0",
	"name":"Exercise stress testing (VA and SCD)"
},
{
	"jumpto":"ENAS5530_17.0.0.0",
	"name":"Exercise stress testing [Sync]"
},
{
	"jumpto":"ENAS5328_6.2.4.0",
	"name":"Exercise testing (VHD)"
},
{
	"jumpto":"ENAS5081_10.3.0.0",
	"name":"Expert Center (PH)"
},
{
	"jumpto":"ENAS5081_11.0.0.0",
	"name":"Expert center (PH)"
},
{
	"jumpto":"ENAS5081_10.1.0.0",
	"name":"Expert center (PH)"
},
{
	"jumpto":"ENAS5081_9.0.0.0",
	"name":"Expert Center, group 3 PAH"
},
{
	"jumpto":"ENAS5081_8.2.0.0",
	"name":"Expert center, PAH"
},
{
	"jumpto":"ENAS5081_6.1.1.0",
	"name":"Extended lab (PH)"
},
{
	"jumpto":"ENAS5327_7.1.5.0",
	"name":"Extracranial CAD, management of [PAD]"
},
{
	"jumpto":"ENAS257_12.3.0.0",
	"name":"extra cranial CAD, mgmt. algorithm [DM]"
},
{
	"jumpto":"ENAS5197_4.1.10.0",
	"name":"factors modifying SCORE risks (Dyslip)"
},
{
	"jumpto":"ENAS5195_13.2.0.0",
	"name":"factors triggering, acute HF"
},
{
	"jumpto":"ENAS5197_11.1.0.0",
	"name":"familial dyslipidaemias"
},
{
	"jumpto":"ENAS5196_9.6.0.0",
	"name":"family history/(epi)genetics (CVD prev)"
},
{
	"jumpto":"ENAS5197_5.3.0.0",
	"name":"fasting (Dyslip)"
},
{
	"jumpto":"ENAS5195_12.11.0.0",
	"name":"felodipine (HF)"
},
{
	"jumpto":"ENAS5196_10.3.0.0",
	"name":"female-specific conditions (CVD prev)"
},
{
	"jumpto":"ENAS5328_12.2.6.2",
	"name":"Fibrinolysis (VHD)"
},
{
	"jumpto":"ENAS5329_6.3.1.0",
	"name":"Fibrinolysis, interventions (STEMI)"
},
{
	"jumpto":"ENAS5329_6.3.1.0",
	"name":"Fibrinolysis, transfer (STEMI)"
},
{
	"jumpto":"ENAS5329_6.3.1.0",
	"name":"Fibrinolysis and pharmacoinvasive strategy (STEMI)"
},
{
	"jumpto":"ENAS5329_8.5.0.0",
	"name":"Fibrinolysis strategy, interventions (STEMI)"
},
{
	"jumpto":"ENAS5329_6.3.1.0",
	"name":"Fibrinolytic therapy (STEMI)"
},
{
	"jumpto":"ENAS5329_6.3.3.0",
	"name":"Fibrinolytic therapy, contra-indications (STEMI)"
},
{
	"jumpto":"ENAS5329_6.3.2.0",
	"name":"Fibrinolytic therapy, doses (STEMI)"
},
{
	"jumpto":"ENAS259_6.7.0.0",
	"name":"first-degree atrioventricular block, pacing"
},
{
	"jumpto":"ENAS5329_5.1.0.0",
	"name":"First medical contact (STEMI)"
},
{
	"jumpto":"ENAS5079_5.2.4.0",
	"name":"Fistula, anatomic definition"
},
{
	"jumpto":"ENAS5079_5.2.4.0",
	"name":"Fistula, echocardiographic definition"
},
{
	"jumpto":"ENAS5194_10.1.3.0",
	"name":"Flecainide (AFib)"
},
{
	"jumpto":"interactive_0001875",
	"name":"Flow diagram for identifying unexplained falls (tool)"
},
{
	"jumpto":"ENAS5193_3.2.1.2",
	"name":"fluoropyrimidines, cardiotoxicity"
},
{
	"jumpto":"ENAS5328_4.2.1.0",
	"name":"Fluoroscopy, non-invasive investigation (VHD)"
},
{
	"jumpto":"ENAS5329_6.1.1.0",
	"name":"FMC (STEMI)"
},
{
	"jumpto":"ENAS5194_5.3.0.0",
	"name":"Focal AF"
},
{
	"jumpto":"ENAS264_14.4.2.0",
	"name":"follow-up after intervention for AAA (after open surgery)"
},
{
	"jumpto":"ENAS264_14.4.1.0",
	"name":"follow-up after intervention for AAA (endovascular repair)"
},
{
	"jumpto":"ENAS5533_12.2.0.0",
	"name":"Follow-up of hypertensive patients [HTN]"
},
{
	"jumpto":"ENAS5080_5.1.0.0",
	"name":"Fondaparinux (NSTE-ACS)"
},
{
	"jumpto":"ENAS5329_6.2.2.0",
	"name":"Fondaparinux (STEMI)"
},
{
	"jumpto":"ENAS5080_5.3.1.0",
	"name":"Fondaparinux, dosing (NSTE-ACS)"
},
{
	"jumpto":"ENAS5531_5.15.0.0",
	"name":"Fontan circulation [CVD Preg]"
},
{
	"jumpto":"ENAS258_9.2.0.0",
	"name":"fractional flow reserve [SCAD]"
},
{
	"jumpto":"ENAS5083_13.2.2.0",
	"name":"Fukutin-related protein"
},
{
	"jumpto":"ENAS5328_7.3.1.0",
	"name":"Functional MR (VHD)"
},
{
	"jumpto":"ENAS5532_4.0.0.0",
	"name":"Functional testing and intravascular imaging for lesion assessment [MR]"
},
{
	"jumpto":"ENAS5195_11.4.0.0",
	"name":"gastrointestinal haemorrhage (HF)"
},
{
	"jumpto":"ENAS5326_10.1.0.0",
	"name":"Gender and special populations, recommendations (DAPT)"
},
{
	"jumpto":"ENAS5082_4.2.3.0",
	"name":"General diagnositic work-up (Pericard.)"
},
{
	"jumpto":"ENAS5531_4.2.6.0",
	"name":"Genetic counselling and prenatal diagnosis [CVD Preg]"
},
{
	"jumpto":"ENAS5195_6.4.0.0",
	"name":"genetic testing, recommendations"
},
{
	"jumpto":"ENAS5533_9.1.0.0",
	"name":"Gestational hypertension, definition [HTN]"
},
{
	"jumpto":"ENAS5193_4.1.4.0",
	"name":"global longitudinal strain reduction, cardiotoxicity"
},
{
	"jumpto":"ENAS257_6.0.0.0",
	"name":"glycaemic continuum"
},
{
	"jumpto":"ENAS5195_15.1.3.0",
	"name":"goal of management (HF)"
},
{
	"jumpto":"ENAS5195_13.10.0.0",
	"name":"goals of treatment, AHF"
},
{
	"jumpto":"ENAS5195_12.8.0.0",
	"name":"gout and arthritis (HF)"
},
{
	"jumpto":"ENAS5329_6.2.2.0",
	"name":"GP IIb/IIIa inhibitors (STEMI)"
},
{
	"jumpto":"ENAS5081_8.1.0.0",
	"name":"Group 2 PH, key factors"
},
{
	"jumpto":"ENAS5081_9.0.0.0",
	"name":"Group 3 PAH, hemodynamic classification"
},
{
	"jumpto":"ENAS5329_9.2.0.0",
	"name":"Haemodynamic assessment (STEMI)"
},
{
	"jumpto":"ENAS5081_6.1.2.0",
	"name":"Haemodynamics (PH)"
},
{
	"jumpto":"ENAS5328_12.2.6.1",
	"name":"Haemolysis and paravalvular leak (VHD)"
},
{
	"jumpto":"interactive_0000284",
	"name":"HAS-BLED score (interactive score)"
},
{
	"jumpto":"ENAS5328_12.2.4.0",
	"name":"HAS-BLED score (VHD)"
},
{
	"jumpto":"ENAS5197_10.0.0.0",
	"name":"HDL-cholesterol and CVD risk (Dyslip)"
},
{
	"jumpto":"ENAS5079_7.5.0.0",
	"name":"Healthcare associated endocarditis"
},
{
	"jumpto":"ENAS5197_3.2.0.0",
	"name":"health impact pyramid, dyslipidaemias (Dyslip)"
},
{
	"jumpto":"ENAS5193_3.1.1.1",
	"name":"heart failure, cancer treatment"
},
{
	"jumpto":"ENAS5193_4.1.5.0",
	"name":"heart failure, cardiotoxicity"
},
{
	"jumpto":"ENAS259_5.4.2.0",
	"name":"Heart failure, clinical perspectives of pacemaker therapy [Pacing]"
},
{
	"jumpto":"ENAS259_5.1.0.0",
	"name":"heart failure, CRT [Pacing]"
},
{
	"jumpto":"ENAS5197_11.7.0.0",
	"name":"heart failure, dyslipidaemias"
},
{
	"jumpto":"ENAS259_5.4.1.0",
	"name":"Heart failure, indications for pacemaker [Pacing]"
},
{
	"jumpto":"ENAS257_10.0.0.0",
	"name":"heart failure, mgmt. in DM"
},
{
	"jumpto":"ENAS5080_5.6.5.0",
	"name":"Heart failure following NSTE-ACS, mgmt."
},
{
	"jumpto":"ENAS5194_10.8.0.0",
	"name":"heart team, AF"
},
{
	"jumpto":"ENAS5532_6.6.0.0",
	"name":"Heart team [MR]"
},
{
	"jumpto":"ENAS5195_14.4.2.0",
	"name":"heart transplantation, indications and contra-indications (HF)"
},
{
	"jumpto":"ENAS5195_14.4.1.0",
	"name":"heart transplantation, introduction"
},
{
	"jumpto":"ENAS5195_14.1.0.0",
	"name":"heart transplantation, overview (HF)"
},
{
	"jumpto":"ENAS259_6.2.0.0",
	"name":"heart transplantation, pacing [Pacing]"
},
{
	"jumpto":"ENAS5081_8.2.0.0",
	"name":"Heart transplantation, PAH"
},
{
	"jumpto":"ENAS5082_7.1.0.0",
	"name":"Hemopericardia"
},
{
	"jumpto":"ENAS5082_5.6.0.0",
	"name":"Hemopericardium"
},
{
	"jumpto":"ENAS5082_7.1.0.0",
	"name":"Hemoperitoneum"
},
{
	"jumpto":"ENAS5329_6.2.2.0",
	"name":"Heparin-induced thrombocytopenia (STEMI)"
},
{
	"jumpto":"ENAS5195_13.3.0.0",
	"name":"hepatojugular reflux (HF)"
},
{
	"jumpto":"ENAS5081_5.1.0.0",
	"name":"Hepatomegaly (PH)"
},
{
	"jumpto":"ENAS5193_4.3.2.0",
	"name":"HER-2 targeted therapy prevention, cardiotoxicity"
},
{
	"jumpto":"ENAS5081_4.2.1.0",
	"name":"Heritable PAH, BMPR2 mutation"
},
{
	"jumpto":"ENAS5081_4.2.1.0",
	"name":"Heritable PAH, other mutations"
},
{
	"jumpto":"ENAS5195_10.0.0.0",
	"name":"HFmrEF, treatment"
},
{
	"jumpto":"ENAS5195_10.0.0.0",
	"name":"HFpEF, treatment"
},
{
	"jumpto":"ENAS5195_8.2.0.0",
	"name":"HFrEF, therapeutic algorithm"
},
{
	"jumpto":"ENAS5195_12.13.1.0",
	"name":"HF treatment"
},
{
	"jumpto":"ENAS5530_6.2.0.0",
	"name":"High-risk and low-risk features [Sync]"
},
{
	"jumpto":"ENAS5326_8.2.0.0",
	"name":"High-risk features of stent-driven events (DAPT)"
},
{
	"jumpto":"ENAS5082_4.2.2.0",
	"name":"High-risk patients, clinical predictors (Pericard.)"
},
{
	"jumpto":"ENAS5080_3.2.0.0",
	"name":"High-sensitivity cardiac troponin assay, implications (NSTE-ACS)"
},
{
	"jumpto":"ENAS5080_3.5.3.0",
	"name":"High-sensitivity troponin 0h/1h rule-in NSTEMI algorithm"
},
{
	"jumpto":"ENAS5080_3.5.3.0",
	"name":"High-sensitivity troponin 0h/1h rule-out NSTEMI algorithm"
},
{
	"jumpto":"ENAS5080_3.5.2.0",
	"name":"High-sensitivity troponin 0h/3h rule-out NSTEMI algorithm"
},
{
	"jumpto":"ENAS5080_3.5.1.0",
	"name":"High-sensitivity troponin negative predictive value of MI"
},
{
	"jumpto":"ENAS5080_3.5.1.0",
	"name":"High-sensitivity troponin positive predictive value of MI"
},
{
	"jumpto":"ENAS5080_3.5.1.0",
	"name":"High-sensitivity troponin rule-in NSTEMI algorithm, overview"
},
{
	"jumpto":"ENAS5080_3.5.1.0",
	"name":"High-sensitivity troponin rule-out NSTEMI algorithm, overview"
},
{
	"jumpto":"ENAS5326_6.2.0.0",
	"name":"High bleeding risk (DAPT)"
},
{
	"jumpto":"ENAS5081_6.1.2.0",
	"name":"High risk, PAH"
},
{
	"jumpto":"ENAS5533_4.1.1.0",
	"name":"History, personal and family [HTN]"
},
{
	"jumpto":"ENAS5197_11.12.0.0",
	"name":"HIV patients, dyslipidaemias"
},
{
	"jumpto":"ENAS5533_3.4.0.0",
	"name":"Home blood pressure monitoring [HTN]"
},
{
	"jumpto":"ENAS5195_13.2.0.0",
	"name":"hormonal derangements (HF)"
},
{
	"jumpto":"ENAS5082_2.0.0.0",
	"name":"Horton disease"
},
{
	"jumpto":"ENAS5533_4.2.0.0",
	"name":"Hospital-based care, referral criteria [HTN]"
},
{
	"jumpto":"ENAS5197_4.1.8.0",
	"name":"how to use the risk estimation charts, dyslipidaemias"
},
{
	"jumpto":"ENAS5533_3.1.0.0",
	"name":"HTN, definition"
},
{
	"jumpto":"ENAS5533_5.5.0.0",
	"name":"HTN, drug therapy"
},
{
	"jumpto":"ENAS5533_5.4.0.0",
	"name":"HTN, lifestyle interventions"
},
{
	"jumpto":"ENAS5533_4.1.2.0",
	"name":"HTN, physical examination"
},
{
	"jumpto":"ENAS5533_4.1.3.0",
	"name":"HTN, routine evaluation"
},
{
	"jumpto":"ENAS5533_2.2.2.0",
	"name":"HTN, What’s changed?"
},
{
	"jumpto":"ENAS5533_2.2.3.0",
	"name":"HTN, What’s new?"
},
{
	"jumpto":"ENAS5533_11.1.0.0",
	"name":"HTN in patients with specific co-morbidities"
},
{
	"jumpto":"ENAS5531_11.3.0.0",
	"name":"HTN in pregnancy, definition and classification [CVD Preg]"
},
{
	"jumpto":"ENAS5533_3.2.0.0",
	"name":"HTN stages classification"
},
{
	"jumpto":"ENAS5195_8.4.0.0",
	"name":"hydralazine (HF)"
},
{
	"jumpto":"ENAS5082_6.2.1.0",
	"name":"Hydropericardium"
},
{
	"jumpto":"ENAS5197_8.6.0.0",
	"name":"hypercholesterolaemia, pharmacological treatment"
},
{
	"jumpto":"ENAS5329_7.2.4.0",
	"name":"Hyperglycaemia, management (STEMI)"
},
{
	"jumpto":"ENAS257_8.2.3.0",
	"name":"hyperglycaemia, mgmt."
},
{
	"jumpto":"ENAS5195_8.5.0.0",
	"name":"hyperkalaemia (HF)"
},
{
	"jumpto":"ENAS5195_12.9.0.0",
	"name":"hyperkalaemia (HF)"
},
{
	"jumpto":"ENAS5195_12.10.0.0",
	"name":"hyperlipidaemia (HF)"
},
{
	"jumpto":"ENAS5196_12.3.2.0",
	"name":"hypertension (CVD prev)"
},
{
	"jumpto":"ENAS5195_12.11.0.0",
	"name":"hypertension (HF)"
},
{
	"jumpto":"ENAS5531_11.7.0.0",
	"name":"Hypertension, management [CVD Preg]"
},
{
	"jumpto":"ENAS5531_11.4.0.0",
	"name":"Hypertension, prevention [CVD Preg]"
},
{
	"jumpto":"ENAS5533_4.1.4.0",
	"name":"Hypertension-mediated organ damage, assessment [HTN]"
},
{
	"jumpto":"ENAS5533_4.1.2.0",
	"name":"Hypertension-mediated organ damage, physical examination"
},
{
	"jumpto":"ENAS5533_8.0.0.0",
	"name":"Hypertension emergencies"
},
{
	"jumpto":"ENAS5533_9.1.0.0",
	"name":"Hypertension in pregnancy"
},
{
	"jumpto":"ENAS5531_11.3.0.0",
	"name":"Hypertension in pregnancy, definition and classification [CVD Preg]"
},
{
	"jumpto":"ENAS5531_11.5.1.0",
	"name":"Hypertension in pregnancy, management [CVD Preg]"
},
{
	"jumpto":"ENAS5531_11.5.2.0",
	"name":"Hypertension in pregnancy, non-pharmacological mgmt. [CVD Preg]"
},
{
	"jumpto":"ENAS5531_11.5.3.0",
	"name":"Hypertension in pregnancy, pharmacological mgmt. [CVD Preg]"
},
{
	"jumpto":"ENAS5196_12.3.3.0",
	"name":"hypertension thresholds (CVD prev)"
},
{
	"jumpto":"ENAS5533_8.0.0.0",
	"name":"Hypertension urgency"
},
{
	"jumpto":"ENAS5531_11.2.0.0",
	"name":"Hypertensive disorders, Dx and assessment [CVD Preg]"
},
{
	"jumpto":"ENAS5531_11.1.0.0",
	"name":"Hypertensive disorders [CVD Preg]"
},
{
	"jumpto":"ENAS5080_3.3.0.0",
	"name":"Hypertensive emergencies, troponin elevation (NSTE-ACS)"
},
{
	"jumpto":"ENAS5533_8.0.0.0",
	"name":"Hypertensive encephalopathy"
},
{
	"jumpto":"ENAS5197_9.1.0.0",
	"name":"hypertriglyceridaemia, causes (Dyslip)"
},
{
	"jumpto":"ENAS5083_8.2.1.0",
	"name":"Hypertrophic cardiomyopathy (VA and SCD)"
},
{
	"jumpto":"ENAS5083_8.2.1.0",
	"name":"Hypertrophic cardiomyopathy, introduction"
},
{
	"jumpto":"ENAS259_6.4.0.0",
	"name":"hypertrophic cardiomyopathy, pacing"
},
{
	"jumpto":"ENAS5083_8.2.2.0",
	"name":"Hypertrophic cardiomyopathy, prevention of SCD"
},
{
	"jumpto":"ENAS5531_9.6.0.0",
	"name":"Hypertrophic cardiomyopathy [CVD Preg]"
},
{
	"jumpto":"ENAS5530_26.3.0.0",
	"name":"Hypertrophic cardiomyopathy [Sync]"
},
{
	"jumpto":"ENAS5195_12.8.0.0",
	"name":"hyperuricemia (HF)"
},
{
	"jumpto":"ENAS5195_12.9.0.0",
	"name":"hypokalaemia (HF)"
},
{
	"jumpto":"ENAS5195_13.3.0.0",
	"name":"hypoperfusion (HF)"
},
{
	"jumpto":"ENAS5081_8.1.0.0",
	"name":"IAS bowing to right, group 2 PH"
},
{
	"jumpto":"ENAS264_8.8.0.0",
	"name":"iatrogenic aortic dissection"
},
{
	"jumpto":"ENAS5082_3.2.6.0",
	"name":"Ibuprofen, anti-inflammatory therapy (Pericard.)"
},
{
	"jumpto":"ENAS5082_6.1.2.0",
	"name":"Ibuprofen, in paediatric pericardial diseases"
},
{
	"jumpto":"ENAS5082_3.3.2.0",
	"name":"Ibuprofen, in recurrent pericarditis"
},
{
	"jumpto":"ENAS5194_10.1.3.0",
	"name":"Ibutilide (AFib)"
},
{
	"jumpto":"ENAS5195_9.1.0.0",
	"name":"ICD (HF)"
},
{
	"jumpto":"ENAS5329_9.3.0.0",
	"name":"ICD implantation (STEMI)"
},
{
	"jumpto":"ENAS5083_10.3.0.0",
	"name":"ICD implantation, in children"
},
{
	"jumpto":"ENAS5530_26.2.0.0",
	"name":"ICD indications in unexplained syncope and LVSD"
},
{
	"jumpto":"ENAS5083_6.2.2.0",
	"name":"ICD placement after MI (VA and SCD)"
},
{
	"jumpto":"ENAS5083_5.5.0.0",
	"name":"ICD treatment, psychosocial impact"
},
{
	"jumpto":"ENAS5083_11.3.0.0",
	"name":"Idiopathic ventricular fibrillation, treatment"
},
{
	"jumpto":"ENAS5083_4.1.0.0",
	"name":"Idiopathic VF, definition"
},
{
	"jumpto":"ENAS5083_11.2.0.0",
	"name":"Idiopathic VT, prevention"
},
{
	"jumpto":"ENAS5083_4.3.3.0",
	"name":"Idioventricular rhythm (VA and SCD)"
},
{
	"jumpto":"ENAS5079_7.5.0.0",
	"name":"IE treatment, acute severe cases/patients"
},
{
	"jumpto":"ENAS5079_12.0.0.0",
	"name":"IE treatment, anti-thrombotic therapy"
},
{
	"jumpto":"ENAS5079_7.2.0.0",
	"name":"IE treatment, beta-lactam allergic patients"
},
{
	"jumpto":"ENAS5079_7.4.0.0",
	"name":"IE treatment, Enterococcus spp."
},
{
	"jumpto":"ENAS5079_7.3.0.0",
	"name":"IE treatment, MRSA"
},
{
	"jumpto":"ENAS5079_7.3.0.0",
	"name":"IE treatment, MSSA"
},
{
	"jumpto":"ENAS5079_7.3.0.0",
	"name":"IE treatment, native valves"
},
{
	"jumpto":"ENAS5079_7.2.0.0",
	"name":"IE treatment, oral Streptococci"
},
{
	"jumpto":"ENAS5079_7.2.0.0",
	"name":"IE treatment, penicillin-susceptible strains"
},
{
	"jumpto":"ENAS5079_7.2.0.0",
	"name":"IE treatment, penicillin resistant strains"
},
{
	"jumpto":"ENAS5079_7.3.0.0",
	"name":"IE treatment, prosthetic valves"
},
{
	"jumpto":"ENAS5079_7.2.0.0",
	"name":"IE treatment, Streptococcus bovis"
},
{
	"jumpto":"ENAS5195_8.4.0.0",
	"name":"If-channel inhibitor (HF)"
},
{
	"jumpto":"ENAS5081_6.2.3.4",
	"name":"Iloprost + bosentan, PAH sequential combination therapy"
},
{
	"jumpto":"ENAS5081_5.7.0.0",
	"name":"Iloprost, in vasoreactivity testing"
},
{
	"jumpto":"ENAS5081_6.2.3.2",
	"name":"Iloprost, PAH monotherapy"
},
{
	"jumpto":"ENAS5081_6.2.3.2",
	"name":"Iloprost, Prostanoids"
},
{
	"jumpto":"ENAS5081_6.2.3.4",
	"name":"Iloprost inhaled added to bosentan, PH"
},
{
	"jumpto":"ENAS5081_6.1.2.0",
	"name":"Imaging (PH)"
},
{
	"jumpto":"ENAS5079_5.4.2.0",
	"name":"Imaging, positive for IE"
},
{
	"jumpto":"ENAS5327_11.2.0.0",
	"name":"Imaging in LEAD [PAD]"
},
{
	"jumpto":"ENAS5327_7.1.3.0",
	"name":"Imaging of extracranial carotid arteries [PAD]"
},
{
	"jumpto":"ENAS5080_5.5.2.0",
	"name":"Immediate invasive strategy, PCI in NSTE-ACS"
},
{
	"jumpto":"ENAS5081_6.2.2.1",
	"name":"Immunization of PAH patients"
},
{
	"jumpto":"ENAS5193_3.1.1.4",
	"name":"immunotherapies, cardiotoxicity"
},
{
	"jumpto":"ENAS5195_9.1.0.0",
	"name":"implantable cardioverter-defibrillator (HF)"
},
{
	"jumpto":"ENAS259_5.5.1.0",
	"name":"implantable cardioverter defibrillator, in CRT patients [Pacing]"
},
{
	"jumpto":"ENAS5195_14.2.0.0",
	"name":"implantation of LVAD (HF)"
},
{
	"jumpto":"ENAS5195_14.3.0.0",
	"name":"implantation of MCS (HF)"
},
{
	"jumpto":"ENAS5197_3.2.0.0",
	"name":"implementing healthy lifestyles, suggestions (Dyslip)"
},
{
	"jumpto":"ENAS5195_12.1.0.0",
	"name":"importance of co-morbidities (HF)"
},
{
	"jumpto":"ENAS5329_6.1.6.0",
	"name":"Important time targets, summary (STEMI)"
},
{
	"jumpto":"ENAS5082_3.2.1.0",
	"name":"Incessant pericarditis, definition"
},
{
	"jumpto":"ENAS5532_18.8.0.0",
	"name":"Indication for anticoagulation undergoing PCI [MR]"
},
{
	"jumpto":"ENAS5195_14.4.2.0",
	"name":"indications and contra-indications, heart transplantation (HF)"
},
{
	"jumpto":"ENAS5328_12.2.2.0",
	"name":"Indications for antithrombotic therapy in patients with a prosthetic valve intervention (VHD)"
},
{
	"jumpto":"ENAS5328_6.3.1.0",
	"name":"Indications for aortic valve interventions (VHD)"
},
{
	"jumpto":"ENAS5328_5.3.1.0",
	"name":"Indications for intervention, recommendations (VHD)"
},
{
	"jumpto":"ENAS5328_7.2.3.1",
	"name":"Indications for intervention in severe primary MR (VHD)"
},
{
	"jumpto":"ENAS5328_7.3.3.0",
	"name":"Indications for mitral valve intervention in chronic secondary mitral regurgitation, recommendation (VHD)"
},
{
	"jumpto":"ENAS5328_4.2.3.0",
	"name":"Indications for myocardial revascularization (VHD)"
},
{
	"jumpto":"ENAS5328_8.3.1.0",
	"name":"Indications for PMC and mitral valve surgery in mitral stenosis (VHD)"
},
{
	"jumpto":"ENAS5328_5.3.2.0",
	"name":"Indications for surgery in aortic root disease (VHD)"
},
{
	"jumpto":"ENAS5328_5.3.2.0",
	"name":"Indications for surgery in severe aortic regurgitation (VHD)"
},
{
	"jumpto":"interactive_0001466",
	"name":"Indications for surgery in TR (tool)"
},
{
	"jumpto":"ENAS5328_9.3.2.0",
	"name":"Indications for surgery in tricuspid regurgitation, algorithm (VHD)"
},
{
	"jumpto":"ENAS5196_10.1.0.0",
	"name":"individuals <50 years of age (CVD prev)"
},
{
	"jumpto":"ENAS5082_6.1.2.0",
	"name":"Indomethacin, in paediatric pericardial diseases"
},
{
	"jumpto":"ENAS5082_3.3.2.0",
	"name":"Indomethacin, in recurrent pericarditis"
},
{
	"jumpto":"ENAS5329_6.1.1.0",
	"name":"Infarct-related artery (STEMI)"
},
{
	"jumpto":"ENAS5329_6.1.3.0",
	"name":"Infarct-related artery, reperfusion strategy (STEMI)"
},
{
	"jumpto":"ENAS5079_12.0.0.0",
	"name":"Infective endocarditis, anti-thrombotic therapy"
},
{
	"jumpto":"ENAS5079_7.1.0.0",
	"name":"Infective endocarditis, antimicrobial therapy"
},
{
	"jumpto":"ENAS5079_10.0.0.0",
	"name":"Infective endocarditis, cardiac device-related"
},
{
	"jumpto":"ENAS5079_4.1.0.0",
	"name":"Infective endocarditis, complicated"
},
{
	"jumpto":"ENAS5079_5.1.0.0",
	"name":"Infective endocarditis, diagnosis"
},
{
	"jumpto":"ENAS5079_5.5.0.0",
	"name":"Infective endocarditis, diagnostic algorithm"
},
{
	"jumpto":"ENAS5079_8.2.0.0",
	"name":"Infective endocarditis, indications for surgery"
},
{
	"jumpto":"ENAS5079_2.0.0.0",
	"name":"Infective endocarditis, introduction"
},
{
	"jumpto":"ENAS5079_8.1.0.0",
	"name":"Infective endocarditis, left-sided"
},
{
	"jumpto":"ENAS5079_5.3.2.0",
	"name":"Infective endocarditis, microbio. diagnosis algorithm"
},
{
	"jumpto":"ENAS5079_5.3.1.0",
	"name":"Infective endocarditis, microbiological diagnosis"
},
{
	"jumpto":"ENAS5079_9.0.0.0",
	"name":"Infective endocarditis, neurological complications"
},
{
	"jumpto":"ENAS5079_4.1.0.0",
	"name":"Infective endocarditis, non-complicated"
},
{
	"jumpto":"ENAS5079_3.4.0.0",
	"name":"Infective endocarditis, non-specific preventive measures"
},
{
	"jumpto":"ENAS5079_6.2.0.0",
	"name":"Infective endocarditis, predictors of poor outcome"
},
{
	"jumpto":"ENAS5079_3.1.0.0",
	"name":"Infective endocarditis, principles of prevention"
},
{
	"jumpto":"ENAS5079_11.0.0.0",
	"name":"Infective endocarditis, right-sided"
},
{
	"jumpto":"ENAS5079_3.1.0.0",
	"name":"Infective endocarditis, role of antibiotic prophylaxis"
},
{
	"jumpto":"ENAS5531_4.2.9.0",
	"name":"Infective endocarditis [CVD Preg]"
},
{
	"jumpto":"ENAS5196_9.10.1.0",
	"name":"influenza (CVD prev)"
},
{
	"jumpto":"ENAS5083_4.3.4.0",
	"name":"Inherited arrhythmogenic disease"
},
{
	"jumpto":"ENAS5194_11.2.0.0",
	"name":"Inherited cardiomyopathies and channelopathies (AFib)"
},
{
	"jumpto":"ENAS5083_9.1.0.0",
	"name":"Inherited primary arrhythmia syndrome"
},
{
	"jumpto":"ENAS5329_5.1.0.0",
	"name":"Initial diagnosis, emergency care (STEMI)"
},
{
	"jumpto":"ENAS5329_5.1.0.0",
	"name":"Initial diagnosis, recommendations (STEMI)"
},
{
	"jumpto":"interactive_0001867",
	"name":"Initial evaluation &amp; risk stratification of syncope (tool)"
},
{
	"jumpto":"ENAS5195_13.5.0.0",
	"name":"initial management, patient with AHF"
},
{
	"jumpto":"interactive_0000593",
	"name":"Initial Management of AHF (interactive algorithm)"
},
{
	"jumpto":"ENAS5329_9.1.0.0",
	"name":"Inotropic agents (STEMI)"
},
{
	"jumpto":"ENAS5326_8.1.0.0",
	"name":"INR (DAPT)"
},
{
	"jumpto":"ENAS5080_4.2.0.0",
	"name":"Intermediate care unit (NSTE-ACS)"
},
{
	"jumpto":"ENAS5081_6.1.2.0",
	"name":"Intermediate risk, PAH"
},
{
	"jumpto":"ENAS259_4.3.2.0",
	"name":"intermittent bradycardia, choice of pacing mode"
},
{
	"jumpto":"ENAS259_4.3.2.0",
	"name":"intermittent bradycardia, clinical perspective"
},
{
	"jumpto":"ENAS259_4.3.1.0",
	"name":"intermittent bradycardia, indications for pacing"
},
{
	"jumpto":"ENAS5327_11.4.0.0",
	"name":"Intermittent claudication, management [PAD]"
},
{
	"jumpto":"ENAS5328_12.2.5.0",
	"name":"Interruption of anticoagulant therapy for planned invasive procedures (VHD)"
},
{
	"jumpto":"ENAS5328_12.2.5.0",
	"name":"interruption of oral anticoagulation (VHD)"
},
{
	"jumpto":"ENAS5081_10.3.0.0",
	"name":"Interventional BPA, CTEPH"
},
{
	"jumpto":"ENAS5083_5.4.1.0",
	"name":"Interventional therapy of VA, catheter ablation"
},
{
	"jumpto":"ENAS5329_8.4.0.0",
	"name":"Interventions in primary PCI strategy (STEMI)"
},
{
	"jumpto":"ENAS5329_8.5.0.0",
	"name":"Interventions in successful fibrinolysis strategy (STEMI)"
},
{
	"jumpto":"ENAS5197_4.2.3.0",
	"name":"intervention strategies, dyslipidaemias"
},
{
	"jumpto":"interactive_0000279",
	"name":"Intervention strategy (interactive calculator)"
},
{
	"jumpto":"ENAS5531_10.4.0.0",
	"name":"Interventions [CVD Preg]"
},
{
	"jumpto":"ENAS5081_5.4.0.0",
	"name":"Interventricular septum flattening (PH)"
},
{
	"jumpto":"ENAS5081_5.6.0.0",
	"name":"Interventricular septum flattening (PH)"
},
{
	"jumpto":"ENAS5329_9.2.0.0",
	"name":"Intra-aortic balloon pump (STEMI)"
},
{
	"jumpto":"ENAS5532_14.0.0.0",
	"name":"Intracoronary imaging for the assessment of stent failure [MR]"
},
{
	"jumpto":"ENAS5195_11.4.0.0",
	"name":"intracranial haemorrhage (HF)"
},
{
	"jumpto":"ENAS264_8.3.0.0",
	"name":"intramural haematoma"
},
{
	"jumpto":"ENAS258_9.2.0.0",
	"name":"intravascular ultrasound [SCAD]"
},
{
	"jumpto":"ENAS5329_9.3.0.0",
	"name":"Intravenous amiodarone (STEMI)"
},
{
	"jumpto":"ENAS5329_9.3.0.0",
	"name":"Intravenous beta-blockers (STEMI)"
},
{
	"jumpto":"ENAS5329_9.3.0.0",
	"name":"Intravenous digitalis (STEMI)"
},
{
	"jumpto":"ENAS5195_12.13.1.0",
	"name":"intravenous FCM (HF)"
},
{
	"jumpto":"ENAS5195_11.4.0.0",
	"name":"intravenous heparin (HF)"
},
{
	"jumpto":"ENAS5195_13.8.2.0",
	"name":"intravenous loop diuretics (HF)"
},
{
	"jumpto":"ENAS5196_3.0.0.0",
	"name":"introduction (CVD prev)"
},
{
	"jumpto":"ENAS5083_3.0.0.0",
	"name":"Introduction (VA and SCD)"
},
{
	"jumpto":"ENAS5195_14.4.1.0",
	"name":"introduction, heart transplantation"
},
{
	"jumpto":"ENAS5329_3.1.0.0",
	"name":"Introduction, overview (STEMI)"
},
{
	"jumpto":"ENAS5083_9.2.2.0",
	"name":"Invasive EPS"
},
{
	"jumpto":"ENAS5080_5.5.2.0",
	"name":"Invasive strategy, PCI in NSTE-ACS"
},
{
	"jumpto":"ENAS5329_6.1.1.0",
	"name":"IRA (STEMI)"
},
{
	"jumpto":"ENAS5329_6.2.1.0",
	"name":"IRA strategy (STEMI)"
},
{
	"jumpto":"ENAS5329_6.2.1.0",
	"name":"IRA technique (STEMI)"
},
{
	"jumpto":"ENAS5195_12.12.0.0",
	"name":"iron deficiency (HF)"
},
{
	"jumpto":"ENAS258_7.1.0.0",
	"name":"ischaemia, diagnosis [SCAD]"
},
{
	"jumpto":"ENAS5329_5.1.0.0",
	"name":"Ischaemia, ECG presentation (STEMI)"
},
{
	"jumpto":"ENAS5326_8.5.0.0",
	"name":"Ischaemic risk (DAPT)"
},
{
	"jumpto":"ENAS5081_4.1.2.0",
	"name":"Isolated post-capillary PH"
},
{
	"jumpto":"ENAS5329_5.1.0.0",
	"name":"Isolated posterior myocardial infarction, ECG presentation (STEMI)"
},
{
	"jumpto":"ENAS5082_5.2.2.3",
	"name":"Isoniazid, in tubercular pericarditis"
},
{
	"jumpto":"ENAS5083_9.4.2.0",
	"name":"Isoproterenol, Brugada syndrome"
},
{
	"jumpto":"ENAS5195_8.4.0.0",
	"name":"isosorbide dinitrate (HF)"
},
{
	"jumpto":"ENAS5195_8.2.0.0",
	"name":"ivabradine (HF)"
},
{
	"jumpto":"ENAS5081_6.2.2.2",
	"name":"Ivabradine (PH)"
},
{
	"jumpto":"ENAS5082_3.3.4.0",
	"name":"IVIG, in recurrent pericarditis"
},
{
	"jumpto":"ENAS5195_13.3.0.0",
	"name":"jugular venous dilatation (HF)"
},
{
	"jumpto":"ENAS5081_5.1.0.0",
	"name":"Jugular venous pressure, elevated (PH)"
},
{
	"jumpto":"ENAS5083_13.2.1.0",
	"name":"Kearns-Sayre syndrome"
},
{
	"jumpto":"ENAS5081_8.1.0.0",
	"name":"Kerley B lines, group 2 PH"
},
{
	"jumpto":"ENAS5197_4.2.2.0",
	"name":"key messages, dyslipidaemias"
},
{
	"jumpto":"ENAS5195_12.14.0.0",
	"name":"kidney dysfunction (HF)"
},
{
	"jumpto":"ENAS5082_3.8.2.0",
	"name":"Kussumal sign (Pericard.)"
},
{
	"jumpto":"ENAS5194_8.8.0.0",
	"name":"LAA exclusion (AFib)"
},
{
	"jumpto":"ENAS5194_8.8.0.0",
	"name":"LAA occlusion (AFib)"
},
{
	"jumpto":"ENAS5197_5.1.0.0",
	"name":"laboratory lipid and apolipoprotein parameters (Dyslip)"
},
{
	"jumpto":"ENAS5327_5.3.0.0",
	"name":"Laboratory tests"
},
{
	"jumpto":"ENAS5083_13.2.2.0",
	"name":"Lamin A/C"
},
{
	"jumpto":"ENAS5195_6.2.0.0",
	"name":"late gadolinium enhancement, LGT (HF)"
},
{
	"jumpto":"ENAS5327_11.2.0.0",
	"name":"LEAD, ABI [PAD]"
},
{
	"jumpto":"ENAS5327_11.1.0.0",
	"name":"LEAD, clinical presentation [PAD]"
},
{
	"jumpto":"ENAS5327_11.2.0.0",
	"name":"LEAD, diagnostic tests [PAD]"
},
{
	"jumpto":"ENAS5327_11.2.0.0",
	"name":"LEAD, doppler waveform analysis [PAD]"
},
{
	"jumpto":"ENAS5327_11.1.0.0",
	"name":"LEAD, Fontaine classification [PAD]"
},
{
	"jumpto":"ENAS5327_11.2.0.0",
	"name":"LEAD, imaging techniques [PAD]"
},
{
	"jumpto":"ENAS5327_11.3.0.0",
	"name":"LEAD, revascularization of aorto-iliac occlusive lesions [PAD]"
},
{
	"jumpto":"ENAS5327_11.3.0.0",
	"name":"LEAD, revascularization of femoro-popliteal occlusive lesions [PAD]"
},
{
	"jumpto":"ENAS5327_11.3.0.0",
	"name":"LEAD, revascularization of infra-popliteal occlusive lesions [PAD]"
},
{
	"jumpto":"ENAS5327_11.1.0.0",
	"name":"LEAD, Rutherford classification [PAD]"
},
{
	"jumpto":"ENAS5327_11.2.0.0",
	"name":"LEAD, toe-brachial index [PAD]"
},
{
	"jumpto":"ENAS5327_11.1.0.0",
	"name":"LEAD [PAD]"
},
{
	"jumpto":"ENAS5079_8.1.0.0",
	"name":"Left-sided valve IE, introduction"
},
{
	"jumpto":"ENAS5195_9.2.0.0",
	"name":"left bundle branch block (HF)"
},
{
	"jumpto":"ENAS259_5.2.1.0",
	"name":"left bundle branch block [Pacing]"
},
{
	"jumpto":"ENAS5083_9.2.2.0",
	"name":"Left cardiac sympathetic denervation"
},
{
	"jumpto":"ENAS5081_8.1.0.0",
	"name":"Left heart failure, group 2 PH"
},
{
	"jumpto":"ENAS5081_8.2.0.0",
	"name":"Left ventricular assist devices (LVAD), PAH"
},
{
	"jumpto":"ENAS5329_9.1.0.0",
	"name":"Left ventricular dysfunction, mgmt. (STEMI)"
},
{
	"jumpto":"ENAS5531_5.5.0.0",
	"name":"Left ventricular outflow tract obstruction [CVD Preg]"
},
{
	"jumpto":"ENAS5079_5.3.2.0",
	"name":"Legionella Pneumophila (IE)"
},
{
	"jumpto":"ENAS5195_9.1.0.0",
	"name":"lethal ventricular arrhythmias (HF)"
},
{
	"jumpto":"ENAS5196_2.0.0.0",
	"name":"levels of evidence (CVD prev)"
},
{
	"jumpto":"ENAS5081_2.0.0.0",
	"name":"Levels of evidence (PH)"
},
{
	"jumpto":"ENAS5083_2.0.0.0",
	"name":"Levels of evidence (VA and SCD)"
},
{
	"jumpto":"ENAS5195_13.8.2.0",
	"name":"levosimendan (HF)"
},
{
	"jumpto":"ENAS5083_6.1.3.0",
	"name":"Lidocaine (VA and SCD)"
},
{
	"jumpto":"ENAS5326_10.2.0.0",
	"name":"Life-threatening bleeding (DAPT)"
},
{
	"jumpto":"ENAS5197_7.2.0.0",
	"name":"lifestyle changes/LDL (Dyslip)"
},
{
	"jumpto":"ENAS5197_7.1.0.0",
	"name":"lifestyle changes/lipids (Dyslip)"
},
{
	"jumpto":"ENAS5197_13.1.0.0",
	"name":"lifestyle changes strategy (Dyslip)"
},
{
	"jumpto":"ENAS5329_8.1.0.0",
	"name":"Lifestyle interventions (STEMI)"
},
{
	"jumpto":"ENAS5083_13.2.1.0",
	"name":"Limb-girdle muscular dystrophy"
},
{
	"jumpto":"ENAS5197_5.2.0.0",
	"name":"lipid analyses before Tx (Dyslip)"
},
{
	"jumpto":"ENAS5197_5.4.0.0",
	"name":"lipid and lipoprotein analyses (Dyslip)"
},
{
	"jumpto":"ENAS5196_11.6.1.0",
	"name":"lipid control (CVD prev)"
},
{
	"jumpto":"ENAS5196_11.6.2.0",
	"name":"lipid intervention (CVD prev)"
},
{
	"jumpto":"ENAS5329_8.3.0.0",
	"name":"Lipid lowering therapies (STEMI)"
},
{
	"jumpto":"ENAS5196_5.0.0.0",
	"name":"lipids (CVD prev)"
},
{
	"jumpto":"ENAS5195_6.3.0.0",
	"name":"liver function tests (HF)"
},
{
	"jumpto":"ENAS5081_7.4.0.0",
	"name":"Liver transplantation (PH)"
},
{
	"jumpto":"ENAS5080_5.1.0.0",
	"name":"LMWH (NSTE-ACS)"
},
{
	"jumpto":"ENAS5328_12.2.5.0",
	"name":"LMWH (VHD)"
},
{
	"jumpto":"ENAS264_10.2.4.0",
	"name":"Loeys-Dietz syndrome"
},
{
	"jumpto":"ENAS5329_7.1.0.0",
	"name":"Logistical issues for hospital stay (STEMI)"
},
{
	"jumpto":"ENAS5329_5.4.0.0",
	"name":"Logistics of prehospital care, recommendations (STEMI)"
},
{
	"jumpto":"interactive_0000559",
	"name":"Long-term HR control of AF (interactive algorithm)"
},
{
	"jumpto":"ENAS5194_10.2.2.0",
	"name":"long-term rhythm control, AF"
},
{
	"jumpto":"ENAS5193_5.1.0.0",
	"name":"long-term surveillance, cancer patients"
},
{
	"jumpto":"ENAS5193_5.2.0.0",
	"name":"long-term surveillance, myocardial dysfunction"
},
{
	"jumpto":"ENAS5193_5.4.0.0",
	"name":"long-term surveillance, valvular disease"
},
{
	"jumpto":"ENAS5193_5.3.0.0",
	"name":"long-term surveillance, vascular disease"
},
{
	"jumpto":"ENAS5329_8.1.0.0",
	"name":"Long-term therapies for STEMI"
},
{
	"jumpto":"ENAS5083_9.2.1.0",
	"name":"Long QT syndrome, diagnosis"
},
{
	"jumpto":"ENAS259_6.5.0.0",
	"name":"long QT syndrome, pacing therapy,"
},
{
	"jumpto":"ENAS5530_26.5.0.0",
	"name":"Long QT syndrome [Sync]"
},
{
	"jumpto":"ENAS5081_9.0.0.0",
	"name":"Long term oxygen therapy, group 3 PAH"
},
{
	"jumpto":"ENAS5328_5.4.0.0",
	"name":"Losartan (VHD)"
},
{
	"jumpto":"ENAS5326_10.1.0.0",
	"name":"Lower-extremities artery disease, LEAD (DAPT)"
},
{
	"jumpto":"ENAS5327_11.1.0.0",
	"name":"Lower extremity artery disease[PAD]"
},
{
	"jumpto":"ENAS5195_11.4.0.0",
	"name":"low molecular weight heparin, LMWH (HF)"
},
{
	"jumpto":"ENAS5081_6.1.2.0",
	"name":"Low risk, PAH"
},
{
	"jumpto":"ENAS5083_9.2.2.0",
	"name":"LQTS, risk stratification and management"
},
{
	"jumpto":"ENAS5530_26.5.0.0",
	"name":"LQTS [Sync]"
},
{
	"jumpto":"ENAS5195_12.15.0.0",
	"name":"lung disease (HF)"
},
{
	"jumpto":"ENAS5081_11.0.0.0",
	"name":"Lung transplantation (PH)"
},
{
	"jumpto":"ENAS5081_10.3.0.0",
	"name":"Lung transplantation (PH)"
},
{
	"jumpto":"ENAS5081_9.0.0.0",
	"name":"Lung transplantation, group 3 PAH"
},
{
	"jumpto":"ENAS5329_9.1.0.0",
	"name":"LV dysfunction (STEMI)"
},
{
	"jumpto":"ENAS5193_3.1.1.1",
	"name":"LV dysfunction, cancer treatment"
},
{
	"jumpto":"ENAS5083_7.1.0.0",
	"name":"LV dysfunction, use of drugs"
},
{
	"jumpto":"ENAS5083_6.2.2.0",
	"name":"LV dysfunction assessment, after dishcharge (VA and SCD)"
},
{
	"jumpto":"ENAS5083_6.2.2.0",
	"name":"LV dysfunction assessment, before dishcharge (VA and SCD)"
},
{
	"jumpto":"ENAS5083_7.1.0.0",
	"name":"LV dysfunctiuon, ICD implant"
},
{
	"jumpto":"ENAS5193_4.1.3.0",
	"name":"LVEF reduction, cardiotoxicity"
},
{
	"jumpto":"ENAS5081_6.2.3.2",
	"name":"Macitentan, PAH monotherapy"
},
{
	"jumpto":"ENAS5081_6.2.3.4",
	"name":"Macitentan added to sildenafil, PH"
},
{
	"jumpto":"ENAS259_8.3.0.0",
	"name":"magnet resonance imaging, implanted cardiac devices"
},
{
	"jumpto":"ENAS5329_8.2.0.0",
	"name":"Maintenance, antithrombotic strategy after STEMI"
},
{
	"jumpto":"ENAS5196_6.0.0.0",
	"name":"major new key messages (CVD prev)"
},
{
	"jumpto":"ENAS5533_8.0.0.0",
	"name":"Malignant hypertension"
},
{
	"jumpto":"ENAS5329_9.3.0.0",
	"name":"Management, atrial fibrillation (STEMI)"
},
{
	"jumpto":"ENAS5195_11.6.0.0",
	"name":"management, bradycardia (HF)"
},
{
	"jumpto":"ENAS5195_13.8.4.0",
	"name":"management, cardiogenic shock (HF)"
},
{
	"jumpto":"ENAS5327_11.5.0.0",
	"name":"Management, chronic limb-threatening ischaemia [PAD]"
},
{
	"jumpto":"ENAS5329_7.2.4.0",
	"name":"Management, hyperglycaemia (STEMI)"
},
{
	"jumpto":"ENAS5329_7.3.2.0",
	"name":"Management, non-invasive imaging (STEMI)"
},
{
	"jumpto":"ENAS5329_9.3.0.0",
	"name":"Management, ventricular arrhythmias (STEMI)"
},
{
	"jumpto":"ENAS5195_11.5.0.0",
	"name":"management, ventricular tachycardia (HF)"
},
{
	"jumpto":"ENAS5328_12.2.2.0",
	"name":"Management after prosthetic valve intervention, recommendations (VHD)"
},
{
	"jumpto":"ENAS5328_12.2.1.0",
	"name":"Management after valve intervention, overview (VHD)"
},
{
	"jumpto":"ENAS5328_13.1.0.0",
	"name":"Management during non-cardiac surgery, overview (VHD)"
},
{
	"jumpto":"ENAS5328_14.2.0.0",
	"name":"Management during pregnancy, native valve disease (VHD)"
},
{
	"jumpto":"ENAS5328_14.1.0.0",
	"name":"Management during pregnancy, overview (VHD)"
},
{
	"jumpto":"ENAS5328_14.3.0.0",
	"name":"Management during pregnancy, prosthetic valves (VHD)"
},
{
	"jumpto":"interactive_0001441",
	"name":"Management of acute limb ischaemia (tool)"
},
{
	"jumpto":"ENAS5327_9.1.0.0",
	"name":"Management of acute mesenteric ischaemia [PAD]"
},
{
	"jumpto":"ENAS5531_12.4.0.0",
	"name":"Management of acute venous thromboembolism [CVD Preg]"
},
{
	"jumpto":"interactive_0000596",
	"name":"Management of AHF (interactive algorithm)"
},
{
	"jumpto":"ENAS5195_13.8.1.0",
	"name":"management of AHF, algorithm"
},
{
	"jumpto":"interactive_0001884",
	"name":"Management of AHF during pregnancy (tool)"
},
{
	"jumpto":"ENAS5194_4.2.0.0",
	"name":"management of AHRE (AFib)"
},
{
	"jumpto":"interactive_0001442",
	"name":"Management of antithromb. Tx in CA stenosis (tool)"
},
{
	"jumpto":"interactive_0001431",
	"name":"Management of aortic regurgitation (tool)"
},
{
	"jumpto":"ENAS5328_5.3.2.0",
	"name":"Management of aortic regurgitation (VHD)"
},
{
	"jumpto":"ENAS5531_10.6.0.0",
	"name":"Management of arrhythmias [CVD Preg]"
},
{
	"jumpto":"ENAS5328_4.8.0.0",
	"name":"Management of associated conditions (VHD)"
},
{
	"jumpto":"ENAS5327_7.1.4.0",
	"name":"Management of asymptomatic CAD [PAD]"
},
{
	"jumpto":"ENAS5328_4.8.0.0",
	"name":"Management of atrial fibrillation, recommendations (VHD)"
},
{
	"jumpto":"ENAS5194_11.7.0.0",
	"name":"management of atrial flutter"
},
{
	"jumpto":"ENAS5194_8.10.3.0",
	"name":"management of bleeding, AF"
},
{
	"jumpto":"ENAS5328_4.2.3.0",
	"name":"Management of CAD (VHD)"
},
{
	"jumpto":"ENAS5328_4.8.0.0",
	"name":"Management of CAD (VHD)"
},
{
	"jumpto":"ENAS5531_9.8.0.0",
	"name":"Management of cardiomyopathies and HF [CVD Preg]"
},
{
	"jumpto":"ENAS5327_9.2.0.0",
	"name":"Management of chronic mesenteric artery disease[PAD]"
},
{
	"jumpto":"ENAS5328_8.3.2.0",
	"name":"Management of clinically significant mitral stenosis (VHD)"
},
{
	"jumpto":"interactive_0001438",
	"name":"Management of clinically significant MS (tool)"
},
{
	"jumpto":"interactive_0001443",
	"name":"Management of CLTI (tool)"
},
{
	"jumpto":"interactive_0001444",
	"name":"Management of extracranial CAD (tool)"
},
{
	"jumpto":"ENAS5327_7.1.5.0",
	"name":"Management of extracranial CAD [PAD]"
},
{
	"jumpto":"ENAS5533_9.2.0.0",
	"name":"Management of hypertension in pregnancy"
},
{
	"jumpto":"ENAS5531_11.5.1.0",
	"name":"Management of hypertension in pregnancy [CVD Preg]"
},
{
	"jumpto":"ENAS5531_11.7.0.0",
	"name":"Management of hypertension [CVD Preg]"
},
{
	"jumpto":"interactive_0001446",
	"name":"Management of intermittent claudication (tool)"
},
{
	"jumpto":"ENAS5328_12.2.6.3",
	"name":"Management of left-sided non-obstructive mechanical prosthetic thrombosis (VHD)"
},
{
	"jumpto":"ENAS5328_12.2.6.2",
	"name":"Management of left-sided obstructive mechanical prosthetic thrombosis (VHD)"
},
{
	"jumpto":"ENAS5531_7.7.0.0",
	"name":"Management of native valvular heart disease [CVD Preg]"
},
{
	"jumpto":"ENAS5531_9.4.0.0",
	"name":"Management of PPCM and DCM [CVD Preg]"
},
{
	"jumpto":"ENAS5531_7.8.0.0",
	"name":"Management of prosthetic heart valves [CVD Preg]"
},
{
	"jumpto":"ENAS5328_6.3.2.0",
	"name":"Management of severe aortic stenosis (VHD)"
},
{
	"jumpto":"ENAS5328_13.3.0.0",
	"name":"Management of severe aortic stenosis and elective non-cardiac surgery (VHD)"
},
{
	"jumpto":"ENAS5328_7.2.3.2",
	"name":"Management of severe chronic primary mitral regurgitation (VHD)"
},
{
	"jumpto":"interactive_0001435",
	"name":"Management of severe chronic primary MR (tool)"
},
{
	"jumpto":"ENAS5080_6.1.0.0",
	"name":"Management strategy, summary (NSTE-ACS)"
},
{
	"jumpto":"ENAS5533_12.1.0.0",
	"name":"Managing concomitant CVD risk & follow-up [HTN]"
},
{
	"jumpto":"ENAS5328_5.4.0.0",
	"name":"Marfan syndrome (VHD)"
},
{
	"jumpto":"ENAS5533_4.1.7.0",
	"name":"Markers of HMOD, sensitivity [HTN]"
},
{
	"jumpto":"ENAS5533_10.3.0.0",
	"name":"Masked hypertension, management [HTN]"
},
{
	"jumpto":"ENAS5533_10.2.0.0",
	"name":"Masked hypertension [HTN]"
},
{
	"jumpto":"ENAS5329_6.1.2.0",
	"name":"Maximum target times (STEMI)"
},
{
	"jumpto":"ENAS5533_3.3.0.0",
	"name":"Measurement of blood pressure [HTN]"
},
{
	"jumpto":"ENAS5326_4.2.3.0",
	"name":"Measures to minimize bleeding, recommendations (DAPT)"
},
{
	"jumpto":"ENAS5195_14.1.0.0",
	"name":"mechanical circulatory support, overview (HF)"
},
{
	"jumpto":"ENAS5328_12.1.0.0",
	"name":"Mechanical prosthesis (VHD)"
},
{
	"jumpto":"ENAS5328_12.2.6.1",
	"name":"Mechanical prosthetic thrombosis (VHD)"
},
{
	"jumpto":"ENAS5328_12.1.0.0",
	"name":"Mechanical valve (VHD)"
},
{
	"jumpto":"ENAS5081_6.1.1.0",
	"name":"Medical assessment and determination of functional class (PH)"
},
{
	"jumpto":"ENAS5327_5.5.0.0",
	"name":"Medical therapy"
},
{
	"jumpto":"ENAS5328_5.4.0.0",
	"name":"Medical therapy, aortic regurgitation (VHD)"
},
{
	"jumpto":"ENAS5328_6.4.0.0",
	"name":"Medical therapy, aortic stenosis (VHD)"
},
{
	"jumpto":"ENAS5532_20.0.0.0",
	"name":"Medical Tx, secondary prev., & strategies for follow-up [MR]"
},
{
	"jumpto":"ENAS5196_12.5.0.0",
	"name":"medication adherence (CVD prev)"
},
{
	"jumpto":"ENAS5533_7.5.0.0",
	"name":"Medications & substances that may increase BP"
},
{
	"jumpto":"ENAS5197_13.2.0.0",
	"name":"medication strategy (Dyslip)"
},
{
	"jumpto":"interactive_0000564",
	"name":"mEHRA scale (interactive score)"
},
{
	"jumpto":"ENAS5194_5.4.0.0",
	"name":"mEHRA symptom scale (AFib)"
},
{
	"jumpto":"ENAS5530_12.0.0.0",
	"name":"Mental arithmetic test [Sync]"
},
{
	"jumpto":"ENAS5197_11.13.0.0",
	"name":"mental disorders, dyslipidaemias"
},
{
	"jumpto":"ENAS5327_9.1.0.0",
	"name":"Mesenteric artery disease [PAD]"
},
{
	"jumpto":"ENAS5195_13.2.0.0",
	"name":"metabolic derangements (HF)"
},
{
	"jumpto":"ENAS5081_8.1.0.0",
	"name":"Metabolic syndrome, group 2 PH"
},
{
	"jumpto":"ENAS5195_12.6.0.0",
	"name":"metformin (HF)"
},
{
	"jumpto":"ENAS5194_9.4.0.0",
	"name":"Metoprolol (AFib)"
},
{
	"jumpto":"interactive_0001868",
	"name":"Mgmt. & risk strat. of pts. referred to the ED for TLOC (tool)"
},
{
	"jumpto":"ENAS5329_9.1.0.0",
	"name":"Mgmt., acute heart failure (STEMI)"
},
{
	"jumpto":"ENAS5329_9.2.0.0",
	"name":"Mgmt., cardiogenic shock (STEMI)"
},
{
	"jumpto":"ENAS5329_7.2.2.0",
	"name":"Mgmt., elderly patients (STEMI)"
},
{
	"jumpto":"ENAS5329_9.1.0.0",
	"name":"Mgmt., left ventricular dysfunction (STEMI)"
},
{
	"jumpto":"ENAS5329_7.2.1.0",
	"name":"Mgmt., patients taking oral anticoagulation (STEMI)"
},
{
	"jumpto":"ENAS5329_7.2.3.0",
	"name":"Mgmt., renal dysfunction (STEMI)"
},
{
	"jumpto":"interactive_0000555",
	"name":"Mgmt. of active bleeding (interactive algorithm)"
},
{
	"jumpto":"interactive_0000551",
	"name":"Mgmt. of AHRE (interactive algorithm)"
},
{
	"jumpto":"ENAS257_11.1.0.0",
	"name":"mgmt. of arrhythmia [DM]"
},
{
	"jumpto":"interactive_0001863",
	"name":"Mgmt. of cardiogenic shock (tool)"
},
{
	"jumpto":"ENAS5328_12.2.6.1",
	"name":"Mgmt. of complications, recommendations (VHD)"
},
{
	"jumpto":"interactive_0001468",
	"name":"Mgmt. of left-sided obstructive mechanical PVT (tool)"
},
{
	"jumpto":"interactive_0001467",
	"name":"Mgmt. of non-obstructive mech. PVT (tool)"
},
{
	"jumpto":"interactive_0001437",
	"name":"Mgmt. of severe aortic stenosis (tool)"
},
{
	"jumpto":"ENAS5524_22.1.0.0",
	"name":"MI, ECG detection [UDMI]"
},
{
	"jumpto":"ENAS5524_23.1.0.0",
	"name":"MI, imaging techniques [UDMI]"
},
{
	"jumpto":"ENAS5524_9.1.0.0",
	"name":"MI, type 4a [UDMI]"
},
{
	"jumpto":"ENAS5524_9.2.0.0",
	"name":"MI, type 4b [UDMI]"
},
{
	"jumpto":"ENAS5524_9.3.0.0",
	"name":"MI, type 4c [UDMI]"
},
{
	"jumpto":"ENAS5524_10.0.0.0",
	"name":"MI, type 5 [UDMI]"
},
{
	"jumpto":"ENAS5524_22.4.0.0",
	"name":"MI, unrecognized or silent [UDMI]"
},
{
	"jumpto":"ENAS5524_10.0.0.0",
	"name":"MI associated with CABG [UDMI]"
},
{
	"jumpto":"ENAS5524_9.1.0.0",
	"name":"MI associated with PCI [UDMI]"
},
{
	"jumpto":"ENAS5524_7.2.0.0",
	"name":"MI caused by athero-thrombotic CAD [UDMI]"
},
{
	"jumpto":"ENAS257_13.2.0.0",
	"name":"microvascular disease, treatment targets [DM]"
},
{
	"jumpto":"ENAS5083_6.2.1.0",
	"name":"Microvolt T-wave alternans"
},
{
	"jumpto":"ENAS5081_8.1.0.0",
	"name":"Mid systolic notching, group 2 PH"
},
{
	"jumpto":"ENAS5530_29.3.0.0",
	"name":"Migraine [Sync]"
},
{
	"jumpto":"ENAS5524_23.4.0.0",
	"name":"MI in clinical trials, regulatory perspective [UDMI]"
},
{
	"jumpto":"ENAS5326_10.2.0.0",
	"name":"Mild bleeding (DAPT)"
},
{
	"jumpto":"ENAS5195_8.3.0.0",
	"name":"mineralocorticoid receptor antagonist, MRA (HF)"
},
{
	"jumpto":"ENAS5326_9.3.0.0",
	"name":"Minimal discont. & re-implementation time (DAPT)"
},
{
	"jumpto":"ENAS5329_10.0.0.0",
	"name":"MINOCA (STEMI)"
},
{
	"jumpto":"ENAS5524_17.0.0.0",
	"name":"MINOCA [UDMI]"
},
{
	"jumpto":"ENAS5531_7.4.0.0",
	"name":"Mitral and aortic regurgitation [CVD Preg]"
},
{
	"jumpto":"ENAS5328_4.2.2.0",
	"name":"Mitral regurgitation (VHD)"
},
{
	"jumpto":"ENAS5328_7.1.0.0",
	"name":"Mitral regurgitation, overview (VHD)"
},
{
	"jumpto":"ENAS5328_8.2.0.0",
	"name":"Mitral stenosis, evaluation (VHD)"
},
{
	"jumpto":"ENAS5328_8.3.1.0",
	"name":"Mitral stenosis, indications for intervention (VHD)"
},
{
	"jumpto":"ENAS5328_8.4.0.0",
	"name":"Mitral stenosis, medical therapy (VHD)"
},
{
	"jumpto":"ENAS5328_8.1.0.0",
	"name":"Mitral stenosis, overview (VHD)"
},
{
	"jumpto":"ENAS5328_8.5.0.0",
	"name":"Mitral stenosis, serial testing (VHD)"
},
{
	"jumpto":"ENAS5328_8.6.0.0",
	"name":"Mitral stenosis, special patient populations (VHD)"
},
{
	"jumpto":"ENAS5531_7.2.0.0",
	"name":"Mitral stenosis [CVD Preg]"
},
{
	"jumpto":"ENAS5524_7.2.0.0",
	"name":"MI type 1 [UDMI]"
},
{
	"jumpto":"ENAS5524_7.3.2.0",
	"name":"MI type 2 & myocardial injury [UDMI]"
},
{
	"jumpto":"ENAS5524_7.3.1.0",
	"name":"MI type 2 [UDMI]"
},
{
	"jumpto":"ENAS5524_7.4.0.0",
	"name":"MI type 3 [UDMI]"
},
{
	"jumpto":"ENAS5524_17.0.0.0",
	"name":"MI with non-obstructive coronary arteries [UDMI]"
},
{
	"jumpto":"ENAS5524_7.3.2.0",
	"name":"Model for interpreting myocardial injury [UDMI]"
},
{
	"jumpto":"ENAS5326_10.2.0.0",
	"name":"Moderate bleeding (DAPT)"
},
{
	"jumpto":"ENAS5329_6.1.5.0",
	"name":"Modes of patient presentation (STEMI)"
},
{
	"jumpto":"ENAS5194_5.4.0.0",
	"name":"modified EHRA symptom scale (AFib)"
},
{
	"jumpto":"ENAS5196_9.5.0.0",
	"name":"Modifiers of calculated total CV risk"
},
{
	"jumpto":"ENAS5080_4.2.0.0",
	"name":"Monitoring, NSTE-ACS"
},
{
	"jumpto":"ENAS5195_15.1.4.0",
	"name":"monitoring and follow-up, older adult (HF)"
},
{
	"jumpto":"ENAS5197_12.1.0.0",
	"name":"Monitoring lipids/enzymes (Dyslip)"
},
{
	"jumpto":"ENAS5195_15.1.2.0",
	"name":"monitoring of patients (HF)"
},
{
	"jumpto":"ENAS5194_5.3.0.0",
	"name":"monogenic AF"
},
{
	"jumpto":"ENAS5194_8.11.2.0",
	"name":"monotherapy after ACS (AFib)"
},
{
	"jumpto":"ENAS5194_8.11.3.0",
	"name":"monotherapy after PCI (AFib)"
},
{
	"jumpto":"ENAS5195_15.2.0.0",
	"name":"morphine (HF)"
},
{
	"jumpto":"ENAS5195_12.11.0.0",
	"name":"moxonidine (HF)"
},
{
	"jumpto":"ENAS5532_4.0.0.0",
	"name":"MR, diagnostic tools"
},
{
	"jumpto":"ENAS5195_8.2.0.0",
	"name":"MR antagonist (HF)"
},
{
	"jumpto":"ENAS5329_8.3.0.0",
	"name":"MRAs (STEMI)"
},
{
	"jumpto":"ENAS5532_11.0.0.0",
	"name":"MR in CKD"
},
{
	"jumpto":"ENAS5532_10.0.0.0",
	"name":"MR in DM"
},
{
	"jumpto":"ENAS5532_9.0.0.0",
	"name":"MR in HF"
},
{
	"jumpto":"ENAS5327_12.1.0.0",
	"name":"MSAD [PAD]"
},
{
	"jumpto":"ENAS5328_6.2.4.0",
	"name":"MSCT (VHD)"
},
{
	"jumpto":"ENAS5080_3.6.0.0",
	"name":"Multi-detector computed tomography (MDCT)(NSTE-ACS)"
},
{
	"jumpto":"ENAS5195_15.1.2.0",
	"name":"multidisciplinary management (HF)"
},
{
	"jumpto":"ENAS5195_15.1.1.0",
	"name":"multidisciplinary team management, charateristics and components"
},
{
	"jumpto":"ENAS5327_12.2.1.0",
	"name":"Multisite artery disease, management [PAD]"
},
{
	"jumpto":"ENAS5327_12.2.1.0",
	"name":"Multisite artery disease, screening [PAD]"
},
{
	"jumpto":"ENAS5327_12.1.0.0",
	"name":"Multisite artery disease [PAD]"
},
{
	"jumpto":"ENAS259_6.5.0.0",
	"name":"muscular dystrophies, pacing therapy"
},
{
	"jumpto":"ENAS5197_12.2.0.0",
	"name":"muscular symptoms (Dyslip)"
},
{
	"jumpto":"interactive_0000594",
	"name":"Muscular symptoms during statin treatment (interactive algorithm)"
},
{
	"jumpto":"ENAS5079_5.3.2.0",
	"name":"Mycoplasma spp (IE)"
},
{
	"jumpto":"interactive_0001883",
	"name":"Myocardial infarction, definition (tool)"
},
{
	"jumpto":"ENAS5329_10.0.0.0",
	"name":"Myocardial infarction with non-obstructive coronary arteries (STEMI)"
},
{
	"jumpto":"ENAS5524_14.0.0.0",
	"name":"Myocardial injury & infarction in noncardiac procedures"
},
{
	"jumpto":"ENAS5524_13.0.0.0",
	"name":"Myocardial injury and infarction in cardiac procedures [UDMI]"
},
{
	"jumpto":"ENAS5524_15.0.0.0",
	"name":"Myocardial injury or infarction with HF [UDMI]"
},
{
	"jumpto":"ENAS5524_2.0.0.0",
	"name":"Myocardial injury [UDMI]"
},
{
	"jumpto":"ENAS258_7.3.7.0",
	"name":"myocardial perfusion scintigraphy [SCAD]"
},
{
	"jumpto":"ENAS5195_12.2.0.0",
	"name":"myocardial revascularization (HF)"
},
{
	"jumpto":"ENAS5080_3.3.0.0",
	"name":"Myocarditis, troponin elevation (NSTE-ACS)"
},
{
	"jumpto":"ENAS5083_13.2.2.0",
	"name":"Myopathy, Becker"
},
{
	"jumpto":"ENAS5083_13.2.2.0",
	"name":"Myopathy, Duchenne"
},
{
	"jumpto":"ENAS5083_13.2.2.0",
	"name":"Myopathy, Emery-Dreifuss"
},
{
	"jumpto":"ENAS5083_13.2.2.0",
	"name":"Myopathy, facioscapulohumeral"
},
{
	"jumpto":"ENAS5083_13.2.2.0",
	"name":"Myopathy, limb-girdle type IB"
},
{
	"jumpto":"ENAS5083_13.2.2.0",
	"name":"Myopathy, limb girdle type 2C-2F"
},
{
	"jumpto":"ENAS5083_13.2.2.0",
	"name":"Myopathy, limb girdle type 2I"
},
{
	"jumpto":"ENAS5083_13.2.2.0",
	"name":"Myopathy, myotonic type 1"
},
{
	"jumpto":"ENAS5083_13.2.2.0",
	"name":"Myopathy, myotonic type 2"
},
{
	"jumpto":"ENAS5082_3.5.0.0",
	"name":"Myopericarditis"
},
{
	"jumpto":"ENAS5195_8.4.0.0",
	"name":"N-3 PUFA (HF)"
},
{
	"jumpto":"ENAS5082_6.1.2.0",
	"name":"Naproxen, in paediatric pericardial diseases"
},
{
	"jumpto":"ENAS5328_6.5.0.0",
	"name":"Natriuretic peptides (VHD)"
},
{
	"jumpto":"ENAS5328_6.2.4.0",
	"name":"Natriuretic peptides (VHD)"
},
{
	"jumpto":"ENAS5194_9.4.0.0",
	"name":"Nebivolol (Afib)"
},
{
	"jumpto":"ENAS5530_4.1.0.0",
	"name":"Neurogenic OH [Sync]"
},
{
	"jumpto":"ENAS5530_29.1.0.0",
	"name":"Neurological causes & mimics of syncope"
},
{
	"jumpto":"ENAS5530_29.6.0.0",
	"name":"Neurological evaluation [Sync]"
},
{
	"jumpto":"ENAS5530_29.8.0.0",
	"name":"Neurological tests [Sync]"
},
{
	"jumpto":"ENAS5329_6.2.1.0",
	"name":"New-generation DES (STEMI)"
},
{
	"jumpto":"ENAS5195_12.2.0.0",
	"name":"nicorandil (HF)"
},
{
	"jumpto":"ENAS5197_8.5.0.0",
	"name":"nicotinic acid, hypercholesterolaemia (Dyslip)"
},
{
	"jumpto":"ENAS5194_8.9.2.0",
	"name":"NIHSS scores and OAC (AFib)"
},
{
	"jumpto":"ENAS5081_5.7.0.0",
	"name":"Nitric oxide, in vasoreactivity testing"
},
{
	"jumpto":"ENAS5194_8.6.0.0",
	"name":"NOACs in AF"
},
{
	"jumpto":"ENAS5195_5.2.0.0",
	"name":"non-acute onset HF, diagnosis"
},
{
	"jumpto":"ENAS5194_10.3.0.0",
	"name":"non-antiarrhythmic drugs, antiarrhythmic effects (AFib)"
},
{
	"jumpto":"ENAS261_3.0.0.0",
	"name":"non-cardiac surgery, cardiovascular complications"
},
{
	"jumpto":"ENAS261_5.0.0.0",
	"name":"non-cardiac surgery, type"
},
{
	"jumpto":"ENAS5079_4.1.0.0",
	"name":"Non-complicated infective endocarditis"
},
{
	"jumpto":"ENAS5080_3.6.0.0",
	"name":"Non-invasive imaging (NSTE-ACS)"
},
{
	"jumpto":"ENAS5329_7.3.2.0",
	"name":"Non-invasive imaging, management (STEMI)"
},
{
	"jumpto":"ENAS5329_7.3.2.0",
	"name":"Non-invasive imaging, risk stratification (STEMI)"
},
{
	"jumpto":"ENAS5532_4.0.0.0",
	"name":"Non-invasive imaging in CAD and HF [MR]"
},
{
	"jumpto":"ENAS5329_9.1.0.0",
	"name":"Non-invasive positive pressure ventilation (STEMI)"
},
{
	"jumpto":"ENAS5329_6.2.1.0",
	"name":"Non-IRA strategy (STEMI)"
},
{
	"jumpto":"ENAS5080_2.0.0.0",
	"name":"Non-ST-elevation ACS, definitions (NSTE-ACS)"
},
{
	"jumpto":"ENAS5326_8.1.0.0",
	"name":"Non-vitamin-K oral anticoagulant, NOAC (DAPT)"
},
{
	"jumpto":"ENAS5328_4.8.0.0",
	"name":"Non-vitamin K antagonist oral anticoagulant, NOAC (VHD)"
},
{
	"jumpto":"ENAS5082_3.2.5.0",
	"name":"NSAID, acute pericarditis"
},
{
	"jumpto":"ENAS5195_8.5.0.0",
	"name":"NSAIDs (HF)"
},
{
	"jumpto":"ENAS5080_5.3.2.0",
	"name":"NSTE-ACS, anticoagulation recommendations"
},
{
	"jumpto":"ENAS5080_5.2.6.0",
	"name":"NSTE-ACS, antiplatelet treatment. general treatment recommendations"
},
{
	"jumpto":"ENAS5080_5.1.0.0",
	"name":"NSTE-ACS, antithrombotic drugs"
},
{
	"jumpto":"ENAS5080_5.4.2.0",
	"name":"NSTE-ACS, antithrombotic strategies"
},
{
	"jumpto":"ENAS5080_6.3.0.0",
	"name":"NSTE-ACS, antithrombotic treatment summary"
},
{
	"jumpto":"ENAS5080_5.4.5.0",
	"name":"NSTE-ACS, bleeding management"
},
{
	"jumpto":"ENAS5080_5.4.5.0",
	"name":"NSTE-ACS, blood transfusion recommendations"
},
{
	"jumpto":"ENAS5080_3.2.0.0",
	"name":"NSTE-ACS, cardiac troponin assay"
},
{
	"jumpto":"ENAS5080_5.4.3.0",
	"name":"NSTE-ACS, chronic oral anticoagulation"
},
{
	"jumpto":"ENAS5080_3.1.0.0",
	"name":"NSTE-ACS, diagnosis"
},
{
	"jumpto":"ENAS5080_6.2.0.0",
	"name":"NSTE-ACS, diagnosis validation"
},
{
	"jumpto":"ENAS5080_3.7.1.0",
	"name":"NSTE-ACS, differential diagnoses"
},
{
	"jumpto":"ENAS5080_6.6.0.0",
	"name":"NSTE-ACS, hospital discharge"
},
{
	"jumpto":"ENAS5080_5.6.2.0",
	"name":"NSTE-ACS, in diabetic patients"
},
{
	"jumpto":"ENAS5080_5.6.1.0",
	"name":"NSTE-ACS, in elderly patients"
},
{
	"jumpto":"ENAS5080_5.6.3.0",
	"name":"NSTE-ACS, in patients with chronic kidney disease"
},
{
	"jumpto":"ENAS5080_5.2.4.0",
	"name":"NSTE-ACS, intravenous antiplatelet therapy"
},
{
	"jumpto":"ENAS5080_6.4.0.0",
	"name":"NSTE-ACS, invasive strategy summary"
},
{
	"jumpto":"ENAS5080_5.2.5.0",
	"name":"NSTE-ACS, long-term P2Y12 inhibition"
},
{
	"jumpto":"ENAS5080_5.6.6.0",
	"name":"NSTE-ACS, mgmt. of Afib"
},
{
	"jumpto":"ENAS5080_5.2.3.0",
	"name":"NSTE-ACS, oral platelet therapy"
},
{
	"jumpto":"ENAS5080_5.5.3.0",
	"name":"NSTE-ACS, patients requiring CABG"
},
{
	"jumpto":"ENAS5080_5.2.3.0",
	"name":"NSTE-ACS, platelet inhibition"
},
{
	"jumpto":"ENAS5080_6.6.0.0",
	"name":"NSTE-ACS, post-discharge management"
},
{
	"jumpto":"ENAS5080_6.5.0.0",
	"name":"NSTE-ACS, revascularisation modalities"
},
{
	"jumpto":"ENAS5080_4.1.0.0",
	"name":"NSTE-ACS, risk assessment"
},
{
	"jumpto":"ENAS5080_6.2.0.0",
	"name":"NSTE-ACS, risk assessment"
},
{
	"jumpto":"ENAS5080_5.6.7.0",
	"name":"NSTE-ACS, thrombocytopenia mgmt."
},
{
	"jumpto":"ENAS5080_5.5.1.0",
	"name":"NSTE-ACS, treatment strategy"
},
{
	"jumpto":"ENAS5080_5.5.1.0",
	"name":"NSTE-ACS, treatment timing"
},
{
	"jumpto":"ENAS5080_5.6.4.0",
	"name":"NSTE-ACS, with acute heart failure"
},
{
	"jumpto":"ENAS5080_6.1.0.0",
	"name":"NSTE-ACS management, initial evaluation"
},
{
	"jumpto":"ENAS5080_6.1.0.0",
	"name":"NSTE-ACS management, pathway"
},
{
	"jumpto":"ENAS5080_5.6.4.0",
	"name":"NSTE-ACS with acute heart failure, mgmt."
},
{
	"jumpto":"ENAS5080_4.2.0.0",
	"name":"NSTEMI, intermediate risk of cardiac arrhythmia"
},
{
	"jumpto":"ENAS5080_4.2.0.0",
	"name":"NSTEMI, low risk for cardiac arrhythmia"
},
{
	"jumpto":"ENAS5081_6.1.2.0",
	"name":"NT-proBNP plasma levels (PH)"
},
{
	"jumpto":"ENAS5196_11.5.0.0",
	"name":"nutrition (CVD prev)"
},
{
	"jumpto":"ENAS5195_12.16.0.0",
	"name":"obesity (HF)"
},
{
	"jumpto":"ENAS5196_9.10.4.0",
	"name":"obstructive sleep apnoea syndrome (CVD prev)"
},
{
	"jumpto":"ENAS5533_3.3.0.0",
	"name":"Office blood pressure measurement [HTN]"
},
{
	"jumpto":"ENAS5195_15.1.4.0",
	"name":"older adult, monitoring and follow-up (HF)"
},
{
	"jumpto":"ENAS5197_11.4.0.0",
	"name":"older persons, dyslipidaemias"
},
{
	"jumpto":"ENAS5524_21.0.0.0",
	"name":"Operationalising criteria for myocardial injury and MI [UDMI]"
},
{
	"jumpto":"ENAS258_9.2.0.0",
	"name":"optical coherence tomography [SCAD]"
},
{
	"jumpto":"ENAS5081_8.2.0.0",
	"name":"Optimized volume status"
},
{
	"jumpto":"ENAS5326_6.1.0.0",
	"name":"Oral anticoagulant, OAC (DAPT)"
},
{
	"jumpto":"ENAS5081_6.2.2.2",
	"name":"Oral anticoagulant, PAH supportive therapy"
},
{
	"jumpto":"ENAS5328_12.2.4.0",
	"name":"Oral anticoagulation with VKA (VHD)"
},
{
	"jumpto":"ENAS5195_13.8.5.0",
	"name":"oral disease-modifying therapies (HF)"
},
{
	"jumpto":"ENAS5195_13.3.0.0",
	"name":"orthopnoea (HF)"
},
{
	"jumpto":"ENAS5530_22.0.0.0",
	"name":"Orthostatic hypotension, treatment [Sync]"
},
{
	"jumpto":"ENAS5530_4.1.0.0",
	"name":"Orthostatic hypotension [Sync]"
},
{
	"jumpto":"ENAS5530_22.0.0.0",
	"name":"Orthostatic intolerance syndromes [Sync]"
},
{
	"jumpto":"ENAS5530_4.1.0.0",
	"name":"Orthostatic vasovagal syncope"
},
{
	"jumpto":"ENAS5079_5.4.2.0",
	"name":"Osler’s nodes (IE)"
},
{
	"jumpto":"ENAS5195_12.13.1.0",
	"name":"other co-morbidities, treatment recommendations (HF)"
},
{
	"jumpto":"ENAS5195_12.13.2.0",
	"name":"other co-morbidities, treatments not recommended (HF)"
},
{
	"jumpto":"ENAS5083_6.1.3.0",
	"name":"Overdrive pacing"
},
{
	"jumpto":"ENAS5195_7.0.0.0",
	"name":"overt heart failure, prevention"
},
{
	"jumpto":"ENAS5195_13.1.0.0",
	"name":"overview, acute heart failure"
},
{
	"jumpto":"ENAS5329_6.2.1.0",
	"name":"Overview, adjunctive therapy (STEMI)"
},
{
	"jumpto":"ENAS5195_11.1.0.0",
	"name":"overview, arrhythmias (HF)"
},
{
	"jumpto":"ENAS5195_6.1.0.0",
	"name":"overview, cardiac imaging (HF)"
},
{
	"jumpto":"ENAS5195_12.1.0.0",
	"name":"overview, co-morbidities (HF)"
},
{
	"jumpto":"ENAS5195_11.1.0.0",
	"name":"overview, conductance disturbance (HF)"
},
{
	"jumpto":"ENAS5195_14.1.0.0",
	"name":"overview, heart transplantation (HF)"
},
{
	"jumpto":"ENAS5195_14.1.0.0",
	"name":"overview, mechanical circulatory support (HF)"
},
{
	"jumpto":"ENAS5329_6.2.1.0",
	"name":"Overview, PCI (STEMI)"
},
{
	"jumpto":"ENAS5195_8.1.0.0",
	"name":"overview,treatment of HFrEF"
},
{
	"jumpto":"ENAS5197_7.3.0.0",
	"name":"overweight (Dyslip)"
},
{
	"jumpto":"ENAS5081_6.2.2.2",
	"name":"Oxygen, PAH supportive therapy"
},
{
	"jumpto":"ENAS5195_13.7.0.0",
	"name":"oxygen therapy, acute heart failure (HF)"
},
{
	"jumpto":"ENAS5081_9.0.0.0",
	"name":"Oxygen therapy, group 3 PAH"
},
{
	"jumpto":"ENAS5329_6.2.2.0",
	"name":"P2Y12 inhibitor (STEMI)"
},
{
	"jumpto":"ENAS5326_9.2.0.0",
	"name":"P2Y12 inhibitor interruption after PCI for elective non-cardiac surgery (DAPT)"
},
{
	"jumpto":"ENAS5326_4.2.4.0",
	"name":"P2Y12 inhibitors (DAPT)"
},
{
	"jumpto":"ENAS5326_4.2.2.0",
	"name":"P2Y12 inhibitor selection and timing, recommendations (DAPT)"
},
{
	"jumpto":"ENAS5326_4.3.0.0",
	"name":"P2Y12 inhibitors in the acute setting (DAPT)"
},
{
	"jumpto":"ENAS5326_4.3.0.0",
	"name":"P2Y12 inhibitors in the chronic setting (DAPT)"
},
{
	"jumpto":"ENAS259_4.1.1.0",
	"name":"pacemaker, implantation rate"
},
{
	"jumpto":"ENAS259_4.1.2.0",
	"name":"pacemaker, indication [Pacing]"
},
{
	"jumpto":"ENAS259_4.1.2.0",
	"name":"pacemaker, type [Pacing]"
},
{
	"jumpto":"ENAS259_7.1.0.0",
	"name":"pacing, complications"
},
{
	"jumpto":"ENAS259_6.3.2.0",
	"name":"pacing mode, children"
},
{
	"jumpto":"ENAS259_6.3.1.0",
	"name":"pacing therapy, children"
},
{
	"jumpto":"ENAS259_8.4.0.0",
	"name":"pacing therapy, emergency transvenous"
},
{
	"jumpto":"ENAS259_6.7.0.0",
	"name":"pacing therapy, first-degree atrioventricular block"
},
{
	"jumpto":"ENAS259_7.2.0.0",
	"name":"pacing therapy, hematomas/infections"
},
{
	"jumpto":"ENAS259_6.6.0.0",
	"name":"pacing therapy, pregnancy"
},
{
	"jumpto":"ENAS259_8.2.0.0",
	"name":"pacing therapy, reimplantation"
},
{
	"jumpto":"ENAS5327_6.5.0.0",
	"name":"PAD, antithrombotic therapy recommendations"
},
{
	"jumpto":"ENAS5327_6.2.0.0",
	"name":"PAD, antithrombotic treatment in CAD"
},
{
	"jumpto":"ENAS5327_6.3.0.0",
	"name":"PAD, antithrombotic treatment in LEAD"
},
{
	"jumpto":"ENAS5327_3.0.0.0",
	"name":"PAD, introduction"
},
{
	"jumpto":"ENAS5327_6.4.0.0",
	"name":"PAD, LEAD with long term OAC"
},
{
	"jumpto":"ENAS5327_6.4.0.0",
	"name":"PAD, long term antithrombotic treatment in LEAD"
},
{
	"jumpto":"ENAS5327_3.0.0.0",
	"name":"PAD, multidisciplinary vascular team"
},
{
	"jumpto":"ENAS5327_3.0.0.0",
	"name":"PAD, presentations"
},
{
	"jumpto":"ENAS5327_13.2.0.0",
	"name":"PAD and AF"
},
{
	"jumpto":"ENAS5327_13.1.0.0",
	"name":"PAD and HF"
},
{
	"jumpto":"ENAS5327_13.3.0.0",
	"name":"PAD and VHD"
},
{
	"jumpto":"ENAS5327_3.0.0.0",
	"name":"PAD management, general recommendations"
},
{
	"jumpto":"ENAS5082_6.1.3.0",
	"name":"Paediatric pericardial diseases, therapy"
},
{
	"jumpto":"ENAS5193_3.10.1.0",
	"name":"paediatric population, cardiotoxicity"
},
{
	"jumpto":"ENAS5081_7.2.0.0",
	"name":"PAH, associated with adult CHD"
},
{
	"jumpto":"ENAS5081_4.2.1.0",
	"name":"PAH, associated with congenital heart disease"
},
{
	"jumpto":"ENAS5081_4.2.1.0",
	"name":"PAH, associated with CTD"
},
{
	"jumpto":"ENAS5081_4.2.1.0",
	"name":"PAH, associated with HIV infection"
},
{
	"jumpto":"ENAS5081_4.2.1.0",
	"name":"PAH, associated with portal hypertension"
},
{
	"jumpto":"ENAS5081_4.2.1.0",
	"name":"PAH, associated with schistosomiasis"
},
{
	"jumpto":"ENAS5081_6.2.4.0",
	"name":"PAH, balloon atrial septostomy"
},
{
	"jumpto":"ENAS5081_6.1.3.0",
	"name":"PAH, clinical response to therapy"
},
{
	"jumpto":"ENAS5081_4.1.1.0",
	"name":"PAH, definition"
},
{
	"jumpto":"ENAS5081_4.2.1.0",
	"name":"PAH, drug and toxins induced"
},
{
	"jumpto":"ENAS5081_6.1.3.0",
	"name":"PAH, evaluation of severity"
},
{
	"jumpto":"ENAS5081_9.0.0.0",
	"name":"PAH, group 3"
},
{
	"jumpto":"ENAS5081_4.2.1.0",
	"name":"PAH, heritable"
},
{
	"jumpto":"ENAS5081_6.2.4.0",
	"name":"PAH, ICU mgmt. efficacy"
},
{
	"jumpto":"ENAS5081_4.2.1.0",
	"name":"PAH, idiopathic"
},
{
	"jumpto":"ENAS5081_6.2.3.3",
	"name":"PAH, initial drug combination therapy"
},
{
	"jumpto":"ENAS5081_6.2.4.0",
	"name":"PAH, inotropic support"
},
{
	"jumpto":"ENAS5081_6.2.4.0",
	"name":"PAH, lung transplantation"
},
{
	"jumpto":"ENAS5081_4.2.1.0",
	"name":"PAH, other pulmonary artery obstructions"
},
{
	"jumpto":"ENAS5081_7.1.0.0",
	"name":"PAH, pediatric"
},
{
	"jumpto":"ENAS5081_6.2.3.4",
	"name":"PAH, sequential drug combination therapy"
},
{
	"jumpto":"ENAS5081_6.2.5.0",
	"name":"PAH, treatment algorithm"
},
{
	"jumpto":"ENAS5081_6.2.1.0",
	"name":"PAH, treatment strategy"
},
{
	"jumpto":"ENAS5081_4.2.2.0",
	"name":"PAH, with coincidental defects"
},
{
	"jumpto":"ENAS5081_7.3.0.0",
	"name":"PAH, with CTD"
},
{
	"jumpto":"ENAS5081_4.2.2.0",
	"name":"PAH, with defect correction"
},
{
	"jumpto":"ENAS5081_7.5.0.0",
	"name":"PAH, with HIV infection"
},
{
	"jumpto":"ENAS5081_9.0.0.0",
	"name":"PAH, with lung disease"
},
{
	"jumpto":"ENAS5081_7.4.0.0",
	"name":"PAH, with portal hypertension"
},
{
	"jumpto":"ENAS5081_4.2.2.0",
	"name":"PAH, with small defects"
},
{
	"jumpto":"ENAS5081_4.2.2.0",
	"name":"PAH, with systemic-to-pulmonary shunts"
},
{
	"jumpto":"ENAS5081_5.5.0.0",
	"name":"PAH mgmt., according to echo probability"
},
{
	"jumpto":"ENAS5081_6.2.2.1",
	"name":"PAH treatment, general measures"
},
{
	"jumpto":"ENAS5081_4.2.2.0",
	"name":"PAH with CHD, clinical classification"
},
{
	"jumpto":"ENAS5195_15.2.0.0",
	"name":"palliative care approaches (HF)"
},
{
	"jumpto":"ENAS5081_5.1.0.0",
	"name":"Pansystolic murmur, of tricuspid regurgitation"
},
{
	"jumpto":"ENAS5081_5.1.0.0",
	"name":"Parasternal lift, symptom of PH"
},
{
	"jumpto":"ENAS5531_10.1.0.0",
	"name":"Paroxysmal supraventricular tachycardia [CVD Preg]"
},
{
	"jumpto":"ENAS5524_5.0.0.0",
	"name":"Pathological characteristics of myocardial ischaemia & infarction [UDMI]"
},
{
	"jumpto":"ENAS5530_4.4.0.0",
	"name":"Pathophysiological basis of the classification of syncope"
},
{
	"jumpto":"ENAS5524_7.3.1.0",
	"name":"Pathophysiological mechanisms [UDMI]"
},
{
	"jumpto":"ENAS5194_12.0.0.0",
	"name":"patient education in AF"
},
{
	"jumpto":"ENAS5329_7.2.1.0",
	"name":"Patients taking oral anticoagulation, mgmt. (STEMI)"
},
{
	"jumpto":"ENAS5326_8.5.0.0",
	"name":"patients with an indication for OAC undergoing PCI (DAPT)"
},
{
	"jumpto":"ENAS5195_13.5.0.0",
	"name":"patient with AHF, initial management"
},
{
	"jumpto":"ENAS5194_5.2.0.0",
	"name":"patterns, AF"
},
{
	"jumpto":"ENAS5532_17.0.0.0",
	"name":"PCI, procedural aspects [MR]"
},
{
	"jumpto":"ENAS5080_5.5.2.0",
	"name":"PCI in NSTE-ACS"
},
{
	"jumpto":"ENAS5080_5.4.1.0",
	"name":"PCI related bleeding, management strategies"
},
{
	"jumpto":"ENAS5329_6.1.1.0",
	"name":"PCI strategy after fibrinolysis (STEMI)"
},
{
	"jumpto":"ENAS5197_8.4.0.0",
	"name":"PCSK9 inhibitors, hypercholesterolaemia (Dyslip)"
},
{
	"jumpto":"ENAS5082_6.1.2.0",
	"name":"Pediatric pericardial diseases, regimens"
},
{
	"jumpto":"ENAS264_8.4.0.0",
	"name":"penetrating aortic ulcer"
},
{
	"jumpto":"ENAS5079_3.2.0.0",
	"name":"Penicillin, dental procedure prophylaxis"
},
{
	"jumpto":"ENAS5326_5.4.0.0",
	"name":"Percutaneous coronary intervention (DAPT)"
},
{
	"jumpto":"ENAS5328_8.1.0.0",
	"name":"Percutaneous mitral commissurotomy, PMC (VHD)"
},
{
	"jumpto":"ENAS5079_5.2.4.0",
	"name":"Perforation, anatomic definition"
},
{
	"jumpto":"ENAS5079_5.2.4.0",
	"name":"Perforation, echocardiographic definition"
},
{
	"jumpto":"ENAS261_9.3.0.0",
	"name":"peri-operative cardiac monitoring, disturbed glucose metabolism"
},
{
	"jumpto":"ENAS261_9.1.0.0",
	"name":"peri-operative cardiac monitoring, ECG"
},
{
	"jumpto":"ENAS261_9.2.0.0",
	"name":"peri-operative cardiac monitoring, TOE"
},
{
	"jumpto":"ENAS5082_5.2.3.1",
	"name":"Pericardial cavity rinsing"
},
{
	"jumpto":"ENAS5082_5.8.6.0",
	"name":"Pericardial cysts"
},
{
	"jumpto":"ENAS5193_3.9.1.0",
	"name":"pericardial disease, cardiotoxicity"
},
{
	"jumpto":"ENAS5082_4.1.0.0",
	"name":"Pericardial disease, diagnostic work-up"
},
{
	"jumpto":"ENAS5082_4.2.1.0",
	"name":"Pericardial disease, general diagnostic workup"
},
{
	"jumpto":"ENAS5082_4.2.2.0",
	"name":"Pericardial disease, high risk patients"
},
{
	"jumpto":"ENAS5082_2.0.0.0",
	"name":"Pericardial disease, infectious cause"
},
{
	"jumpto":"ENAS5082_4.1.0.0",
	"name":"Pericardial disease, multimodality imaging"
},
{
	"jumpto":"ENAS5082_2.0.0.0",
	"name":"Pericardial disease, non-infectious cause"
},
{
	"jumpto":"ENAS5082_2.0.0.0",
	"name":"Pericardial disease, traumatic and iatrogenic"
},
{
	"jumpto":"ENAS5082_2.0.0.0",
	"name":"Pericardial diseases, aetiology"
},
{
	"jumpto":"ENAS5082_2.0.0.0",
	"name":"Pericardial diseases, definition"
},
{
	"jumpto":"ENAS5082_6.1.1.0",
	"name":"Pericardial diseases, in children"
},
{
	"jumpto":"ENAS5082_6.2.1.0",
	"name":"Pericardial diseases, in pregnancy"
},
{
	"jumpto":"ENAS5082_2.0.0.0",
	"name":"Pericardial diseases, introduction"
},
{
	"jumpto":"ENAS5082_7.2.1.0",
	"name":"Pericardial diseases, surgery"
},
{
	"jumpto":"ENAS5082_7.1.0.0",
	"name":"Pericardial drainage, interventional techniques"
},
{
	"jumpto":"ENAS5082_3.6.1.0",
	"name":"Pericardial effusion, acute"
},
{
	"jumpto":"ENAS5082_3.6.1.0",
	"name":"Pericardial effusion, chronic"
},
{
	"jumpto":"ENAS5082_3.6.1.0",
	"name":"Pericardial effusion, circumferential"
},
{
	"jumpto":"ENAS5082_3.6.1.0",
	"name":"Pericardial effusion, classification"
},
{
	"jumpto":"ENAS5082_3.6.4.0",
	"name":"Pericardial effusion, diagnosis"
},
{
	"jumpto":"ENAS5082_5.8.3.0",
	"name":"Pericardial effusion, drug-related"
},
{
	"jumpto":"ENAS5082_3.6.3.0",
	"name":"Pericardial effusion, echocardiographic assessment"
},
{
	"jumpto":"ENAS5082_5.8.4.0",
	"name":"Pericardial effusion, in endocrine disorders"
},
{
	"jumpto":"ENAS5082_3.6.6.0",
	"name":"Pericardial effusion, initial management"
},
{
	"jumpto":"ENAS5082_5.8.4.0",
	"name":"Pericardial effusion, in metabolic disorders"
},
{
	"jumpto":"ENAS5082_5.8.5.0",
	"name":"Pericardial effusion, in PAH"
},
{
	"jumpto":"ENAS5082_3.6.1.0",
	"name":"Pericardial effusion, large"
},
{
	"jumpto":"ENAS5082_3.6.1.0",
	"name":"Pericardial effusion, loculated"
},
{
	"jumpto":"ENAS5082_3.6.5.0",
	"name":"Pericardial effusion, management"
},
{
	"jumpto":"ENAS5082_3.6.1.0",
	"name":"Pericardial effusion, mild"
},
{
	"jumpto":"ENAS5082_3.6.1.0",
	"name":"Pericardial effusion, moderate"
},
{
	"jumpto":"ENAS5082_3.6.1.0",
	"name":"Pericardial effusion, overview"
},
{
	"jumpto":"ENAS5082_3.6.8.0",
	"name":"Pericardial effusion, prognosis"
},
{
	"jumpto":"ENAS5082_3.6.2.0",
	"name":"Pericardial effusion, rapid"
},
{
	"jumpto":"ENAS5082_3.6.2.0",
	"name":"Pericardial effusion, slow"
},
{
	"jumpto":"ENAS5082_3.6.1.0",
	"name":"Pericardial effusion, subacute"
},
{
	"jumpto":"ENAS5082_3.6.7.0",
	"name":"Pericardial effusion, therapy"
},
{
	"jumpto":"ENAS5082_5.6.0.0",
	"name":"Pericardial effusion, traumatic"
},
{
	"jumpto":"ENAS5082_3.6.5.0",
	"name":"Pericardial effusion, triage"
},
{
	"jumpto":"ENAS5082_4.2.5.0",
	"name":"Pericardial fluid, analyses"
},
{
	"jumpto":"ENAS5082_3.8.2.0",
	"name":"Pericardial knock"
},
{
	"jumpto":"ENAS5082_3.1.0.0",
	"name":"Pericardial syndromes, definition"
},
{
	"jumpto":"ENAS5530_4.1.0.0",
	"name":"Pericardial tamponade [Sync]"
},
{
	"jumpto":"ENAS5082_7.2.1.0",
	"name":"Pericardial window"
},
{
	"jumpto":"ENAS5082_7.2.2.0",
	"name":"Pericardiectomy, surgery in pericardial diseases"
},
{
	"jumpto":"ENAS5082_3.6.5.0",
	"name":"Pericardiocentesis (Pericard.)"
},
{
	"jumpto":"ENAS5082_7.1.0.0",
	"name":"Pericardiocentesis, complications"
},
{
	"jumpto":"ENAS5082_7.1.0.0",
	"name":"Pericardiocentesis, interventional techniques"
},
{
	"jumpto":"ENAS5082_5.2.1.0",
	"name":"Pericarditis, bacterial"
},
{
	"jumpto":"ENAS5082_3.2.1.0",
	"name":"Pericarditis, chronic"
},
{
	"jumpto":"ENAS5082_3.2.1.0",
	"name":"Pericarditis, definition"
},
{
	"jumpto":"ENAS5082_5.8.3.0",
	"name":"Pericarditis, drug-related"
},
{
	"jumpto":"ENAS5082_4.2.4.0",
	"name":"Pericarditis, first level investigations"
},
{
	"jumpto":"ENAS5082_5.4.0.0",
	"name":"Pericarditis, in autoimmune diseases"
},
{
	"jumpto":"ENAS5082_5.4.0.0",
	"name":"Pericarditis, in autoinflammatory diseases"
},
{
	"jumpto":"ENAS5082_3.2.1.0",
	"name":"Pericarditis, incessant"
},
{
	"jumpto":"ENAS5082_5.7.0.0",
	"name":"Pericarditis, in neoplastic disease"
},
{
	"jumpto":"ENAS5082_5.3.0.0",
	"name":"Pericarditis, in renal failure"
},
{
	"jumpto":"ENAS5082_5.2.3.1",
	"name":"Pericarditis, purulent"
},
{
	"jumpto":"ENAS5082_3.2.1.0",
	"name":"Pericarditis, recurrent"
},
{
	"jumpto":"ENAS5082_4.2.4.0",
	"name":"pericarditis, second level investigations"
},
{
	"jumpto":"ENAS5082_3.4.0.0",
	"name":"Pericarditis, therapeutic algorithm"
},
{
	"jumpto":"ENAS5082_5.2.2.1",
	"name":"Pericarditis, tubercular"
},
{
	"jumpto":"ENAS5082_5.1.0.0",
	"name":"Pericarditis, viral"
},
{
	"jumpto":"ENAS5082_3.5.0.0",
	"name":"Pericarditis, with pericardial involvement"
},
{
	"jumpto":"ENAS5082_6.2.2.0",
	"name":"Pericarditis during pregnancy, treatment"
},
{
	"jumpto":"ENAS5080_5.5.3.0",
	"name":"Perioperative mgmt. in patients requiring CABG"
},
{
	"jumpto":"ENAS5328_13.4.0.0",
	"name":"Perioperative monitoring (VHD)"
},
{
	"jumpto":"ENAS5531_9.2.0.0",
	"name":"Peripartum cardiomyopathy [CVD Preg]"
},
{
	"jumpto":"ENAS5197_11.10.0.0",
	"name":"peripheral arterial disease, dyslipidaemias"
},
{
	"jumpto":"ENAS5196_13.5.0.0",
	"name":"peripheral artery disease (CVD prev)"
},
{
	"jumpto":"ENAS257_12.2.2.0",
	"name":"peripheral artery disease (PAD), case history [DM]"
},
{
	"jumpto":"ENAS257_12.2.5.0",
	"name":"peripheral artery disease (PAD), CLI mgmt. [DM]"
},
{
	"jumpto":"ENAS257_12.2.4.0",
	"name":"peripheral artery disease (PAD), intermittent claudication treatment algorithm [DM]"
},
{
	"jumpto":"ENAS257_12.2.1.0",
	"name":"peripheral artery disease (PAD), introduction [DM]"
},
{
	"jumpto":"ENAS257_12.1.0.0",
	"name":"peripheral artery disease (PAD), mgmt. in DM"
},
{
	"jumpto":"ENAS257_12.2.3.0",
	"name":"peripheral artery disease (PAD), physical examination [DM]"
},
{
	"jumpto":"ENAS261_8.7.0.0",
	"name":"peripheral artery disease in non-cardiac surgery"
},
{
	"jumpto":"ENAS5532_13.0.0.0",
	"name":"Peripheral artery diseases [MR]"
},
{
	"jumpto":"ENAS5081_5.1.0.0",
	"name":"Peripheral oedema (PH)"
},
{
	"jumpto":"ENAS5193_3.7.1.1",
	"name":"peripheral vascular disease, cardiotoxicity"
},
{
	"jumpto":"ENAS5193_3.7.2.0",
	"name":"peripheral vascular disease, cardiotoxicity"
},
{
	"jumpto":"ENAS5329_6.2.2.0",
	"name":"Periprocedural antithrombotic therapy (STEMI)"
},
{
	"jumpto":"ENAS5081_8.1.0.0",
	"name":"Persistent atrial fibrillation, group 2 PH"
},
{
	"jumpto":"ENAS259_4.2.2.0",
	"name":"persistent bradycardia, choice of pacing mode"
},
{
	"jumpto":"ENAS259_4.2.2.0",
	"name":"persistent bradycardia, clinical perspective"
},
{
	"jumpto":"ENAS259_4.2.1.0",
	"name":"persistent bradycardia, indications for pacing"
},
{
	"jumpto":"ENAS259_4.2.3.0",
	"name":"persistent bradycardia, optimal pacing mode"
},
{
	"jumpto":"ENAS5081_4.2.1.0",
	"name":"Persistent PH of newborn"
},
{
	"jumpto":"ENAS5081_5.2.0.0",
	"name":"PH, abdominal ultrasound scan"
},
{
	"jumpto":"ENAS5081_5.2.0.0",
	"name":"PH, blood tests and immunology"
},
{
	"jumpto":"ENAS5081_5.2.0.0",
	"name":"PH, cardiac magnetic resonance imaging"
},
{
	"jumpto":"ENAS5081_5.2.0.0",
	"name":"PH, chest radiograph"
},
{
	"jumpto":"ENAS5081_4.2.1.0",
	"name":"PH, clinical classification"
},
{
	"jumpto":"ENAS5081_5.1.0.0",
	"name":"PH, clinical presentation"
},
{
	"jumpto":"ENAS5081_4.1.1.0",
	"name":"PH, definition"
},
{
	"jumpto":"ENAS5081_5.1.0.0",
	"name":"PH, diagnosis"
},
{
	"jumpto":"ENAS5081_5.8.0.0",
	"name":"PH, diagnostic algorithm"
},
{
	"jumpto":"ENAS5081_5.2.0.0",
	"name":"PH, diagnostic investigations"
},
{
	"jumpto":"ENAS5081_5.3.0.0",
	"name":"PH, echocardiographic probability"
},
{
	"jumpto":"ENAS5081_5.4.0.0",
	"name":"PH, echocardiographic signs"
},
{
	"jumpto":"ENAS5081_5.2.0.0",
	"name":"PH, echocardiography"
},
{
	"jumpto":"ENAS5081_5.3.0.0",
	"name":"PH, echocardiography"
},
{
	"jumpto":"ENAS5081_5.2.0.0",
	"name":"PH, electrocardiogram"
},
{
	"jumpto":"ENAS5081_4.1.1.0",
	"name":"PH, exercise"
},
{
	"jumpto":"ENAS5081_6.2.4.0",
	"name":"PH, further treatment strategies"
},
{
	"jumpto":"ENAS5081_4.1.2.0",
	"name":"PH, hemodynamic definitions"
},
{
	"jumpto":"ENAS5081_5.2.0.0",
	"name":"PH, high-resolution computed tomography, contrast enhanced computed tomography"
},
{
	"jumpto":"ENAS5081_5.1.0.0",
	"name":"PH, physical signs"
},
{
	"jumpto":"ENAS5081_5.2.0.0",
	"name":"PH, pulmonary angiography"
},
{
	"jumpto":"ENAS5081_5.2.0.0",
	"name":"PH, pulmonary function tests and arterial blood gases"
},
{
	"jumpto":"ENAS5081_5.6.0.0",
	"name":"PH, right heart catheterization"
},
{
	"jumpto":"ENAS5081_5.2.0.0",
	"name":"PH, right heart catheterization and vasoreactivity"
},
{
	"jumpto":"ENAS5081_5.1.0.0",
	"name":"PH, symptoms"
},
{
	"jumpto":"ENAS5081_5.2.0.0",
	"name":"PH, ventilation/perfusion lung scan"
},
{
	"jumpto":"ENAS5329_6.1.1.0",
	"name":"Pharmacoinvasive strategy (STEMI)"
},
{
	"jumpto":"ENAS5195_11.3.0.0",
	"name":"pharmacological cardioversion (HF)"
},
{
	"jumpto":"ENAS258_8.4.1.0",
	"name":"pharmacological mgmt., side effects, CI and drug-drug interactions [SCAD]"
},
{
	"jumpto":"ENAS5083_4.3.1.0",
	"name":"Pharmacological stress testing (VA and SCD)"
},
{
	"jumpto":"ENAS5197_8.6.0.0",
	"name":"pharmacological treatment, hypercholesterolaemia (Dyslip)"
},
{
	"jumpto":"ENAS5195_8.3.0.0",
	"name":"pharmacological treatment in HFrEF"
},
{
	"jumpto":"ENAS5195_13.8.2.0",
	"name":"pharmacotherapy, AHF (HF)"
},
{
	"jumpto":"ENAS5081_5.9.0.0",
	"name":"PH diagnostic strategy"
},
{
	"jumpto":"ENAS5081_4.2.1.0",
	"name":"PH due to lung disease, clinical classification"
},
{
	"jumpto":"ENAS5081_3.2.0.0",
	"name":"PH guidelines, new aspects"
},
{
	"jumpto":"ENAS5081_3.1.0.0",
	"name":"PH guidelines, principles"
},
{
	"jumpto":"ENAS5081_8.2.0.0",
	"name":"PH in left heart disease, mgmt."
},
{
	"jumpto":"ENAS5195_13.8.2.0",
	"name":"phosphodiesterase III inhibitors (HF)"
},
{
	"jumpto":"ENAS5195_12.7.0.0",
	"name":"phosphodiesterase type 5 inhibitors (HF)"
},
{
	"jumpto":"ENAS5081_11.0.0.0",
	"name":"PH referral centre"
},
{
	"jumpto":"ENAS5082_7.1.0.0",
	"name":"Phrenic nerve damage"
},
{
	"jumpto":"ENAS5081_4.2.1.0",
	"name":"PH with unclear mechanisms, clinical classification"
},
{
	"jumpto":"ENAS5196_14.2.0.0",
	"name":"physical activity, population-based approach (CVD prev)"
},
{
	"jumpto":"ENAS5327_5.2.0.0",
	"name":"Physical examination"
},
{
	"jumpto":"ENAS5533_4.1.2.0",
	"name":"Physical examination, HMOD [HTN]"
},
{
	"jumpto":"ENAS5533_4.1.2.0",
	"name":"Physical examination, secondary HTN [HTN]"
},
{
	"jumpto":"ENAS5081_6.2.2.1",
	"name":"Physical exercise (PH)"
},
{
	"jumpto":"ENAS5531_4.2.1.0",
	"name":"Physiological adaptations to pregnancy [CVD Preg]"
},
{
	"jumpto":"ENAS5195_5.2.0.0",
	"name":"plasma natriuretic peptides (HF)"
},
{
	"jumpto":"ENAS5193_3.9.2.0",
	"name":"pleural effusion, cardiotoxicity"
},
{
	"jumpto":"ENAS5194_5.3.0.0",
	"name":"polygenic AF"
},
{
	"jumpto":"ENAS5082_4.2.5.0",
	"name":"Polymerase chain reaction (PCR)(Pericard.)"
},
{
	"jumpto":"ENAS5079_5.3.2.0",
	"name":"Polymerase chain reaction, microbiological diagnosis of IE"
},
{
	"jumpto":"ENAS5329_9.3.0.0",
	"name":"Positive chronotropic medication (STEMI)"
},
{
	"jumpto":"ENAS5195_6.2.0.0",
	"name":"positron emission tomography, PET (HF)"
},
{
	"jumpto":"ENAS5081_8.2.0.0",
	"name":"Post-capillary PH"
},
{
	"jumpto":"ENAS5081_4.1.2.0",
	"name":"Post-capillary PH, hemodynamic definitions of PH"
},
{
	"jumpto":"ENAS5082_5.5.1.0",
	"name":"Post-cardiac injury syndrome, definition"
},
{
	"jumpto":"ENAS5082_5.5.1.0",
	"name":"Post-cardiac injury syndrome, diagnosis"
},
{
	"jumpto":"ENAS5082_5.5.2.0",
	"name":"Post-cardiac injury syndrome, management"
},
{
	"jumpto":"ENAS5532_18.4.0.0",
	"name":"Post-interventional & maint. Tx in NSTE-ACS & STEMI undergoing PCI [MR]"
},
{
	"jumpto":"ENAS5082_2.0.0.0",
	"name":"Postmyocardial infarction syndrome"
},
{
	"jumpto":"ENAS5080_5.7.0.0",
	"name":"Post NSTE-ACS, long term management"
},
{
	"jumpto":"ENAS5194_5.3.0.0",
	"name":"postoperative AF"
},
{
	"jumpto":"ENAS5194_11.5.0.0",
	"name":"postoperative AF"
},
{
	"jumpto":"ENAS5082_2.0.0.0",
	"name":"Postpericardiotomy syndrome"
},
{
	"jumpto":"ENAS5329_6.2.2.0",
	"name":"Postprocedural antithrombotic therapy (STEMI)"
},
{
	"jumpto":"ENAS5326_4.2.3.0",
	"name":"PPI (DAPT)"
},
{
	"jumpto":"ENAS5326_10.2.0.0",
	"name":"Practical recom. for management (DAPT)"
},
{
	"jumpto":"ENAS5080_5.1.0.0",
	"name":"Prasugrel (NSTE-ACS)"
},
{
	"jumpto":"ENAS5329_6.2.3.0",
	"name":"Prasugrel (STEMI)"
},
{
	"jumpto":"ENAS5326_6.2.0.0",
	"name":"Prasugrel, in ACS undergoing CABG (DAPT)"
},
{
	"jumpto":"ENAS5326_5.4.0.0",
	"name":"Prasugrel, in PCI (DAPT)"
},
{
	"jumpto":"ENAS5080_5.2.1.0",
	"name":"Prasugrel, P2Y12 inhibitor (NSTE-ACS)"
},
{
	"jumpto":"ENAS5326_4.2.2.0",
	"name":"Prasugrel, P2Y12 inhibitor selection (DAPT)"
},
{
	"jumpto":"ENAS5326_4.3.0.0",
	"name":"Prasugrel LD (DAPT)"
},
{
	"jumpto":"ENAS5326_4.3.0.0",
	"name":"Prasugrel MD (DAPT)"
},
{
	"jumpto":"ENAS5532_18.3.0.0",
	"name":"Pre- and peri-interventional antithrombotic treatment [MR]"
},
{
	"jumpto":"ENAS5081_4.1.1.0",
	"name":"Pre-capillary PH"
},
{
	"jumpto":"ENAS5081_4.1.2.0",
	"name":"Pre-capillary PH, hemodynamic definitions of PH"
},
{
	"jumpto":"ENAS5533_9.1.0.0",
	"name":"Pre-eclampsia, definition [HTN]"
},
{
	"jumpto":"ENAS5533_9.1.0.0",
	"name":"Pre-existing hypertension, definition [HTN]"
},
{
	"jumpto":"ENAS261_4.3.0.0",
	"name":"pre-op cardiac risk, cardiac condition"
},
{
	"jumpto":"ENAS261_4.6.0.0",
	"name":"pre-op cardiac risk, cardiac diagnostic"
},
{
	"jumpto":"ENAS261_4.8.0.0",
	"name":"pre-op cardiac risk, consideration of individual benefit"
},
{
	"jumpto":"ENAS261_4.5.0.0",
	"name":"pre-op cardiac risk, functional capacity"
},
{
	"jumpto":"ENAS261_4.7.0.0",
	"name":"pre-op cardiac risk, further testing"
},
{
	"jumpto":"ENAS261_4.4.0.0",
	"name":"pre-op cardiac risk, surgical risk estimate"
},
{
	"jumpto":"ENAS261_4.2.0.0",
	"name":"pre-op cardiac risk, urgency of surgery"
},
{
	"jumpto":"ENAS261_11.0.0.0",
	"name":"pre-op cardiac risk evaluation (algorithm)"
},
{
	"jumpto":"ENAS261_12.0.0.0",
	"name":"pre-op cardiac risk evaluation (table)"
},
{
	"jumpto":"ENAS261_4.1.0.0",
	"name":"pre-operative cardiac risk assessment, non-cardiac surgery,"
},
{
	"jumpto":"ENAS261_6.2.0.0",
	"name":"pre-operative evaluation, electrocardiography"
},
{
	"jumpto":"ENAS261_6.4.0.0",
	"name":"pre-operative evaluation, invasive coronary angiography"
},
{
	"jumpto":"ENAS261_6.3.0.0",
	"name":"pre-operative evaluation, non-invasive assessment of LV function"
},
{
	"jumpto":"ENAS261_6.1.0.0",
	"name":"pre-operative evaluation, risk indices"
},
{
	"jumpto":"ENAS5083_13.7.0.0",
	"name":"Pre-participation evaluation protocol"
},
{
	"jumpto":"ENAS258_7.3.4.0",
	"name":"pre-test probability (PTP)"
},
{
	"jumpto":"ENAS258_7.5.2.0",
	"name":"pre-test probability, confirmed SCAD"
},
{
	"jumpto":"ENAS258_7.3.5.0",
	"name":"pre-test probability, initial diagnostic mgmt. [SCAD]"
},
{
	"jumpto":"ENAS258_7.3.6.0",
	"name":"pre-test probability, intermediate [SCAD]"
},
{
	"jumpto":"ENAS258_7.3.3.0",
	"name":"pre-test probability, suspected SCAD"
},
{
	"jumpto":"ENAS5195_11.1.0.0",
	"name":"precipitating factors (HF)"
},
{
	"jumpto":"ENAS5326_4.1.0.0",
	"name":"PRECISE-DAPT score (DAPT)"
},
{
	"jumpto":"ENAS5196_9.9.0.0",
	"name":"preclinical vascular damage measurements (CVD prev)"
},
{
	"jumpto":"ENAS5531_4.2.3.0",
	"name":"Predictors of maternal and neonatal events [CVD Preg]"
},
{
	"jumpto":"ENAS5082_3.2.4.0",
	"name":"Predictors of prognosis, major"
},
{
	"jumpto":"ENAS5082_3.2.4.0",
	"name":"Predictors of prognosis, minor"
},
{
	"jumpto":"ENAS5196_12.3.4.0",
	"name":"preferred drugs (CVD prev)"
},
{
	"jumpto":"ENAS5081_6.2.2.1",
	"name":"Pregnancy (PH)"
},
{
	"jumpto":"ENAS262_10.1.0.0",
	"name":"pregnancy, pulmonary embolism [PE]"
},
{
	"jumpto":"ENAS5531_5.16.0.0",
	"name":"Pregnancy and pulmonary arterial hypertension [CVD Preg]"
},
{
	"jumpto":"ENAS5531_4.2.4.0",
	"name":"Pregnancy heart team [CVD Preg]"
},
{
	"jumpto":"ENAS5193_3.10.3.0",
	"name":"pregnant women, cardiotoxicity"
},
{
	"jumpto":"ENAS259_6.6.0.0",
	"name":"pregnany, pacing therapy [Pacing]"
},
{
	"jumpto":"ENAS5329_5.4.0.0",
	"name":"Prehospital logistics of care (STEMI)"
},
{
	"jumpto":"ENAS5083_4.3.3.0",
	"name":"Premature ventricular complex (VA and SCD)"
},
{
	"jumpto":"ENAS5083_7.3.0.0",
	"name":"Premature ventricular complexes"
},
{
	"jumpto":"ENAS5328_13.2.0.0",
	"name":"Preoperative evaluation (VHD)"
},
{
	"jumpto":"ENAS5082_3.6.2.0",
	"name":"Pressure/volume curve"
},
{
	"jumpto":"ENAS5193_4.1.1.0",
	"name":"prevention, cardiotoxicity"
},
{
	"jumpto":"ENAS5195_7.0.0.0",
	"name":"prevention, overt heart failure"
},
{
	"jumpto":"ENAS5193_4.2.0.0",
	"name":"prevention, thromboembolic events, cancer"
},
{
	"jumpto":"ENAS5531_12.5.0.0",
	"name":"Prevention and treatment of venous thromboembolism [CVD Preg]"
},
{
	"jumpto":"ENAS5531_11.4.0.0",
	"name":"Prevention of hypertension and pre-eclampsia [CVD Preg]"
},
{
	"jumpto":"ENAS5195_11.4.0.0",
	"name":"prevention of thromboembolism (HF)"
},
{
	"jumpto":"ENAS5531_12.3.0.0",
	"name":"Prevention of venous thromboembolism [CVD Preg]"
},
{
	"jumpto":"ENAS5532_15.0.0.0",
	"name":"Prevention of ventricular arrhythmias by revascularization [MR]"
},
{
	"jumpto":"ENAS5328_7.2.1.0",
	"name":"Primary mitral regurgitation (VHD)"
},
{
	"jumpto":"ENAS5328_7.2.2.0",
	"name":"Primary mitral regurgitation, evaluation (VHD)"
},
{
	"jumpto":"ENAS5328_7.2.4.0",
	"name":"Primary mitral regurgitation, medical therapy (VHD)"
},
{
	"jumpto":"ENAS5328_7.2.5.0",
	"name":"Primary mitral regurgitation, serial testing (VHD)"
},
{
	"jumpto":"ENAS5329_6.1.1.0",
	"name":"Primary PCI (STEMI)"
},
{
	"jumpto":"ENAS5329_6.2.1.0",
	"name":"Primary PCI, overview (STEMI)"
},
{
	"jumpto":"ENAS5532_8.2.0.0",
	"name":"Primary PCI in STEMI, indications and logistics [MR]"
},
{
	"jumpto":"ENAS5532_8.3.0.0",
	"name":"Primary PCI in STEMI, procedural aspects [MR]"
},
{
	"jumpto":"ENAS5329_6.1.1.0",
	"name":"Primary PCI strategy (STEMI)"
},
{
	"jumpto":"ENAS5329_8.4.0.0",
	"name":"Primary PCI strategy, interventions (STEMI)"
},
{
	"jumpto":"ENAS5329_6.2.1.0",
	"name":"Primary PCI strategy, procedural aspects (STEMI)"
},
{
	"jumpto":"ENAS5195_9.1.0.0",
	"name":"primary prevention (HF)"
},
{
	"jumpto":"ENAS5083_4.1.0.0",
	"name":"Primary prevention of SCD"
},
{
	"jumpto":"ENAS5083_13.5.0.0",
	"name":"Pro-arrhythmia, drug related"
},
{
	"jumpto":"ENAS5329_6.2.1.0",
	"name":"Procedural aspects, primary PCI strategy (STEMI)"
},
{
	"jumpto":"ENAS5532_14.0.0.0",
	"name":"Procedural aspects of the revascularization modalities [MR]"
},
{
	"jumpto":"ENAS5079_6.1.0.0",
	"name":"Prognostic assessment of IE patients"
},
{
	"jumpto":"ENAS5083_6.2.3.0",
	"name":"Programmed ventricular stimulation (PVS)"
},
{
	"jumpto":"ENAS5081_6.1.2.0",
	"name":"Progression of symptoms (PH)"
},
{
	"jumpto":"ENAS5194_10.1.3.0",
	"name":"Propafenone (AFib)"
},
{
	"jumpto":"ENAS5328_4.6.0.0",
	"name":"Prophylaxis for rheumatic fever (VHD)"
},
{
	"jumpto":"ENAS5079_3.6.0.0",
	"name":"Prophylaxis of IE, cardiac interventions"
},
{
	"jumpto":"ENAS5079_3.2.0.0",
	"name":"Prophylaxis of IE, dental procedures"
},
{
	"jumpto":"ENAS5079_3.5.0.0",
	"name":"Prophylaxis of IE, GI procedures"
},
{
	"jumpto":"ENAS5079_3.3.0.0",
	"name":"Prophylaxis of IE, high risk cardiac conditions"
},
{
	"jumpto":"ENAS5079_3.5.0.0",
	"name":"Prophylaxis of IE, high risk dental procedures"
},
{
	"jumpto":"ENAS5079_3.5.0.0",
	"name":"Prophylaxis of IE, high risk procedures"
},
{
	"jumpto":"ENAS5079_3.5.0.0",
	"name":"Prophylaxis of IE, in TOE"
},
{
	"jumpto":"ENAS5079_3.5.0.0",
	"name":"Prophylaxis of IE, respiratory tract procedures"
},
{
	"jumpto":"ENAS5079_3.5.0.0",
	"name":"Prophylaxis of IE, skin and soft tissue procedures"
},
{
	"jumpto":"ENAS5079_3.5.0.0",
	"name":"Prophylaxis of IE, urogenital procedures"
},
{
	"jumpto":"ENAS5079_3.6.0.0",
	"name":"Prophylaxis of IE, vascular interventions"
},
{
	"jumpto":"ENAS5079_5.2.4.0",
	"name":"Prosthetic valve, dehiscence"
},
{
	"jumpto":"ENAS5079_5.2.4.0",
	"name":"Prosthetic valve dehiscence, anatomic definition"
},
{
	"jumpto":"ENAS5079_5.2.4.0",
	"name":"Prosthetic valve dehiscence, echocardiographic definition"
},
{
	"jumpto":"ENAS5530_4.1.0.0",
	"name":"Prosthetic valve dysfunction [Sync]"
},
{
	"jumpto":"ENAS5531_7.6.1.0",
	"name":"Prosthetic valves [CVD Preg]"
},
{
	"jumpto":"ENAS5193_3.1.1.7",
	"name":"proteasome inhibitors, cardiotoxicity"
},
{
	"jumpto":"ENAS5326_4.2.3.0",
	"name":"Proton pump inhibitor (DAPT)"
},
{
	"jumpto":"ENAS5533_6.2.0.0",
	"name":"Pseudo-resistant hypertension, causes"
},
{
	"jumpto":"ENAS5079_5.2.4.0",
	"name":"Pseudoaneurysm, anatomic definition"
},
{
	"jumpto":"ENAS5079_5.2.4.0",
	"name":"Pseudoaneurysm, echocardiographic definition"
},
{
	"jumpto":"ENAS5530_4.3.0.0",
	"name":"Pseudocoma [Sync]"
},
{
	"jumpto":"ENAS5531_10.1.0.0",
	"name":"PSVT [CVD Preg]"
},
{
	"jumpto":"ENAS5530_28.0.0.0",
	"name":"Psychogenic TLOC & its evaluation [Sync]"
},
{
	"jumpto":"ENAS5196_11.2.0.0",
	"name":"psychosocial factors change (CVD prev)"
},
{
	"jumpto":"ENAS5196_9.7.0.0",
	"name":"psychosocial risk factors (CVD prev)"
},
{
	"jumpto":"ENAS5081_6.2.2.1",
	"name":"Psychosocial support (PH)"
},
{
	"jumpto":"ENAS5326_8.5.0.0",
	"name":"Pts. with an indication for OAC undergoing PCI (DAPT)"
},
{
	"jumpto":"interactive_0001445",
	"name":"Pts. with an indication for OAC undergoing PCI (tool)"
},
{
	"jumpto":"ENAS5081_5.2.0.0",
	"name":"Pulmonary angiography (PH)"
},
{
	"jumpto":"ENAS5081_4.1.1.0",
	"name":"Pulmonary arterial pressure, PH definition"
},
{
	"jumpto":"ENAS5081_4.1.1.0",
	"name":"Pulmonary artery wedge pressure, PH definition"
},
{
	"jumpto":"ENAS5081_7.6.0.0",
	"name":"Pulmonary capillary hemangiomatosis (PCH)"
},
{
	"jumpto":"ENAS261_8.8.0.0",
	"name":"pulmonary disease in non-cardiac surgery"
},
{
	"jumpto":"ENAS262_7.7.0.0",
	"name":"pulmonary embolism, acute phase treatment strategy"
},
{
	"jumpto":"ENAS262_7.1.0.0",
	"name":"pulmonary embolism, anticoagulation in acute phase"
},
{
	"jumpto":"ENAS262_6.3.0.0",
	"name":"pulmonary embolism, biomarkers"
},
{
	"jumpto":"ENAS262_10.2.0.0",
	"name":"pulmonary embolism, cancer"
},
{
	"jumpto":"ENAS262_4.4.0.0",
	"name":"pulmonary embolism, clinical classification"
},
{
	"jumpto":"ENAS262_6.1.0.0",
	"name":"pulmonary embolism, clinical parameters"
},
{
	"jumpto":"ENAS262_5.1.0.0",
	"name":"pulmonary embolism, clinical presentation"
},
{
	"jumpto":"ENAS262_5.2.0.0",
	"name":"pulmonary embolism, clinical probability"
},
{
	"jumpto":"ENAS262_5.3.4.0",
	"name":"pulmonary embolism, diagnostic strategies"
},
{
	"jumpto":"ENAS262_8.0.0.0",
	"name":"pulmonary embolism, duration of anticoagulation"
},
{
	"jumpto":"ENAS262_4.1.0.0",
	"name":"pulmonary embolism, epidemiology"
},
{
	"jumpto":"ENAS262_6.2.0.0",
	"name":"pulmonary embolism, imaging"
},
{
	"jumpto":"ENAS262_4.4.0.0",
	"name":"pulmonary embolism, initial risk stratification"
},
{
	"jumpto":"ENAS262_6.3.0.0",
	"name":"pulmonary embolism, laboratory tests"
},
{
	"jumpto":"ENAS262_10.3.0.0",
	"name":"pulmonary embolism, non-thrombotic"
},
{
	"jumpto":"ENAS262_4.3.0.0",
	"name":"pulmonary embolism, pathophysiology"
},
{
	"jumpto":"ENAS262_7.4.0.0",
	"name":"pulmonary embolism, percutaneous catheter-directed treatment"
},
{
	"jumpto":"ENAS262_6.1.0.0",
	"name":"pulmonary embolism, PESI"
},
{
	"jumpto":"ENAS262_4.2.0.0",
	"name":"pulmonary embolism, predisposing factors"
},
{
	"jumpto":"ENAS262_10.1.0.0",
	"name":"pulmonary embolism, pregnancy"
},
{
	"jumpto":"ENAS262_6.4.0.0",
	"name":"pulmonary embolism, prognostic assessment strategy"
},
{
	"jumpto":"ENAS262_5.2.0.0",
	"name":"pulmonary embolism, revised Geneva score"
},
{
	"jumpto":"ENAS262_6.1.0.0",
	"name":"pulmonary embolism, sPESI"
},
{
	"jumpto":"ENAS262_7.3.0.0",
	"name":"pulmonary embolism, surgical embolectomy"
},
{
	"jumpto":"ENAS262_5.3.1.0",
	"name":"pulmonary embolism, suspected PE with shock/hypotension"
},
{
	"jumpto":"ENAS262_5.3.2.0",
	"name":"pulmonary embolism, suspected without shock/hypotension"
},
{
	"jumpto":"ENAS262_7.6.0.0",
	"name":"pulmonary embolism, therapeutic strategies"
},
{
	"jumpto":"ENAS262_7.2.0.0",
	"name":"pulmonary embolism, thrombolytic treatment in acute phase"
},
{
	"jumpto":"ENAS5080_3.3.0.0",
	"name":"Pulmonary embolism, troponin elevation (NSTE-ACS)"
},
{
	"jumpto":"ENAS262_5.3.3.0",
	"name":"pulmonary embolism, validated diagnostic criteria"
},
{
	"jumpto":"ENAS262_7.5.0.0",
	"name":"pulmonary embolism, venous filters in acute phase"
},
{
	"jumpto":"ENAS262_5.2.0.0",
	"name":"pulmonary embolism, Wells rule"
},
{
	"jumpto":"ENAS5081_10.3.0.0",
	"name":"Pulmonary endarterectomy (PEA)"
},
{
	"jumpto":"ENAS5081_10.2.0.0",
	"name":"Pulmonary endarterectomy, CTEPH"
},
{
	"jumpto":"ENAS5193_3.8.1.0",
	"name":"pulmonary hypertension, cardiotoxicity"
},
{
	"jumpto":"ENAS5193_3.8.2.0",
	"name":"pulmonary hypertension mgmt., cardiotoxicity"
},
{
	"jumpto":"ENAS5531_5.2.0.0",
	"name":"Pulmonary hypertension [CVD Preg]"
},
{
	"jumpto":"ENAS5531_5.10.0.0",
	"name":"Pulmonary valve & RVOT disease [CVD Preg]"
},
{
	"jumpto":"ENAS5081_4.1.2.0",
	"name":"Pulmonary Vascular Resistance (PVR)"
},
{
	"jumpto":"ENAS5081_7.2.0.0",
	"name":"Pulmonary Vascular Resistance (PVR), PAH"
},
{
	"jumpto":"ENAS5081_7.6.0.0",
	"name":"Pulmonary veno-occlusive disease (PVOD)"
},
{
	"jumpto":"ENAS5082_5.2.3.2",
	"name":"Purulent pericarditis, diagnosis"
},
{
	"jumpto":"ENAS5082_5.2.3.1",
	"name":"Purulent pericarditis, overview"
},
{
	"jumpto":"ENAS5082_5.2.3.3",
	"name":"Purulent pericarditis, therapy"
},
{
	"jumpto":"ENAS5081_4.2.1.0",
	"name":"PVOD, heritable"
},
{
	"jumpto":"ENAS5081_4.2.1.0",
	"name":"PVOD, idiopathic"
},
{
	"jumpto":"ENAS5082_5.2.2.3",
	"name":"Pyrazinamide, in tubercular pericarditis"
},
{
	"jumpto":"ENAS5193_4.3.3.0",
	"name":"pyrimidine analogues prevention, cardiotoxicity"
},
{
	"jumpto":"ENAS5193_3.4.1.2",
	"name":"QT prolongation, cardiotoxicity"
},
{
	"jumpto":"ENAS5193_3.4.2.1",
	"name":"QT prolongation risk factors, cardiotoxicity"
},
{
	"jumpto":"ENAS5197_4.1.9.0",
	"name":"qualifiers, dyslipidaemias"
},
{
	"jumpto":"ENAS5329_11.0.0.0",
	"name":"Quality indicators (STEMI)"
},
{
	"jumpto":"ENAS5326_8.1.0.0",
	"name":"Quinidine (DAPT)"
},
{
	"jumpto":"ENAS5083_9.4.2.0",
	"name":"Quinidine, Brugada syndrome"
},
{
	"jumpto":"ENAS5083_9.3.2.0",
	"name":"Quinidine, SQTS management"
},
{
	"jumpto":"ENAS5327_10.0.0.0",
	"name":"RAD, diagnostic strategies [PAD]"
},
{
	"jumpto":"ENAS5327_10.0.0.0",
	"name":"RAD, treatment strategies [PAD]"
},
{
	"jumpto":"ENAS5329_6.2.1.0",
	"name":"Radial access (STEMI)"
},
{
	"jumpto":"ENAS5082_5.8.1.0",
	"name":"Radiation pericarditis"
},
{
	"jumpto":"ENAS5329_9.3.0.0",
	"name":"Radiofrequency catheter ablation (STEMI)"
},
{
	"jumpto":"ENAS5079_5.4.1.0",
	"name":"Radiolabelled leukocytes"
},
{
	"jumpto":"ENAS5193_3.1.1.8",
	"name":"radiotherapy, cardiotoxicity"
},
{
	"jumpto":"ENAS5193_4.3.5.0",
	"name":"radiotherapy prevention, cardiotoxicity"
},
{
	"jumpto":"ENAS5327_10.0.0.0",
	"name":"RAD [PAD]"
},
{
	"jumpto":"ENAS258_9.5.0.0",
	"name":"randomized trials [SCAD]"
},
{
	"jumpto":"ENAS5195_12.2.0.0",
	"name":"ranolazine (HF)"
},
{
	"jumpto":"ENAS5195_11.2.0.0",
	"name":"rapid ventricular rate management (HF)"
},
{
	"jumpto":"ENAS5195_11.2.0.0",
	"name":"rapid ventricular rate management, AFib"
},
{
	"jumpto":"ENAS5194_9.4.0.0",
	"name":"rate control therapy (AFib)"
},
{
	"jumpto":"ENAS5329_5.1.0.0",
	"name":"Recommendations, initial diagnosis (STEMI)"
},
{
	"jumpto":"ENAS5329_6.1.4.0",
	"name":"Recommendations, reperfusion therapy (STEMI)"
},
{
	"jumpto":"ENAS5329_4.0.0.0",
	"name":"Recommendations, STEMI"
},
{
	"jumpto":"ENAS5328_8.3.1.0",
	"name":"Recommendations for indications for intervention in mitral stenosis (VHD)"
},
{
	"jumpto":"ENAS5328_7.2.3.1",
	"name":"Recommendations for indications for intervention in severe primary MR (VHD)"
},
{
	"jumpto":"ENAS5328_9.3.1.0",
	"name":"Recommendations for indications for intervention in tricuspid regurgitation (VHD)"
},
{
	"jumpto":"ENAS5328_4.2.3.0",
	"name":"Recommendations for management of CAD (VHD)"
},
{
	"jumpto":"ENAS5326_7.1.0.0",
	"name":"Recommendations on DAPT in patients with ACS (DAPT)"
},
{
	"jumpto":"ENAS5326_8.4.0.0",
	"name":"Recommendations on DAPT with indication for OAC (DAPT)"
},
{
	"jumpto":"ENAS5328_9.3.1.0",
	"name":"Recommendations on primary tricuspid regurgitation (VHD)"
},
{
	"jumpto":"ENAS5328_9.3.1.0",
	"name":"Recommendations on secondary tricuspid regurgitation (VHD)"
},
{
	"jumpto":"ENAS5328_9.3.1.0",
	"name":"Recommendations on tricuspid stenosis (VHD)"
},
{
	"jumpto":"ENAS5329_7.2.3.0",
	"name":"Recommended doses, antithrombotic agents (STEMI)"
},
{
	"jumpto":"ENAS5328_4.7.0.0",
	"name":"Recommended requirements of a heart valve centre (VHD)"
},
{
	"jumpto":"ENAS5524_12.0.0.0",
	"name":"Recurrent myocardial infarction [UDMI]"
},
{
	"jumpto":"ENAS5082_3.3.2.0",
	"name":"Recurrent pericarditis, anti-inflammatory therapy"
},
{
	"jumpto":"ENAS5082_3.3.4.0",
	"name":"Recurrent pericarditis, biological drugs"
},
{
	"jumpto":"ENAS5082_3.3.3.0",
	"name":"Recurrent pericarditis, corticosteroid tapering"
},
{
	"jumpto":"ENAS5082_3.2.1.0",
	"name":"Recurrent pericarditis, definition"
},
{
	"jumpto":"ENAS5082_3.3.4.0",
	"name":"Recurrent pericarditis, immunosuppresant drugs"
},
{
	"jumpto":"ENAS5082_3.3.5.0",
	"name":"Recurrent pericarditis, management"
},
{
	"jumpto":"ENAS5082_3.3.1.0",
	"name":"Recurrent pericarditis, overview"
},
{
	"jumpto":"ENAS5079_4.2.0.0",
	"name":"Reference centre, recommendations (IE)"
},
{
	"jumpto":"ENAS259_4.4.2.0",
	"name":"reflex syncope, choice of pacing mode"
},
{
	"jumpto":"ENAS5530_5.3.0.0",
	"name":"Reflex syncope, clinical features"
},
{
	"jumpto":"ENAS259_4.4.2.0",
	"name":"reflex syncope, indications for cardiac pacing"
},
{
	"jumpto":"ENAS5524_11.0.0.0",
	"name":"Reinfarction [UDMI]"
},
{
	"jumpto":"ENAS5329_6.3.3.0",
	"name":"Relative contra-indications (STEMI)"
},
{
	"jumpto":"ENAS5197_4.1.4.0",
	"name":"relative risk chart for CV mortality, dyslipidaemias"
},
{
	"jumpto":"ENAS5196_7.0.0.0",
	"name":"relevance of CVD prevention"
},
{
	"jumpto":"ENAS5329_5.2.0.0",
	"name":"Relief of anxiety (STEMI)"
},
{
	"jumpto":"ENAS5329_5.2.0.0",
	"name":"Relief of breathlessness (STEMI)"
},
{
	"jumpto":"ENAS5329_5.2.0.0",
	"name":"Relief of hypoxaemia (STEMI)"
},
{
	"jumpto":"ENAS5329_5.2.0.0",
	"name":"Relief of pain (STEMI)"
},
{
	"jumpto":"ENAS5329_5.2.0.0",
	"name":"Relief of symptoms (STEMI)"
},
{
	"jumpto":"ENAS5327_10.0.0.0",
	"name":"Renal artery disease [PAD]"
},
{
	"jumpto":"ENAS261_8.5.0.0",
	"name":"renal disease in non-cardiac surgery"
},
{
	"jumpto":"ENAS5329_7.2.3.0",
	"name":"Renal dysfunction, mgmt. (STEMI)"
},
{
	"jumpto":"ENAS5195_13.8.3.0",
	"name":"renal replacement therapy (HF)"
},
{
	"jumpto":"ENAS5532_14.0.0.0",
	"name":"Repeat revascularization & hybrid procedures [MR]"
},
{
	"jumpto":"ENAS5329_6.1.1.0",
	"name":"Reperfusion strategies, selection (STEMI)"
},
{
	"jumpto":"ENAS5329_6.1.3.0",
	"name":"Reperfusion strategy, infarct-related artery (STEMI)"
},
{
	"jumpto":"ENAS5329_6.1.2.0",
	"name":"Reperfusion strategy selection, maximum target times (STEMI)"
},
{
	"jumpto":"ENAS5329_6.1.5.0",
	"name":"Reperfusion strategy selection flowchart (STEMI)"
},
{
	"jumpto":"ENAS5329_6.1.1.0",
	"name":"Reperfusion therapy, definition of terms (STEMI)"
},
{
	"jumpto":"ENAS5329_6.1.4.0",
	"name":"Reperfusion therapy, recommendations (STEMI)"
},
{
	"jumpto":"ENAS5329_6.1.1.0",
	"name":"Rescue PCI (STEMI)"
},
{
	"jumpto":"ENAS5533_6.1.0.0",
	"name":"Resistant Hypertension"
},
{
	"jumpto":"ENAS5533_6.1.0.0",
	"name":"Resistant Hypertension, definition"
},
{
	"jumpto":"ENAS5533_6.3.0.0",
	"name":"Resistant hypertension, treatment"
},
{
	"jumpto":"ENAS5524_9.3.0.0",
	"name":"Restenosis associated with PCI [UDMI]"
},
{
	"jumpto":"ENAS5532_14.0.0.0",
	"name":"Restenosis [MR]"
},
{
	"jumpto":"ENAS5083_4.3.1.0",
	"name":"Resting 12-lead ECG (VA and SCD)"
},
{
	"jumpto":"ENAS5082_3.8.2.0",
	"name":"Restrictive cardiomyopathy (Pericard.)"
},
{
	"jumpto":"ENAS5329_6.3.2.0",
	"name":"Reteplase (STEMI)"
},
{
	"jumpto":"ENAS5328_6.2.4.0",
	"name":"Retrograde LV catheterization (VHD)"
},
{
	"jumpto":"ENAS5327_11.3.0.0",
	"name":"Revascularization, LEAD [PAD]"
},
{
	"jumpto":"ENAS261_7.6.0.0",
	"name":"revascularization, risk reduction in non-cardiac surgery"
},
{
	"jumpto":"ENAS5532_6.1.0.0",
	"name":"Revascularization for SCAD [MR]"
},
{
	"jumpto":"ENAS5532_7.0.0.0",
	"name":"Revascularization in NSTE-ACS [MR]"
},
{
	"jumpto":"ENAS5532_8.1.0.0",
	"name":"Revascularization in STEMI [MR]"
},
{
	"jumpto":"ENAS5327_7.1.7.0",
	"name":"Revascularization in symptomatic carotid disease [PAD]"
},
{
	"jumpto":"ENAS258_9.7.0.0",
	"name":"revascularized SCAD, secondary prevention"
},
{
	"jumpto":"ENAS5328_4.6.0.0",
	"name":"Rheumatic heart disease (VHD)"
},
{
	"jumpto":"ENAS5194_10.7.2.0",
	"name":"rhythm control, surgical (AFib)"
},
{
	"jumpto":"ENAS5194_10.6.0.0",
	"name":"rhythm control after Tx failure (AFib)"
},
{
	"jumpto":"interactive_0000563",
	"name":"Rhythm control foll. treat. failure (interactive algorithm)"
},
{
	"jumpto":"interactive_0000561",
	"name":"Rhythm control in sym. pts. (interactive algorithm)"
},
{
	"jumpto":"ENAS5195_11.3.0.0",
	"name":"rhythm control management strategy (HF)"
},
{
	"jumpto":"ENAS5194_10.1.2.0",
	"name":"rhythm control mgmt. in AF, algorithm"
},
{
	"jumpto":"interactive_0000560",
	"name":"Rhythm control of acute AF (interactive algorithm)"
},
{
	"jumpto":"ENAS5194_10.3.0.0",
	"name":"rhythm control therapy, AF"
},
{
	"jumpto":"ENAS5080_4.2.0.0",
	"name":"Rhythm monitoring (NSTE-ACS)"
},
{
	"jumpto":"ENAS5082_5.2.2.3",
	"name":"Rifampicin, in tubercular pericarditis"
},
{
	"jumpto":"ENAS5081_5.2.0.0",
	"name":"Right heart catherterization (PH)"
},
{
	"jumpto":"ENAS5081_9.0.0.0",
	"name":"Right Heart Catheterization, group 3 PAH"
},
{
	"jumpto":"ENAS5081_8.2.0.0",
	"name":"Right Heart Catheterization, PAH"
},
{
	"jumpto":"ENAS5082_7.1.0.0",
	"name":"Right ventricle-to-abdomen fistula"
},
{
	"jumpto":"ENAS5082_7.1.0.0",
	"name":"Right ventricle pseudoaneurism"
},
{
	"jumpto":"ENAS5081_6.2.3.2",
	"name":"Riocigaut, Guanylate cyclase stimulators"
},
{
	"jumpto":"ENAS5081_6.2.3.2",
	"name":"Riocigaut, PAH monotherapy"
},
{
	"jumpto":"ENAS5081_10.3.0.0",
	"name":"Riociguat, CTEPH"
},
{
	"jumpto":"ENAS5081_6.2.3.4",
	"name":"Riociguat added to bosentan, PH"
},
{
	"jumpto":"ENAS5081_6.2.3.4",
	"name":"Riociguat added to sildenafil, PH"
},
{
	"jumpto":"ENAS5196_9.3.4.0",
	"name":"risk age, derived from SCORE (CVD prev)"
},
{
	"jumpto":"ENAS5197_4.1.5.0",
	"name":"risk age concept Illustration, dyslipidaemias"
},
{
	"jumpto":"ENAS5197_4.2.3.0",
	"name":"risk based intervention strategies, dyslipidaemias"
},
{
	"jumpto":"ENAS5197_4.2.1.0",
	"name":"risk categories, dyslipidaemias"
},
{
	"jumpto":"ENAS5196_9.4.0.0",
	"name":"risk categories: priorities (CVD prev)"
},
{
	"jumpto":"ENAS5197_4.2.4.0",
	"name":"risk estimation, dyslipidaemias"
},
{
	"jumpto":"ENAS5196_9.3.1.0",
	"name":"risk estimation charts (CVD prev)"
},
{
	"jumpto":"ENAS5329_8.1.0.0",
	"name":"Risk factor control (STEMI)"
},
{
	"jumpto":"ENAS5327_4.0.0.0",
	"name":"Risk factors"
},
{
	"jumpto":"ENAS5194_6.1.0.0",
	"name":"risk factors, AF"
},
{
	"jumpto":"ENAS5193_3.1.2.1",
	"name":"risk factors, cardiotoxicity"
},
{
	"jumpto":"ENAS5197_4.1.7.0",
	"name":"risk function without HDL-C for men, at high CVD risk (Dyslip)"
},
{
	"jumpto":"ENAS5197_4.1.6.0",
	"name":"risk function without HDL-C for women, at high CVD risk"
},
{
	"jumpto":"ENAS5197_4.2.1.0",
	"name":"risk levels, dyslipidaemias"
},
{
	"jumpto":"interactive_0001464",
	"name":"Risk of amputation: the WIfI class. (tool)"
},
{
	"jumpto":"ENAS5328_4.3.0.0",
	"name":"Risk stratification (VHD)"
},
{
	"jumpto":"ENAS5193_3.1.2.1",
	"name":"risk stratification, cardiotoxicity"
},
{
	"jumpto":"ENAS5329_7.3.2.0",
	"name":"Risk stratification, non-invasive imaging (STEMI)"
},
{
	"jumpto":"ENAS5531_12.2.0.0",
	"name":"Risk stratification for pregnancy-related VTE [CVD Preg]"
},
{
	"jumpto":"ENAS5530_5.1.0.0",
	"name":"Risk stratification of patients with syncope"
},
{
	"jumpto":"ENAS5326_8.1.0.0",
	"name":"Rivaroxaban (DAPT)"
},
{
	"jumpto":"ENAS5080_5.1.0.0",
	"name":"Rivaroxaban (NSTE-ACS)"
},
{
	"jumpto":"ENAS5079_5.4.2.0",
	"name":"Roth’s spots (IE)"
},
{
	"jumpto":"ENAS5329_8.3.0.0",
	"name":"Routine therapies in acute phases"
},
{
	"jumpto":"ENAS5329_8.3.0.0",
	"name":"Routine therapies in long-term phases"
},
{
	"jumpto":"ENAS5329_8.3.0.0",
	"name":"Routine therapies in subacute phases"
},
{
	"jumpto":"ENAS264_8.6.0.0",
	"name":"rupture of aortic aneurysm"
},
{
	"jumpto":"ENAS5329_5.1.0.0",
	"name":"RV infarction (STEMI)"
},
{
	"jumpto":"ENAS5081_5.4.0.0",
	"name":"RV outflow doppler acceleration"
},
{
	"jumpto":"ENAS5081_5.6.0.0",
	"name":"RV outflow doppler acceleration"
},
{
	"jumpto":"ENAS5081_5.1.0.0",
	"name":"RV third heart sound, symptom of PH"
},
{
	"jumpto":"ENAS5530_23.0.0.0",
	"name":"SA and AV conduction disease [Sync]"
},
{
	"jumpto":"ENAS5195_11.5.0.0",
	"name":"sacubitril (HF)"
},
{
	"jumpto":"ENAS5327_6.2.0.0",
	"name":"SAPT, in CA stenosis [PAD]"
},
{
	"jumpto":"ENAS5328_6.3.3.0",
	"name":"SAVR and TAVI: decision aspects (VHD)"
},
{
	"jumpto":"ENAS258_7.3.2.0",
	"name":"SCAD, basic testing"
},
{
	"jumpto":"ENAS258_4.0.0.0",
	"name":"SCAD, definition and pathophysiology"
},
{
	"jumpto":"ENAS258_7.6.0.0",
	"name":"SCAD, diagnostics in asympt. patients without known CAD"
},
{
	"jumpto":"ENAS258_5.0.0.0",
	"name":"SCAD, epidemiology"
},
{
	"jumpto":"ENAS257_9.1.0.0",
	"name":"SCAD, in diabetes [DM]"
},
{
	"jumpto":"ENAS258_4.0.0.0",
	"name":"SCAD, main features"
},
{
	"jumpto":"ENAS258_8.4.3.0",
	"name":"SCAD, medical mgmt."
},
{
	"jumpto":"ENAS258_8.2.0.0",
	"name":"SCAD, mgmt.: recommended diet intakes"
},
{
	"jumpto":"ENAS258_6.0.0.0",
	"name":"SCAD, natural history and prognosis"
},
{
	"jumpto":"ENAS258_7.7.0.0",
	"name":"SCAD, reassessment"
},
{
	"jumpto":"ENAS258_8.4.5.0",
	"name":"SCAD, revascularization"
},
{
	"jumpto":"ENAS258_7.5.3.0",
	"name":"SCAD, risk stratification"
},
{
	"jumpto":"ENAS258_9.3.0.0",
	"name":"SCAD, strategy of intervention"
},
{
	"jumpto":"ENAS258_7.3.3.0",
	"name":"SCAD, suspected, diagnostic steps"
},
{
	"jumpto":"ENAS258_9.5.0.0",
	"name":"SCAD, trials"
},
{
	"jumpto":"ENAS5083_6.2.3.0",
	"name":"SCAD after MI, revascularization"
},
{
	"jumpto":"ENAS5083_6.2.3.0",
	"name":"SCAD after MI, use of antiarrhythmic drugs"
},
{
	"jumpto":"ENAS5083_6.2.3.0",
	"name":"SCAD after MI, with preserved EF"
},
{
	"jumpto":"ENAS258_8.3.0.0",
	"name":"SCAD mgmt.: blood pressure thresholds"
},
{
	"jumpto":"ENAS258_8.4.2.0",
	"name":"SCAD mgmt.: event prevention"
},
{
	"jumpto":"ENAS258_9.7.0.0",
	"name":"SCAD mgmt.: follow-up after revascularization"
},
{
	"jumpto":"ENAS258_9.6.0.0",
	"name":"SCAD mgmt.: indications for CABG"
},
{
	"jumpto":"ENAS258_9.6.0.0",
	"name":"SCAD mgmt.: indications for PCI"
},
{
	"jumpto":"ENAS258_9.4.0.0",
	"name":"SCAD mgmt.: indications for revascularization"
},
{
	"jumpto":"ENAS258_8.4.4.0",
	"name":"SCAD mgmt.: pharmacological treatment"
},
{
	"jumpto":"ENAS258_9.1.0.0",
	"name":"SCAD mgmt.: revasularization"
},
{
	"jumpto":"ENAS258_8.4.1.0",
	"name":"SCAD mgmt.: side effects, CI and drug-drug interactions"
},
{
	"jumpto":"ENAS5083_5.4.1.0",
	"name":"Scar-related VT"
},
{
	"jumpto":"ENAS5083_5.1.0.0",
	"name":"SCD, preventive pharmacotherapy"
},
{
	"jumpto":"ENAS5083_4.3.4.0",
	"name":"SCD, secondary prevention"
},
{
	"jumpto":"ENAS5083_6.2.1.0",
	"name":"SCD early after MI, risk stratification"
},
{
	"jumpto":"ENAS5083_10.2.0.0",
	"name":"SCD prevention, in congenital heart disease"
},
{
	"jumpto":"ENAS5083_6.1.2.2",
	"name":"SCD with ACS, cardioversion"
},
{
	"jumpto":"ENAS5083_6.1.2.2",
	"name":"SCD with ACS, catheter ablation"
},
{
	"jumpto":"ENAS5083_6.1.2.2",
	"name":"SCD with ACS, defibrillation"
},
{
	"jumpto":"ENAS5083_6.1.2.2",
	"name":"SCD with ACS, drugs"
},
{
	"jumpto":"ENAS5083_6.1.2.1",
	"name":"SCD with ACS, hospital phase"
},
{
	"jumpto":"ENAS5083_6.1.2.3",
	"name":"SCD with ACS, implantable cardioverter defibrillator"
},
{
	"jumpto":"ENAS5083_6.1.2.1",
	"name":"SCD with ACS, indications for revascularization"
},
{
	"jumpto":"ENAS5083_6.1.2.3",
	"name":"SCD with ACS, pacing"
},
{
	"jumpto":"ENAS5083_6.1.1.0",
	"name":"SCD with ACS, pre-hospital phase"
},
{
	"jumpto":"ENAS5083_6.1.2.1",
	"name":"SCD with ACS, prevention and management"
},
{
	"jumpto":"ENAS5197_4.1.2.0",
	"name":"SCORE high risk chart, dyslipidaemias"
},
{
	"jumpto":"ENAS5196_9.3.2.1",
	"name":"SCORE in populations at HIGH CV risk"
},
{
	"jumpto":"ENAS5196_9.3.2.2",
	"name":"SCORE in populations at LOW CV risk"
},
{
	"jumpto":"ENAS5197_4.1.3.0",
	"name":"SCORE low risk chart, dyslipidaemias"
},
{
	"jumpto":"ENAS5196_9.3.1.0",
	"name":"SCORE overview (CVD prev)"
},
{
	"jumpto":"ENAS5196_9.3.3.0",
	"name":"SCORE relative risk chart (CVD prev)"
},
{
	"jumpto":"ENAS5197_4.1.10.0",
	"name":"SCORE risks, modifying factors (Dyslip)"
},
{
	"jumpto":"ENAS5081_11.0.0.0",
	"name":"Screening (PH)"
},
{
	"jumpto":"ENAS5194_4.3.0.0",
	"name":"screening, AF"
},
{
	"jumpto":"ENAS5193_3.1.2.5",
	"name":"screening, cardiotoxicity"
},
{
	"jumpto":"ENAS5193_3.1.2.1",
	"name":"screening, cardiotoxicity"
},
{
	"jumpto":"ENAS5081_7.3.0.0",
	"name":"Screening, PAH"
},
{
	"jumpto":"ENAS5533_3.6.0.0",
	"name":"Screening and diagnosis of hypertension [HTN]"
},
{
	"jumpto":"ENAS5533_3.6.0.0",
	"name":"Screening for the detection of HTN [HTN]"
},
{
	"jumpto":"ENAS5533_7.1.0.0",
	"name":"Secondary HTN"
},
{
	"jumpto":"interactive_0001877",
	"name":"Secondary HTN, causes (tool)"
},
{
	"jumpto":"ENAS5533_7.3.0.0",
	"name":"Secondary HTN, common causes"
},
{
	"jumpto":"ENAS5533_7.4.0.0",
	"name":"Secondary HTN, incidence and typical causes"
},
{
	"jumpto":"ENAS5533_7.2.0.0",
	"name":"Secondary HTN, patient characteristics"
},
{
	"jumpto":"ENAS5533_4.1.2.0",
	"name":"Secondary HTN, physical examination [HTN]"
},
{
	"jumpto":"ENAS5328_7.3.2.0",
	"name":"Secondary mitral regurgitation, evaluation (VHD)"
},
{
	"jumpto":"ENAS5328_7.3.3.0",
	"name":"Secondary mitral regurgitation, indications for intervention (VHD)"
},
{
	"jumpto":"ENAS5328_7.3.1.0",
	"name":"Secondary mitral regurgitation, introduction (VHD)"
},
{
	"jumpto":"ENAS5328_7.3.4.0",
	"name":"Secondary mitral regurgitation, medical therapy (VHD)"
},
{
	"jumpto":"ENAS5195_9.1.0.0",
	"name":"secondary prevention (HF)"
},
{
	"jumpto":"ENAS5083_4.1.0.0",
	"name":"Secondary prevention of SCD"
},
{
	"jumpto":"ENAS5194_8.9.4.0",
	"name":"secondary stroke prevention"
},
{
	"jumpto":"ENAS5196_11.3.0.0",
	"name":"sedentary behaviour and physical activity (CVD prev)"
},
{
	"jumpto":"ENAS5530_4.3.0.0",
	"name":"Seizures [Sync]"
},
{
	"jumpto":"ENAS5532_6.5.0.0",
	"name":"Selection of the type of myocardial revascularization [MR]"
},
{
	"jumpto":"ENAS5081_6.2.3.2",
	"name":"Selexipag, PAH monotherapy"
},
{
	"jumpto":"ENAS5081_6.2.3.4",
	"name":"Selexipag added to ERA and/or PDE-5i, PH"
},
{
	"jumpto":"ENAS5194_12.0.0.0",
	"name":"self-management in AF"
},
{
	"jumpto":"ENAS5328_5.5.0.0",
	"name":"Serial testing, aortic regurgitation (VHD)"
},
{
	"jumpto":"ENAS5328_6.5.0.0",
	"name":"Serial testing, aortic stenosis (VHD)"
},
{
	"jumpto":"ENAS5082_3.2.7.0",
	"name":"Serum CRP, acute pericarditis therapy"
},
{
	"jumpto":"ENAS5326_10.2.0.0",
	"name":"Severe bleeding (DAPT)"
},
{
	"jumpto":"ENAS5083_11.4.0.0",
	"name":"Short-coupled torsade de pointes, treatment"
},
{
	"jumpto":"ENAS5083_9.3.1.0",
	"name":"Short QT syndrome, diagnosis"
},
{
	"jumpto":"ENAS5195_5.1.0.0",
	"name":"signs (HF)"
},
{
	"jumpto":"ENAS5081_6.2.3.2",
	"name":"Sildenafil, PAH monotherapy"
},
{
	"jumpto":"ENAS5081_6.2.3.4",
	"name":"Sildenafil added to bosentan, PH"
},
{
	"jumpto":"ENAS5081_6.2.3.4",
	"name":"Sildenafil added to epoprostenol, PH"
},
{
	"jumpto":"ENAS5195_6.2.0.0",
	"name":"single-photon emission computed tomography, SPET (HF)"
},
{
	"jumpto":"ENAS259_4.3.1.0",
	"name":"sinus arrest [Pacing]"
},
{
	"jumpto":"ENAS259_4.2.3.0",
	"name":"sinus node disease, pacing mode"
},
{
	"jumpto":"ENAS5193_3.4.1.5",
	"name":"sinus node dysfunction, cardiotoxicity"
},
{
	"jumpto":"ENAS5194_10.1.1.0",
	"name":"Sinus rhythm restoration (AFib)"
},
{
	"jumpto":"ENAS5082_2.0.0.0",
	"name":"SjÃ¶gren syndrome (Pericard.)"
},
{
	"jumpto":"ENAS5195_12.17.0.0",
	"name":"sleep-disordered breathing (HF)"
},
{
	"jumpto":"ENAS5083_13.4.0.0",
	"name":"Sleep apnea syndrome"
},
{
	"jumpto":"ENAS5195_12.17.0.0",
	"name":"sleep disturbance (HF)"
},
{
	"jumpto":"ENAS5196_5.0.0.0",
	"name":"smoking (CVD prev)"
},
{
	"jumpto":"ENAS5196_14.3.0.0",
	"name":"smoking, population-based approach (CVD prev)"
},
{
	"jumpto":"ENAS257_8.1.2.0",
	"name":"smoking cessation, the five A principles [DM]"
},
{
	"jumpto":"ENAS5196_11.4.0.0",
	"name":"smoking intervention (CVD prev)"
},
{
	"jumpto":"ENAS5083_9.2.2.0",
	"name":"Sodium channel blocker, flecainide"
},
{
	"jumpto":"ENAS5083_9.2.2.0",
	"name":"Sodium channel blocker, mexiletine"
},
{
	"jumpto":"ENAS5083_9.2.2.0",
	"name":"Sodium channel blocker, ranolazine"
},
{
	"jumpto":"ENAS5083_9.3.2.0",
	"name":"Sotalol, SQTS management"
},
{
	"jumpto":"ENAS5328_4.4.0.0",
	"name":"Special considerations in elderly patients (VHD)"
},
{
	"jumpto":"ENAS5328_13.3.0.0",
	"name":"Specific valve lesions (VHD)"
},
{
	"jumpto":"ENAS5083_9.3.2.0",
	"name":"SQTS, risk stratification and management"
},
{
	"jumpto":"ENAS5082_3.8.2.0",
	"name":"Square root sign"
},
{
	"jumpto":"ENAS5195_12.2.0.0",
	"name":"stable angina pectoris, treatment (HF)"
},
{
	"jumpto":"ENAS5326_5.4.0.0",
	"name":"Stable coronary artery disease (DAPT)"
},
{
	"jumpto":"ENAS258_7.3.2.0",
	"name":"stable coronary artery disease (SCAD), blood tests"
},
{
	"jumpto":"ENAS258_7.3.5.0",
	"name":"stable coronary artery disease (SCAD), initial diagnostic management"
},
{
	"jumpto":"ENAS258_9.3.0.0",
	"name":"stable coronary artery disease, global strategy of intervention"
},
{
	"jumpto":"ENAS258_7.5.2.0",
	"name":"stable coronary artery disease, mgmt. based on risk determination"
},
{
	"jumpto":"ENAS258_7.5.1.0",
	"name":"stable coronary artery disease, predictors of long-term survival"
},
{
	"jumpto":"ENAS5079_5.4.2.0",
	"name":"Staphylococcus aureus (IE)"
},
{
	"jumpto":"ENAS5079_7.3.0.0",
	"name":"Staphylococcus spp., infective endocarditis"
},
{
	"jumpto":"ENAS5197_8.1.0.0",
	"name":"statin, hypercholesterolaemia (Dyslip)"
},
{
	"jumpto":"ENAS261_7.2.0.0",
	"name":"statins, risk reduction in non-cardiac surgery"
},
{
	"jumpto":"ENAS5533_12.1.0.0",
	"name":"Statins and anti-platelet therapy [HTN]"
},
{
	"jumpto":"ENAS5083_13.2.1.0",
	"name":"Steinert disease"
},
{
	"jumpto":"ENAS5329_9.1.0.0",
	"name":"STEMI, complications"
},
{
	"jumpto":"ENAS5329_3.3.0.0",
	"name":"STEMI, epidemiology"
},
{
	"jumpto":"ENAS5329_4.0.0.0",
	"name":"STEMI, Recommendations"
},
{
	"jumpto":"ENAS5329_6.1.1.0",
	"name":"STEMI diagnosis (STEMI)"
},
{
	"jumpto":"ENAS5524_9.2.0.0",
	"name":"Stent/scaffold thrombosis with PCI"
},
{
	"jumpto":"ENAS258_9.1.0.0",
	"name":"stenting and peri-procedural strategies [SCAD]"
},
{
	"jumpto":"ENAS5328_6.2.2.0",
	"name":"Stepwise integrated approach for the assessment of AS severity (VHD)"
},
{
	"jumpto":"ENAS5326_8.1.0.0",
	"name":"Strategies to avoid bleeding complications on patients with OAC (DAPT)"
},
{
	"jumpto":"ENAS5079_7.2.0.0",
	"name":"Streptococci oral, infective endocarditis"
},
{
	"jumpto":"ENAS5079_5.4.2.0",
	"name":"Streptococcus bovis (IE)"
},
{
	"jumpto":"ENAS5079_7.2.0.0",
	"name":"Streptococcus bovis, infective endocarditis"
},
{
	"jumpto":"ENAS5079_5.4.2.0",
	"name":"Streptococcus gallolyticus (IE)"
},
{
	"jumpto":"ENAS5329_6.3.2.0",
	"name":"Streptokinase (STEMI)"
},
{
	"jumpto":"ENAS258_7.3.7.0",
	"name":"stress cardiac magnetic resonance [SCAD]"
},
{
	"jumpto":"ENAS258_7.3.7.0",
	"name":"stress echocardiography [SCAD]"
},
{
	"jumpto":"ENAS5080_3.6.0.0",
	"name":"Stress imaging (NSTE-ACS)"
},
{
	"jumpto":"ENAS258_7.3.7.0",
	"name":"stress imaging techniques [SCAD]"
},
{
	"jumpto":"ENAS5328_4.2.1.0",
	"name":"Stress testing, non-invasive investigation (VHD)"
},
{
	"jumpto":"ENAS258_7.3.7.0",
	"name":"stress testing [SCAD]"
},
{
	"jumpto":"ENAS5193_3.7.1.2",
	"name":"stroke, cardiotoxicity"
},
{
	"jumpto":"ENAS5197_11.11.0.0",
	"name":"stroke, dyslipidaemias"
},
{
	"jumpto":"ENAS5194_8.7.0.0",
	"name":"Stroke prevention in AF"
},
{
	"jumpto":"ENAS5194_8.3.0.0",
	"name":"Stroke prevention in AF, algorithm"
},
{
	"jumpto":"interactive_0000552",
	"name":"Stroke prevention in AFib (interactive algorithm)"
},
{
	"jumpto":"ENAS5327_7.1.6.0",
	"name":"Stroke risk, features associated with increase of [PAD]"
},
{
	"jumpto":"ENAS5080_3.3.0.0",
	"name":"Structural heart disease, troponin elevation (NSTE-ACS)"
},
{
	"jumpto":"ENAS5195_15.1.4.0",
	"name":"structured telephone support (HF)"
},
{
	"jumpto":"ENAS5327_8.0.0.0",
	"name":"Subclavian artery stenosis [PAD]"
},
{
	"jumpto":"ENAS5530_4.3.0.0",
	"name":"Subclavian steal syndrome [Sync]"
},
{
	"jumpto":"ENAS5082_5.2.3.1",
	"name":"Subxiphoid pericardiostomy"
},
{
	"jumpto":"ENAS5083_4.1.0.0",
	"name":"Sudden arrhythmic death syndrome (SADS)"
},
{
	"jumpto":"ENAS5083_4.1.0.0",
	"name":"Sudden cardiac death (SCD)"
},
{
	"jumpto":"ENAS5083_13.6.0.0",
	"name":"Sudden cardiac death, in athletes"
},
{
	"jumpto":"ENAS5083_4.2.0.0",
	"name":"Sudden cardiac death, indications for autopsy"
},
{
	"jumpto":"ENAS5083_7.2.2.0",
	"name":"Sudden cardiac death, in patients with Afib"
},
{
	"jumpto":"ENAS5083_7.2.3.0",
	"name":"Sudden cardiac death, in patients with mild HF"
},
{
	"jumpto":"ENAS5083_7.2.1.0",
	"name":"Sudden cardiac death, in patients with sinus rhythm"
},
{
	"jumpto":"ENAS5083_4.2.0.0",
	"name":"Sudden cardiac death, molecular autopsy"
},
{
	"jumpto":"ENAS5083_7.1.0.0",
	"name":"Sudden cardiac death, primary prevention"
},
{
	"jumpto":"ENAS5083_4.1.0.0",
	"name":"Sudden death, definition"
},
{
	"jumpto":"ENAS5083_4.2.0.0",
	"name":"Sudden death, indications for autopsy"
},
{
	"jumpto":"ENAS5083_4.1.0.0",
	"name":"SUDI, definition"
},
{
	"jumpto":"ENAS5083_4.1.0.0",
	"name":"SUDS, definition"
},
{
	"jumpto":"ENAS5079_3.7.0.0",
	"name":"Summary, antibiotic prophylaxis in IE"
},
{
	"jumpto":"ENAS5329_6.1.6.0",
	"name":"Summary, important time targets (STEMI)"
},
{
	"jumpto":"interactive_0001858",
	"name":"Summary of indications for pacing in pts. with reflex syncope (tool)"
},
{
	"jumpto":"interactive_0001873",
	"name":"Summary of indications for pacing in sync. due to bradycardia (tool)"
},
{
	"jumpto":"ENAS5327_11.4.0.0",
	"name":"Supervised exercise training, intermittent claudication [PAD]"
},
{
	"jumpto":"ENAS5081_6.2.2.1",
	"name":"Supervised exercise training, PAH"
},
{
	"jumpto":"ENAS5524_22.3.0.0",
	"name":"Supplemental ECG leads, application [UDMI]"
},
{
	"jumpto":"ENAS5193_3.4.1.3",
	"name":"supraventricular arrhythmia, cardiotoxicity"
},
{
	"jumpto":"ENAS5079_8.2.0.0",
	"name":"Surgery in IE, heart failure"
},
{
	"jumpto":"ENAS5079_8.2.0.0",
	"name":"Surgery in IE, left-sided valve IE"
},
{
	"jumpto":"ENAS5079_8.2.0.0",
	"name":"Surgery in IE, prevention of embolism"
},
{
	"jumpto":"ENAS5079_8.2.0.0",
	"name":"Surgery in IE, uncontrolled infection"
},
{
	"jumpto":"ENAS5328_6.3.2.0",
	"name":"Surgical aortic valve replacement, SAVR (VHD)"
},
{
	"jumpto":"ENAS5081_10.3.0.0",
	"name":"Surgical PEA, CTEPH"
},
{
	"jumpto":"ENAS5194_10.7.2.0",
	"name":"surgical rhythm control (AFib)"
},
{
	"jumpto":"interactive_0000562",
	"name":"Surgical rhythm control (interactive algorithm)"
},
{
	"jumpto":"ENAS5079_11.0.0.0",
	"name":"Surgical treatment of right-sided IE"
},
{
	"jumpto":"ENAS5531_10.5.0.0",
	"name":"Surveillance levels at time of delivery arrhythmias [CVD Preg]"
},
{
	"jumpto":"ENAS5080_3.4.0.0",
	"name":"Suspected ACS, initial assessment (NSTE-ACS)"
},
{
	"jumpto":"ENAS5080_4.3.1.0",
	"name":"Suspected NSTE-ACS, diagnosis"
},
{
	"jumpto":"ENAS5080_4.3.2.0",
	"name":"Suspected NSTE-ACS, imaging"
},
{
	"jumpto":"ENAS5080_4.3.3.0",
	"name":"Suspected NSTE-ACS, monitoring"
},
{
	"jumpto":"ENAS5080_4.3.1.0",
	"name":"Suspected NSTE-ACS, risk stratification"
},
{
	"jumpto":"ENAS5530_12.0.0.0",
	"name":"Sustained hand grip test [Sync]"
},
{
	"jumpto":"ENAS5083_5.4.1.0",
	"name":"Sustained monomorphic VT, treatment"
},
{
	"jumpto":"ENAS5083_5.3.0.0",
	"name":"Sustained ventricular arrhythmia, acute treatment"
},
{
	"jumpto":"ENAS5083_5.3.0.0",
	"name":"Sustained ventricular arrhythmia, cardioversion"
},
{
	"jumpto":"ENAS5083_5.3.0.0",
	"name":"Sustained ventricular arrhythmia, defibrillation"
},
{
	"jumpto":"ENAS5083_6.1.3.0",
	"name":"Sustained ventricular arrhythmia and ACS, diagnostic workup"
},
{
	"jumpto":"ENAS5083_4.3.4.0",
	"name":"Sustained ventricular tachycardia (VA and SCD)"
},
{
	"jumpto":"ENAS5083_7.4.2.0",
	"name":"SVT, catheter ablation"
},
{
	"jumpto":"ENAS5083_4.3.4.0",
	"name":"SVT, diagnostic workup"
},
{
	"jumpto":"ENAS5083_7.4.1.0",
	"name":"SVT, drug therapy"
},
{
	"jumpto":"ENAS5326_4.3.0.0",
	"name":"Switching algorithms, acute setting (DAPT)"
},
{
	"jumpto":"ENAS5326_4.3.0.0",
	"name":"Switching algorithms, chronic setting (DAPT)"
},
{
	"jumpto":"interactive_0001463",
	"name":"Switching bet. oral P2Y12 inhibitors (tool)"
},
{
	"jumpto":"ENAS5326_4.2.4.0",
	"name":"Switching between oral P2Y12 inhibitors, recommendations (DAPT)"
},
{
	"jumpto":"ENAS5328_6.3.1.0",
	"name":"Symptomatic aortic stenosis, recommendations (VHD)"
},
{
	"jumpto":"ENAS5195_5.1.0.0",
	"name":"symptoms (HF)"
},
{
	"jumpto":"ENAS5081_6.1.2.0",
	"name":"Syncope (PH)"
},
{
	"jumpto":"ENAS5530_30.1.0.0",
	"name":"Syncope (TLOC) management unit"
},
{
	"jumpto":"ENAS5530_7.0.0.0",
	"name":"Syncope, admission criteria"
},
{
	"jumpto":"ENAS259_4.4.2.0",
	"name":"syncope, carotid sinus"
},
{
	"jumpto":"ENAS5530_4.1.0.0",
	"name":"Syncope, classification"
},
{
	"jumpto":"ENAS5530_3.0.0.0",
	"name":"Syncope, definition"
},
{
	"jumpto":"ENAS5530_5.1.0.0",
	"name":"Syncope, initial evaluation"
},
{
	"jumpto":"ENAS259_4.4.2.0",
	"name":"syncope, recurrence rate"
},
{
	"jumpto":"ENAS259_4.4.2.0",
	"name":"syncope, tilt-induced cardioinhibitory"
},
{
	"jumpto":"ENAS259_4.4.2.0",
	"name":"syncope, tilt-induced non-cardioinhibitory"
},
{
	"jumpto":"ENAS259_4.4.2.0",
	"name":"syncope, tilt-induced vasovagal"
},
{
	"jumpto":"ENAS259_4.4.1.0",
	"name":"syncope, unexplained [Pacing]"
},
{
	"jumpto":"ENAS5530_5.3.0.0",
	"name":"Syncope due to OH, clinical features"
},
{
	"jumpto":"ENAS5530_27.0.0.0",
	"name":"Syncope in patients with comorbidity and frailty"
},
{
	"jumpto":"interactive_0001866",
	"name":"Syncope in the context of TLOC (tool)"
},
{
	"jumpto":"ENAS5530_6.1.0.0",
	"name":"Syncope management in the ED"
},
{
	"jumpto":"ENAS5530_25.0.0.0",
	"name":"Syncope secondary to structural diseases"
},
{
	"jumpto":"ENAS5530_30.2.0.0",
	"name":"Syncope specialist, definition"
},
{
	"jumpto":"ENAS5530_19.0.0.0",
	"name":"Syncope treatment [Sync]"
},
{
	"jumpto":"ENAS5530_30.1.0.0",
	"name":"Syncope unit ,definition"
},
{
	"jumpto":"ENAS5530_30.3.0.0",
	"name":"Syncope unit, goal"
},
{
	"jumpto":"ENAS5530_30.4.0.0",
	"name":"Syncope unit, key components"
},
{
	"jumpto":"ENAS5530_30.7.0.0",
	"name":"Syncope unit, role of physician and staff"
},
{
	"jumpto":"ENAS5530_30.5.0.0",
	"name":"Syncope unit, structure"
},
{
	"jumpto":"ENAS5530_30.6.0.0",
	"name":"Syncope unit, test and assessments"
},
{
	"jumpto":"ENAS5326_4.2.2.0",
	"name":"SYNTAX score (DAPT)"
},
{
	"jumpto":"ENAS5532_6.4.0.0",
	"name":"SYNTAX score [MR]"
},
{
	"jumpto":"ENAS5081_7.2.0.0",
	"name":"Systemic-to-pulmonary shunt (PH)"
},
{
	"jumpto":"ENAS5083_7.4.3.0",
	"name":"Tachycardia, bundle branch re-entrant"
},
{
	"jumpto":"ENAS5081_6.2.3.4",
	"name":"Tadalafil + bosentan, PAH sequential combination therapy"
},
{
	"jumpto":"ENAS5081_6.2.3.2",
	"name":"Tadalafil, PAH monotherapy"
},
{
	"jumpto":"ENAS5081_6.2.3.4",
	"name":"Tadalafil added to bosentan, PH"
},
{
	"jumpto":"ENAS5080_3.3.0.0",
	"name":"Tako-Tsubo cardiomyopathy, troponin elevation (NSTE-ACS)"
},
{
	"jumpto":"ENAS5524_16.0.0.0",
	"name":"Takotsubo syndrome [UDMI]"
},
{
	"jumpto":"ENAS5081_10.3.0.0",
	"name":"Targeted medical therapy (PH)"
},
{
	"jumpto":"ENAS5081_11.0.0.0",
	"name":"Targeted medical therapy (PH)"
},
{
	"jumpto":"ENAS5193_3.1.1.4",
	"name":"targeted therapies, cardiotoxicity"
},
{
	"jumpto":"ENAS5328_12.2.3.0",
	"name":"Target INR for mechanical prostheses (VHD)"
},
{
	"jumpto":"ENAS5531_7.6.4.0",
	"name":"Target INR for mechanical prostheses [CVD Preg]"
},
{
	"jumpto":"ENAS5328_4.3.0.0",
	"name":"TAVI (VHD)"
},
{
	"jumpto":"ENAS5328_6.3.1.0",
	"name":"TAVI, transcatheter aortic valve implantation (VHD)"
},
{
	"jumpto":"ENAS259_8.4.0.0",
	"name":"temporary pacing"
},
{
	"jumpto":"ENAS5329_6.3.2.0",
	"name":"Tenecteplase (STEMI)"
},
{
	"jumpto":"ENAS5533_3.2.0.0",
	"name":"Ten year CV risk categories [HTN]"
},
{
	"jumpto":"ENAS5531_5.11.0.0",
	"name":"Tetralogy of Fallot [CVD Preg]"
},
{
	"jumpto":"ENAS5196_5.0.0.0",
	"name":"the main targets (CVD prev)"
},
{
	"jumpto":"ENAS5530_23.0.0.0",
	"name":"Therapeutic algo. for unexplained syncope and BBB [Sync]"
},
{
	"jumpto":"ENAS5195_8.2.0.0",
	"name":"therapeutic algorithm, HFrEF"
},
{
	"jumpto":"interactive_0001859",
	"name":"Therapeutic algorithm for patients presenting with unexplained syncope and BBB (tool)"
},
{
	"jumpto":"interactive_0001874",
	"name":"Therapy for syncope due to tachyarrhythmias (tool)"
},
{
	"jumpto":"ENAS5195_12.11.0.0",
	"name":"thiazide diuretic (HF)"
},
{
	"jumpto":"ENAS5195_8.5.0.0",
	"name":"thiazolidinediones (HF)"
},
{
	"jumpto":"ENAS264_9.2.0.0",
	"name":"thoracic aortic aneurysms"
},
{
	"jumpto":"ENAS5194_10.7.2.0",
	"name":"thoracoscopic AF surgery, complications"
},
{
	"jumpto":"ENAS5193_3.6.1.1",
	"name":"thrombembolic disease, cardiotoxicity"
},
{
	"jumpto":"ENAS5193_3.6.2.0",
	"name":"thrombembolic disease mgmt., cardiotoxicity"
},
{
	"jumpto":"ENAS5195_13.8.2.0",
	"name":"thrombo-embolism prophylaxis (HF)"
},
{
	"jumpto":"ENAS5328_12.1.0.0",
	"name":"Thromboembolism (VHD)"
},
{
	"jumpto":"ENAS5329_6.2.1.0",
	"name":"Thrombus aspiration (STEMI)"
},
{
	"jumpto":"ENAS5080_5.1.0.0",
	"name":"Ticagrelor (NSTE-ACS)"
},
{
	"jumpto":"ENAS5329_6.2.3.0",
	"name":"Ticagrelor (STEMI)"
},
{
	"jumpto":"ENAS5326_6.2.0.0",
	"name":"Ticagrelor, in ACS undergoing CABG (DAPT)"
},
{
	"jumpto":"ENAS5326_7.2.0.0",
	"name":"Ticagrelor, in ACS with medical management (DAPT)"
},
{
	"jumpto":"ENAS5326_5.4.0.0",
	"name":"Ticagrelor, in PCI (DAPT)"
},
{
	"jumpto":"ENAS5080_5.2.1.0",
	"name":"Ticagrelor, P2Y12 inhibitor (NSTE-ACS)"
},
{
	"jumpto":"ENAS5326_4.2.2.0",
	"name":"Ticagrelor, P2Y12 inhibitor selection (DAPT)"
},
{
	"jumpto":"ENAS5326_4.3.0.0",
	"name":"Ticagrelor LD (DAPT)"
},
{
	"jumpto":"ENAS5326_4.3.0.0",
	"name":"Ticagrelor MD (DAPT)"
},
{
	"jumpto":"ENAS5530_11.0.0.0",
	"name":"Tilt testing [Sync]"
},
{
	"jumpto":"ENAS5080_4.1.0.0",
	"name":"TIMI risk score (NSTE-ACS)"
},
{
	"jumpto":"ENAS5329_6.2.3.0",
	"name":"Tirofiban (STEMI)"
},
{
	"jumpto":"ENAS5080_5.2.2.0",
	"name":"Tirofiban, glycoprotein IIb/IIIa inhibitor (NSTE-ACS)"
},
{
	"jumpto":"ENAS5530_4.1.0.0",
	"name":"TLOC, classification [Sync]"
},
{
	"jumpto":"ENAS5530_3.0.0.0",
	"name":"TLOC, definition [Sync]"
},
{
	"jumpto":"ENAS5328_6.2.4.0",
	"name":"TOE (VHD)"
},
{
	"jumpto":"ENAS5327_11.2.0.0",
	"name":"Toe-brachial index [PAD]"
},
{
	"jumpto":"ENAS5083_4.3.3.0",
	"name":"Torsades de pointes"
},
{
	"jumpto":"ENAS5197_4.1.1.0",
	"name":"total cardiovascular risk estimation (Dyslip)"
},
{
	"jumpto":"ENAS5196_9.2.0.0",
	"name":"total CV risk assessment (CVD prev)"
},
{
	"jumpto":"ENAS5195_12.18.0.0",
	"name":"transaortic valve implantation, TAVI (HF)"
},
{
	"jumpto":"ENAS259_6.2.0.0",
	"name":"transcatheter aortic valve implantation, pacing"
},
{
	"jumpto":"ENAS5328_4.2.3.0",
	"name":"Transcatheter aortic valve implantation, TAVI (VHD)"
},
{
	"jumpto":"ENAS5328_6.3.2.0",
	"name":"Transcatheter aortic valve implantation, TAVI (VHD)"
},
{
	"jumpto":"ENAS5530_4.1.0.0",
	"name":"Transient loss of consciousness, classification [Sync]"
},
{
	"jumpto":"ENAS5530_3.0.0.0",
	"name":"Transient loss of consciousness, definition [Sync]"
},
{
	"jumpto":"ENAS5195_11.4.0.0",
	"name":"transoesophageal echocardiography, TOE (HF)"
},
{
	"jumpto":"ENAS5197_11.9.0.0",
	"name":"transplantation, dyslipidaemias"
},
{
	"jumpto":"ENAS5531_5.13.0.0",
	"name":"Transposition of the great arteries [CVD Preg]"
},
{
	"jumpto":"ENAS5080_3.6.0.0",
	"name":"Transthoracic echocardiography (NSTE-ACS)"
},
{
	"jumpto":"ENAS5081_5.2.0.0",
	"name":"Transthoracic echocardiography (PH)"
},
{
	"jumpto":"ENAS5329_9.3.0.0",
	"name":"Transvenous catheter pace termination (STEMI)"
},
{
	"jumpto":"ENAS264_8.7.0.0",
	"name":"traumatic aortic injury"
},
{
	"jumpto":"ENAS5081_6.2.2.1",
	"name":"Travels (PH)"
},
{
	"jumpto":"ENAS5195_12.2.0.0",
	"name":"treatment, stable angina pectoris (HF)"
},
{
	"jumpto":"ENAS5195_8.5.0.0",
	"name":"treatment causing harm (HF)"
},
{
	"jumpto":"interactive_0000592",
	"name":"Treatment for symptomatic HFrEF (interactive algorithm)"
},
{
	"jumpto":"ENAS5532_15.0.0.0",
	"name":"Treatment of AF in the setting of MR"
},
{
	"jumpto":"ENAS5195_10.0.0.0",
	"name":"treatment of HFmrEF"
},
{
	"jumpto":"ENAS5195_10.0.0.0",
	"name":"treatment of HFpEF"
},
{
	"jumpto":"ENAS5195_8.1.0.0",
	"name":"treatment of HFrEF, overview"
},
{
	"jumpto":"ENAS5533_11.7.0.0",
	"name":"Treatment of HTN with AF"
},
{
	"jumpto":"ENAS5533_11.4.0.0",
	"name":"Treatment of HTN with CAD"
},
{
	"jumpto":"ENAS5533_11.6.0.0",
	"name":"Treatment of HTN with cerebrovascular disease"
},
{
	"jumpto":"ENAS5533_11.3.0.0",
	"name":"Treatment of HTN with CKD"
},
{
	"jumpto":"ENAS5533_11.2.0.0",
	"name":"Treatment of HTN with DM"
},
{
	"jumpto":"ENAS5533_11.5.0.0",
	"name":"Treatment of HTN with HF"
},
{
	"jumpto":"ENAS5533_11.8.0.0",
	"name":"Treatment of HTN with LEAD"
},
{
	"jumpto":"ENAS5533_11.5.0.0",
	"name":"Treatment of HTN with LVH"
},
{
	"jumpto":"ENAS5533_11.6.0.0",
	"name":"Treatment of HTN with stroke"
},
{
	"jumpto":"ENAS5533_5.1.0.0",
	"name":"Treatment of hypertension [HTN]"
},
{
	"jumpto":"interactive_0000594",
	"name":"Treatment of muscular symptoms during statin Rx (interactive algorithm)"
},
{
	"jumpto":"ENAS5530_22.0.0.0",
	"name":"Treatment of orthostatic hypotension and orthostatic intolerance syndromes [Sync]"
},
{
	"jumpto":"ENAS5530_20.4.0.0",
	"name":"Treatment of reflex syncope, advice and clinical perspective [Sync]"
},
{
	"jumpto":"ENAS5530_20.1.0.0",
	"name":"Treatment of reflex syncope, overview [Sync]"
},
{
	"jumpto":"ENAS5530_20.3.0.0",
	"name":"Treatment of reflex syncope, recommendations [Sync]"
},
{
	"jumpto":"ENAS5530_24.0.0.0",
	"name":"Treatment of syncope due to cardiac tachyarrhythmias"
},
{
	"jumpto":"ENAS5530_19.0.0.0",
	"name":"Treatment of syncope [Sync]"
},
{
	"jumpto":"ENAS5193_4.1.1.0",
	"name":"treatment options, cardiotoxicity"
},
{
	"jumpto":"ENAS5195_12.13.1.0",
	"name":"treatment recommendations, other co-morbidities (HF)"
},
{
	"jumpto":"ENAS5195_12.13.2.0",
	"name":"treatments not recommended, other co-morbidities (HF)"
},
{
	"jumpto":"ENAS5327_10.0.0.0",
	"name":"Treatment strategies for RAD [PAD]"
},
{
	"jumpto":"ENAS5081_6.2.3.2",
	"name":"Treprostinil, PAH monotherapy"
},
{
	"jumpto":"ENAS5081_6.2.3.4",
	"name":"Treprostinil inhaled added to sildenafil or bosentan, PH"
},
{
	"jumpto":"ENAS5081_5.2.0.0",
	"name":"Tricuspid regurgitant velocity (TRV)(PH)"
},
{
	"jumpto":"ENAS5328_4.2.2.0",
	"name":"Tricuspid regurgitation (VHD)"
},
{
	"jumpto":"ENAS5328_9.2.0.0",
	"name":"Tricuspid regurgitation, evaluation (VHD)"
},
{
	"jumpto":"ENAS5328_9.3.1.0",
	"name":"Tricuspid regurgitation, indications for intervention (VHD)"
},
{
	"jumpto":"ENAS5328_9.1.0.0",
	"name":"Tricuspid regurgitation, overview (VHD)"
},
{
	"jumpto":"ENAS5328_10.2.0.0",
	"name":"Tricuspid stenosis, evaluation (VHD)"
},
{
	"jumpto":"ENAS5328_10.3.0.0",
	"name":"Tricuspid stenosis, indications for intervention (VHD)"
},
{
	"jumpto":"ENAS5328_10.4.0.0",
	"name":"Tricuspid stenosis, medical therapy (VHD)"
},
{
	"jumpto":"ENAS5328_10.1.0.0",
	"name":"Tricuspid stenosis, overview (VHD)"
},
{
	"jumpto":"ENAS5197_9.2.0.0",
	"name":"triglycerides and CVD risk (Dyslip)"
},
{
	"jumpto":"ENAS5195_12.2.0.0",
	"name":"trimetazidine (HF)"
},
{
	"jumpto":"ENAS5326_8.1.0.0",
	"name":"Triple therapy (DAPT)"
},
{
	"jumpto":"ENAS5326_8.5.0.0",
	"name":"Triple Therapy (DAPT)"
},
{
	"jumpto":"ENAS5194_8.11.2.0",
	"name":"triple therapy after ACS (AFib)"
},
{
	"jumpto":"ENAS5194_8.11.3.0",
	"name":"triple therapy after PCI (AFib)"
},
{
	"jumpto":"ENAS5326_10.2.0.0",
	"name":"Trivial bleeding (DAPT)"
},
{
	"jumpto":"ENAS5193_4.1.2.0",
	"name":"troponin elevation, cardiotoxicity"
},
{
	"jumpto":"ENAS5080_3.3.0.0",
	"name":"Troponin elevation, non MI conditions"
},
{
	"jumpto":"ENAS5524_19.0.0.0",
	"name":"Troponin kinetics [UDMI]"
},
{
	"jumpto":"ENAS5524_6.0.0.0",
	"name":"Troponin values in myocardial injury [UDMI]"
},
{
	"jumpto":"ENAS5082_5.2.2.2",
	"name":"Tubercular pericarditis, evaluation"
},
{
	"jumpto":"ENAS5082_5.2.2.3",
	"name":"Tubercular pericarditis, management"
},
{
	"jumpto":"ENAS5082_5.2.2.2",
	"name":"Tubercular pericarditis evaluation, emperic chemotherapy"
},
{
	"jumpto":"ENAS5082_5.2.2.2",
	"name":"Tubercular pericarditis evaluation, initial non-invasive"
},
{
	"jumpto":"ENAS5082_5.2.2.2",
	"name":"Tubercular pericarditis evaluation, pericardial biopsy"
},
{
	"jumpto":"ENAS5082_5.2.2.2",
	"name":"Tubercular pericarditis evaluation, pericardiocentesis"
},
{
	"jumpto":"interactive_0001870",
	"name":"Tx based on risk strat. & identification of sp. mechanisms (tool)"
},
{
	"jumpto":"ENAS5197_6.2.0.0",
	"name":"tx goals LDL-cholesterol (Dyslip)"
},
{
	"jumpto":"ENAS5197_6.3.0.0",
	"name":"tx goals secondary targets (Dyslip)"
},
{
	"jumpto":"ENAS5530_26.1.0.0",
	"name":"Tx of unexplained syncope in patients at high risk of SCD"
},
{
	"jumpto":"ENAS5197_6.1.0.0",
	"name":"tx targets (Dyslip)"
},
{
	"jumpto":"ENAS5080_2.0.0.0",
	"name":"Type 1 MI, definition (NSTE-ACS)"
},
{
	"jumpto":"ENAS5080_2.0.0.0",
	"name":"Type 2 MI, definition (NSTE-ACS)"
},
{
	"jumpto":"ENAS258_7.2.0.0",
	"name":"typical angina, definition [SCAD]"
},
{
	"jumpto":"ENAS5524_2.0.0.0",
	"name":"UDMI, definitions"
},
{
	"jumpto":"ENAS5524_3.0.0.0",
	"name":"UDMI, introduction"
},
{
	"jumpto":"ENAS5524_4.0.0.0",
	"name":"UDMI fourth, initiation"
},
{
	"jumpto":"ENAS5080_5.1.0.0",
	"name":"UFH (NSTE-ACS)"
},
{
	"jumpto":"ENAS5329_6.2.3.0",
	"name":"UFH (STEMI)"
},
{
	"jumpto":"ENAS5328_12.2.5.0",
	"name":"UFH (VHD)"
},
{
	"jumpto":"ENAS5080_5.3.1.0",
	"name":"UFH, dosing (NSTE-ACS)"
},
{
	"jumpto":"ENAS5329_9.2.0.0",
	"name":"Ultrafiltration (STEMI)"
},
{
	"jumpto":"ENAS259_4.4.3.0",
	"name":"unexplained syncope, indications for cardiac pacing"
},
{
	"jumpto":"ENAS5326_8.3.0.0",
	"name":"Unfavourable pt. profile for OAC & APT (DAPT)"
},
{
	"jumpto":"ENAS5080_2.0.0.0",
	"name":"Universal definition of myocardial infarction (NSTE-ACS)"
},
{
	"jumpto":"ENAS5327_8.0.0.0",
	"name":"Upper extremity artery disease, DDx [PAD]"
},
{
	"jumpto":"ENAS5082_5.3.0.0",
	"name":"Uremic pericarditis"
},
{
	"jumpto":"ENAS5326_4.2.1.0",
	"name":"Use of risk scores, recommendation (DAPT)"
},
{
	"jumpto":"ENAS5530_12.0.0.0",
	"name":"Valsalva manoeuvre [Sync]"
},
{
	"jumpto":"ENAS5195_11.5.0.0",
	"name":"valsartan (HF)"
},
{
	"jumpto":"ENAS5079_5.2.4.0",
	"name":"Valve aneurysm, anatomic definition"
},
{
	"jumpto":"ENAS5079_5.2.4.0",
	"name":"Valve aneurysm, echocardiographic definition"
},
{
	"jumpto":"ENAS5328_12.2.4.0",
	"name":"valve prosthesis after an ACS or elective PCI (VHD)"
},
{
	"jumpto":"ENAS5532_12.0.0.0",
	"name":"Valvular and coronary interventions [MR]"
},
{
	"jumpto":"ENAS5531_7.3.0.0",
	"name":"Valvular aortic stenosis [CVD Preg]"
},
{
	"jumpto":"ENAS5193_3.3.1.0",
	"name":"valvular disease, cardiotoxicity"
},
{
	"jumpto":"ENAS5197_11.7.0.0",
	"name":"valvular diseases, dyslipidaemias"
},
{
	"jumpto":"ENAS5195_12.18.0.0",
	"name":"valvular heart disease (HF)"
},
{
	"jumpto":"ENAS261_8.3.0.0",
	"name":"Valvular heart disease in non-cardiac surgery"
},
{
	"jumpto":"ENAS5531_7.1.0.0",
	"name":"Valvular heart disease [CVD Preg]"
},
{
	"jumpto":"ENAS5083_10.2.0.0",
	"name":"VA prevention, in congenital heart disease"
},
{
	"jumpto":"ENAS5081_6.2.3.2",
	"name":"Vardenafil, PAH monotherapy"
},
{
	"jumpto":"ENAS5083_4.3.2.0",
	"name":"VA screening, invasive evaluation"
},
{
	"jumpto":"ENAS5083_4.3.1.0",
	"name":"VA screening, non-invasive evaluation"
},
{
	"jumpto":"ENAS5530_4.2.0.0",
	"name":"Vasodepression [Sync]"
},
{
	"jumpto":"ENAS5195_13.8.2.0",
	"name":"vasodilators (HF)"
},
{
	"jumpto":"ENAS5329_9.2.0.0",
	"name":"Vasopressor agents (STEMI)"
},
{
	"jumpto":"ENAS5195_13.8.2.0",
	"name":"vasopressors (HF)"
},
{
	"jumpto":"ENAS5081_5.7.0.0",
	"name":"Vasoreactivity testing (PH)"
},
{
	"jumpto":"ENAS5081_8.2.0.0",
	"name":"Vasoreactivity testing, PAH"
},
{
	"jumpto":"ENAS5081_5.7.0.0",
	"name":"Vasoreactivity testing, positive response"
},
{
	"jumpto":"ENAS5081_5.7.0.0",
	"name":"Vasoreactivity testing in PH, recommendations"
},
{
	"jumpto":"ENAS258_7.8.2.0",
	"name":"vasospastic angina, diagnosis [SCAD]"
},
{
	"jumpto":"ENAS5530_4.1.0.0",
	"name":"Vasovagal syncope"
},
{
	"jumpto":"ENAS5079_5.2.4.0",
	"name":"Vegetation, anatomic definition"
},
{
	"jumpto":"ENAS5079_5.2.4.0",
	"name":"Vegetation, echocardiographic definition"
},
{
	"jumpto":"ENAS5193_3.1.1.5",
	"name":"VEGF inhibitores, cardiotoxicity"
},
{
	"jumpto":"ENAS5193_4.3.4.0",
	"name":"VEGF inhibitors prevention, cardiotoxicity"
},
{
	"jumpto":"ENAS5531_12.1.0.0",
	"name":"Venous thromboembolism during pregnancy & the puerperium [CVD Preg]"
},
{
	"jumpto":"ENAS5193_3.6.1.3",
	"name":"venous thrombosis, cardiotoxicity"
},
{
	"jumpto":"ENAS5081_5.2.0.0",
	"name":"Ventilation/perfusion lung scan (PH)"
},
{
	"jumpto":"ENAS5195_13.7.0.0",
	"name":"ventilatory support, acute heart failure (HF)"
},
{
	"jumpto":"ENAS5083_4.3.3.0",
	"name":"Ventricular arrhythmia, bidirectional"
},
{
	"jumpto":"ENAS5083_10.1.0.0",
	"name":"Ventricular arrhythmia, children with normal heart"
},
{
	"jumpto":"ENAS5083_5.2.1.0",
	"name":"Ventricular arrhythmia, device therapy"
},
{
	"jumpto":"ENAS5083_10.1.0.0",
	"name":"Ventricular arrhythmia, in childern"
},
{
	"jumpto":"ENAS5083_12.1.0.0",
	"name":"Ventricular arrhythmia, in IHD"
},
{
	"jumpto":"ENAS5083_13.4.0.0",
	"name":"Ventricular arrhythmia, in sleep apnea"
},
{
	"jumpto":"ENAS5083_5.4.1.0",
	"name":"Ventricular arrhythmia, interventional therapy"
},
{
	"jumpto":"ENAS5083_12.2.0.0",
	"name":"Ventricular arrhythmia, in VHD"
},
{
	"jumpto":"ENAS5083_4.3.3.0",
	"name":"Ventricular arrhythmia, monomorphic"
},
{
	"jumpto":"ENAS5083_4.3.3.0",
	"name":"Ventricular arrhythmia, non-sustained"
},
{
	"jumpto":"ENAS5083_5.1.0.0",
	"name":"Ventricular arrhythmia, pharmacotherapy"
},
{
	"jumpto":"ENAS5083_4.3.3.0",
	"name":"Ventricular arrhythmia, pleomorphic"
},
{
	"jumpto":"ENAS5083_4.3.3.0",
	"name":"Ventricular arrhythmia, polymorphic"
},
{
	"jumpto":"ENAS5083_4.3.1.0",
	"name":"Ventricular arrhythmia, screening"
},
{
	"jumpto":"ENAS5083_4.3.3.0",
	"name":"Ventricular arrhythmia, sustained"
},
{
	"jumpto":"ENAS5083_6.1.3.0",
	"name":"Ventricular arrhythmia, sustained"
},
{
	"jumpto":"ENAS5083_12.2.0.0",
	"name":"Ventricular arrhythmia in VHD, management"
},
{
	"jumpto":"ENAS5193_3.4.1.4",
	"name":"ventricular arrhythmias, cardiotoxicity"
},
{
	"jumpto":"ENAS5329_9.3.0.0",
	"name":"Ventricular arrhythmias, management (STEMI)"
},
{
	"jumpto":"ENAS5195_11.6.0.0",
	"name":"ventricular dyssynchrony (HF)"
},
{
	"jumpto":"ENAS5329_5.3.0.0",
	"name":"Ventricular fibrillation (STEMI)"
},
{
	"jumpto":"ENAS5083_11.3.0.0",
	"name":"Ventricular fibrillation, idiopathic"
},
{
	"jumpto":"ENAS5083_4.3.3.0",
	"name":"Ventricular flutter (VA and SCD)"
},
{
	"jumpto":"ENAS5329_5.1.0.0",
	"name":"Ventricular paced rhythm, ECG presentation (STEMI)"
},
{
	"jumpto":"ENAS5531_5.7.0.0",
	"name":"Ventricular septal defect [CVD Preg]"
},
{
	"jumpto":"ENAS5083_4.3.3.0",
	"name":"Ventricular tachycardia (VA and SCD)"
},
{
	"jumpto":"ENAS5083_5.3.0.0",
	"name":"Ventricular tachycardia, cardioversion (VA and SCD)"
},
{
	"jumpto":"ENAS5083_11.2.0.0",
	"name":"Ventricular tachycardia, idiopathic"
},
{
	"jumpto":"ENAS5195_11.5.0.0",
	"name":"ventricular tachycardia, management (HF)"
},
{
	"jumpto":"ENAS5083_11.2.0.0",
	"name":"Ventricular tachycardia, miscellaneous origin"
},
{
	"jumpto":"ENAS5083_11.1.0.0",
	"name":"Ventricular tachycardia, outflow tract"
},
{
	"jumpto":"ENAS5083_5.4.2.0",
	"name":"Ventricular tachycardia, surgical ablation"
},
{
	"jumpto":"ENAS5531_10.2.0.0",
	"name":"Ventricular tachycardia [CVD Preg]"
},
{
	"jumpto":"ENAS5194_9.4.0.0",
	"name":"Verapamil (AFib)"
},
{
	"jumpto":"ENAS5326_8.1.0.0",
	"name":"Verapamil (DAPT)"
},
{
	"jumpto":"ENAS5195_8.5.0.0",
	"name":"verapamil (HF)"
},
{
	"jumpto":"ENAS5194_10.1.3.0",
	"name":"Vernakalant (AFib)"
},
{
	"jumpto":"ENAS5327_7.2.0.0",
	"name":"vertebral artery disease, management [PAD]"
},
{
	"jumpto":"ENAS5530_4.3.0.0",
	"name":"Vertebrobasilar TIA [Sync]"
},
{
	"jumpto":"ENAS5193_3.3.2.0",
	"name":"VHD mgmt., cardiotoxicity"
},
{
	"jumpto":"ENAS5530_14.0.0.0",
	"name":"Video recording in suspected syncope"
},
{
	"jumpto":"ENAS5079_5.4.2.0",
	"name":"Viridans streptococci (IE)"
},
{
	"jumpto":"ENAS5326_8.1.0.0",
	"name":"Vitamin K antagonist, VKA (DAPT)"
},
{
	"jumpto":"ENAS5328_4.8.0.0",
	"name":"Vitamin K antagonist,VKA (VHD)"
},
{
	"jumpto":"ENAS5194_8.10.2.0",
	"name":"VKA and NOAC in active bleeding (AFib)"
},
{
	"jumpto":"ENAS5532_19.0.0.0",
	"name":"Volume–outcome relationship for revasc. procedures [MR]"
},
{
	"jumpto":"ENAS5080_5.1.0.0",
	"name":"Vorapraxar (NSTE-ACS)"
},
{
	"jumpto":"ENAS5531_12.3.0.0",
	"name":"VTE, prevention [CVD Preg]"
},
{
	"jumpto":"ENAS5531_12.1.0.0",
	"name":"VTE during pregnancy and the puerperium [CVD Preg]"
},
{
	"jumpto":"ENAS5083_5.2.3.0",
	"name":"Wearable cardioverter"
},
{
	"jumpto":"interactive_0000320",
	"name":"Wells criteria for thromboembolism (interactive score)"
},
{
	"jumpto":"interactive_0000317",
	"name":"Wells score (interactive score)"
},
{
	"jumpto":"ENAS5533_10.3.0.0",
	"name":"White coat hypertension, management [HTN]"
},
{
	"jumpto":"ENAS5533_10.1.0.0",
	"name":"White coat hypertension [HTN]"
},
{
	"jumpto":"ENAS5531_4.2.2.0",
	"name":"WHO classification of maternal CV risk [CVD Preg]"
},
{
	"jumpto":"ENAS5081_6.1.2.0",
	"name":"WHO functional class (PH)"
},
{
	"jumpto":"ENAS5327_11.5.0.0",
	"name":"WIFI classification, amputation risk [PAD]"
},
{
	"jumpto":"ENAS5328_8.3.4.0",
	"name":"Wilkins score, assessment of mitral valve anatomy (VHD)"
},
{
	"jumpto":"ENAS5083_13.8.1.0",
	"name":"Wolff-Parkinson-White syndrome"
},
{
	"jumpto":"ENAS5083_13.8.1.0",
	"name":"Wolff-Parkinson-White syndrome, ablation"
},
{
	"jumpto":"ENAS5083_13.8.2.0",
	"name":"Wolff-Parkinson-White syndrome, end of life issues"
},
{
	"jumpto":"ENAS5197_11.3.0.0",
	"name":"women, dyslipidaemias"
},
{
	"jumpto":"ENAS5194_11.2.0.0",
	"name":"WPW syndrome (AFib)"
}
]